WO2022170081A1 - Antiarrhythmic formulation - Google Patents
Antiarrhythmic formulation Download PDFInfo
- Publication number
- WO2022170081A1 WO2022170081A1 PCT/US2022/015293 US2022015293W WO2022170081A1 WO 2022170081 A1 WO2022170081 A1 WO 2022170081A1 US 2022015293 W US2022015293 W US 2022015293W WO 2022170081 A1 WO2022170081 A1 WO 2022170081A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclodextrin
- pharmaceutical composition
- acid
- flecainide
- pharmaceutically acceptable
- Prior art date
Links
- 239000003416 antiarrhythmic agent Substances 0.000 title abstract description 69
- 230000003288 anthiarrhythmic effect Effects 0.000 title abstract description 62
- 239000000203 mixture Substances 0.000 title description 128
- 238000009472 formulation Methods 0.000 title description 75
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 311
- 239000000843 powder Substances 0.000 claims abstract description 226
- 238000000034 method Methods 0.000 claims abstract description 108
- 238000011282 treatment Methods 0.000 claims abstract description 28
- 229920000858 Cyclodextrin Polymers 0.000 claims description 294
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 claims description 270
- 239000002245 particle Substances 0.000 claims description 164
- 229960000449 flecainide Drugs 0.000 claims description 150
- 229960003670 flecainide acetate Drugs 0.000 claims description 104
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 101
- 150000003839 salts Chemical class 0.000 claims description 95
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 70
- 239000002775 capsule Substances 0.000 claims description 51
- 239000002253 acid Substances 0.000 claims description 48
- 238000001694 spray drying Methods 0.000 claims description 44
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 42
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 42
- 239000000443 aerosol Substances 0.000 claims description 41
- 229940112141 dry powder inhaler Drugs 0.000 claims description 40
- -1 hydroxy propyl Chemical group 0.000 claims description 34
- 206010003130 Arrhythmia supraventricular Diseases 0.000 claims description 23
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 23
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 22
- 230000009477 glass transition Effects 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 19
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 18
- 239000003937 drug carrier Substances 0.000 claims description 17
- 229960003136 leucine Drugs 0.000 claims description 17
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 16
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 15
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 15
- 235000015165 citric acid Nutrition 0.000 claims description 14
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 208000001871 Tachycardia Diseases 0.000 claims description 11
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 11
- 230000006794 tachycardia Effects 0.000 claims description 11
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 10
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 10
- 238000000889 atomisation Methods 0.000 claims description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 10
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- 229940024606 amino acid Drugs 0.000 claims description 8
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 238000002425 crystallisation Methods 0.000 claims description 8
- 230000008025 crystallization Effects 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims description 7
- 229960005070 ascorbic acid Drugs 0.000 claims description 7
- 239000011668 ascorbic acid Substances 0.000 claims description 7
- 238000004108 freeze drying Methods 0.000 claims description 7
- 239000004310 lactic acid Substances 0.000 claims description 7
- 235000014655 lactic acid Nutrition 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 150000004804 polysaccharides Chemical class 0.000 claims description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 7
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 claims description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 6
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 6
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 6
- 239000006174 pH buffer Substances 0.000 claims description 6
- 239000008117 stearic acid Substances 0.000 claims description 6
- 239000011975 tartaric acid Substances 0.000 claims description 6
- 235000002906 tartaric acid Nutrition 0.000 claims description 6
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 5
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 5
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 claims description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 5
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 5
- ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 claims description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 5
- 239000005711 Benzoic acid Substances 0.000 claims description 5
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 5
- 239000004380 Cholic acid Substances 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- 239000001263 FEMA 3042 Substances 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 239000003490 Thiodipropionic acid Substances 0.000 claims description 5
- 229940091181 aconitic acid Drugs 0.000 claims description 5
- 239000001361 adipic acid Substances 0.000 claims description 5
- 235000011037 adipic acid Nutrition 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 239000000783 alginic acid Substances 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 229960001126 alginic acid Drugs 0.000 claims description 5
- 150000004781 alginic acids Chemical class 0.000 claims description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 5
- 235000010233 benzoic acid Nutrition 0.000 claims description 5
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 5
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 5
- 235000019416 cholic acid Nutrition 0.000 claims description 5
- 229960002471 cholic acid Drugs 0.000 claims description 5
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 claims description 5
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 5
- 239000008121 dextrose Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 235000010350 erythorbic acid Nutrition 0.000 claims description 5
- 239000004318 erythorbic acid Substances 0.000 claims description 5
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 5
- 235000019253 formic acid Nutrition 0.000 claims description 5
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 5
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 229960003943 hypromellose Drugs 0.000 claims description 5
- 229940026239 isoascorbic acid Drugs 0.000 claims description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
- 239000011976 maleic acid Substances 0.000 claims description 5
- 239000001630 malic acid Substances 0.000 claims description 5
- 235000011090 malic acid Nutrition 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 229960002446 octanoic acid Drugs 0.000 claims description 5
- 235000011007 phosphoric acid Nutrition 0.000 claims description 5
- 235000019260 propionic acid Nutrition 0.000 claims description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 5
- 235000010199 sorbic acid Nutrition 0.000 claims description 5
- 239000004334 sorbic acid Substances 0.000 claims description 5
- 229940075582 sorbic acid Drugs 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 235000010356 sorbitol Nutrition 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 235000015523 tannic acid Nutrition 0.000 claims description 5
- 229920002258 tannic acid Polymers 0.000 claims description 5
- 229940033123 tannic acid Drugs 0.000 claims description 5
- 235000019303 thiodipropionic acid Nutrition 0.000 claims description 5
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 claims description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- 239000004386 Erythritol Substances 0.000 claims description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 4
- 235000019414 erythritol Nutrition 0.000 claims description 4
- 229940009714 erythritol Drugs 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 4
- 235000010449 maltitol Nutrition 0.000 claims description 4
- 239000000845 maltitol Substances 0.000 claims description 4
- 229940035436 maltitol Drugs 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 3
- 229930182844 L-isoleucine Natural products 0.000 claims description 3
- 239000004395 L-leucine Substances 0.000 claims description 3
- 235000019454 L-leucine Nutrition 0.000 claims description 3
- 239000001099 ammonium carbonate Substances 0.000 claims description 3
- 239000004621 biodegradable polymer Substances 0.000 claims description 3
- 229920002988 biodegradable polymer Polymers 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 3
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 claims description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 239000008177 pharmaceutical agent Substances 0.000 abstract description 62
- 229940126534 drug product Drugs 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 80
- 229940079593 drug Drugs 0.000 description 62
- 239000003814 drug Substances 0.000 description 62
- 239000007921 spray Substances 0.000 description 48
- 238000009826 distribution Methods 0.000 description 44
- 150000003904 phospholipids Chemical class 0.000 description 41
- 239000013543 active substance Substances 0.000 description 38
- 206010003119 arrhythmia Diseases 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 23
- 229960000583 acetic acid Drugs 0.000 description 22
- 238000011068 loading method Methods 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 22
- 230000006793 arrhythmia Effects 0.000 description 19
- 210000004072 lung Anatomy 0.000 description 19
- 230000008569 process Effects 0.000 description 18
- 238000003860 storage Methods 0.000 description 17
- 238000000634 powder X-ray diffraction Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 14
- 229940097362 cyclodextrins Drugs 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 235000003599 food sweetener Nutrition 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 12
- 239000003765 sweetening agent Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 150000007513 acids Chemical class 0.000 description 10
- 238000012387 aerosolization Methods 0.000 description 10
- 238000005375 photometry Methods 0.000 description 10
- 230000033764 rhythmic process Effects 0.000 description 10
- 230000002861 ventricular Effects 0.000 description 10
- 239000006185 dispersion Substances 0.000 description 9
- 230000002209 hydrophobic effect Effects 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- 239000013078 crystal Substances 0.000 description 8
- 230000008021 deposition Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 7
- 208000016709 aortopulmonary window Diseases 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000013194 cardioversion Methods 0.000 description 7
- 150000001768 cations Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 210000002837 heart atrium Anatomy 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 229960000448 lactic acid Drugs 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000001179 sorption measurement Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000035488 systolic blood pressure Effects 0.000 description 6
- 230000010512 thermal transition Effects 0.000 description 6
- 206010003662 Atrial flutter Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000010419 fine particle Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000001788 irregular Effects 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 238000002663 nebulization Methods 0.000 description 5
- 229910017604 nitric acid Inorganic materials 0.000 description 5
- 239000003002 pH adjusting agent Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 150000008105 phosphatidylcholines Chemical class 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000013557 residual solvent Substances 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 206010047302 ventricular tachycardia Diseases 0.000 description 5
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 238000013195 electrical cardioversion Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000000297 inotrophic effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 210000001331 nose Anatomy 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 235000019204 saccharin Nutrition 0.000 description 4
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 4
- 229940081974 saccharin Drugs 0.000 description 4
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 239000006068 taste-masking agent Substances 0.000 description 4
- 238000002076 thermal analysis method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- DNDWZFHLZVYOGF-KKUMJFAQSA-N Leu-Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O DNDWZFHLZVYOGF-KKUMJFAQSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 241000544066 Stevia Species 0.000 description 3
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 229960000250 adipic acid Drugs 0.000 description 3
- 239000012296 anti-solvent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 238000010668 complexation reaction Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229940013688 formic acid Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000021472 generally recognized as safe Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000003434 inspiratory effect Effects 0.000 description 3
- 108010049589 leucyl-leucyl-leucine Proteins 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 102100033735 Bactericidal permeability-increasing protein Human genes 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 208000002790 Cytochrome P-450 CYP2D6 Inducers Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 108700012941 GNRH1 Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 2
- 101000871785 Homo sapiens Bactericidal permeability-increasing protein Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000003109 Karl Fischer titration Methods 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000004384 Neotame Substances 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 102400000058 Neuregulin-1 Human genes 0.000 description 2
- 108090000556 Neuregulin-1 Proteins 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710142969 Somatoliberin Proteins 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000002763 arrhythmic effect Effects 0.000 description 2
- 239000008122 artificial sweetener Substances 0.000 description 2
- 235000021311 artificial sweeteners Nutrition 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 206010003668 atrial tachycardia Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 229960004365 benzoic acid Drugs 0.000 description 2
- 230000002902 bimodal effect Effects 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 230000036471 bradycardia Effects 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000012159 carrier gas Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000003869 coulometry Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 230000002332 fibrillatory effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000002314 glycerols Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000002563 ionic surfactant Substances 0.000 description 2
- 150000003893 lactate salts Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000004973 liquid crystal related substance Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 235000019412 neotame Nutrition 0.000 description 2
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 2
- 108010070257 neotame Proteins 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 150000002960 penicillins Chemical class 0.000 description 2
- BPHQIXJDBIHMLT-UHFFFAOYSA-N perfluorodecane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F BPHQIXJDBIHMLT-UHFFFAOYSA-N 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 125000005498 phthalate group Chemical class 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000011164 primary particle Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 238000000718 qrs complex Methods 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000000235 small-angle X-ray scattering Methods 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- 229940073585 tromethamine hydrochloride Drugs 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- ALYUMNAHLSSTOU-CIRGZYLNSA-N (6r,7r)-7-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 ALYUMNAHLSSTOU-CIRGZYLNSA-N 0.000 description 1
- WKJGTOYAEQDNIA-IOOZKYRYSA-N (6r,7r)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 WKJGTOYAEQDNIA-IOOZKYRYSA-N 0.000 description 1
- MMRINLZOZVAPDZ-LSGRDSQZSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;chloride Chemical compound Cl.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 MMRINLZOZVAPDZ-LSGRDSQZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- QKDHBVNJCZBTMR-LLVKDONJSA-N (R)-temafloxacin Chemical compound C1CN[C@H](C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F QKDHBVNJCZBTMR-LLVKDONJSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- RZLHGQLYNZQZQQ-UHFFFAOYSA-N 1-ethyl-6-fluoro-4-oxo-7-pyrrol-1-ylquinoline-3-carboxylic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1C=CC=C1 RZLHGQLYNZQZQQ-UHFFFAOYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- YKIOPDIXYAUOFN-UHFFFAOYSA-N 2,3-di(icosanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC YKIOPDIXYAUOFN-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical class OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical class OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- WUWFMDMBOJLQIV-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 description 1
- VCCNKWWXYVWTLT-CYZBKYQRSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VCCNKWWXYVWTLT-CYZBKYQRSA-N 0.000 description 1
- MPORYQCGWFQFLA-ONPDANIMSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 MPORYQCGWFQFLA-ONPDANIMSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 240000004246 Agave americana Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- RUXPNBWPIRDVTH-UHFFFAOYSA-N Amifloxacin Chemical compound C1=C2N(NC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 RUXPNBWPIRDVTH-UHFFFAOYSA-N 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 208000006808 Atrioventricular Nodal Reentry Tachycardia Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010059027 Brugada syndrome Diseases 0.000 description 1
- 206010006578 Bundle-Branch Block Diseases 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010065839 Capreomycin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000014526 Conduction disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical class OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 241001069765 Fridericia <angiosperm> Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 235000021559 Fruit Juice Concentrate Nutrition 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 description 1
- 208000010271 Heart Block Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- XAGMUUZPGZWTRP-ZETCQYMHSA-N LSM-5745 Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1C1(N)CC1 XAGMUUZPGZWTRP-ZETCQYMHSA-N 0.000 description 1
- IEMDOFXTVAPVLX-YWQHLDGFSA-N Leucomycin A1 Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 IEMDOFXTVAPVLX-YWQHLDGFSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- DMUAPQTXSSNEDD-QALJCMCCSA-N Midecamycin Chemical compound C1[C@](O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C DMUAPQTXSSNEDD-QALJCMCCSA-N 0.000 description 1
- 208000020128 Mitral stenosis Diseases 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N O-methylsalicylic acid Chemical class COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 1
- 239000004104 Oleandomycin Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- IGVPBCZDHMIOJH-UHFFFAOYSA-N Phenyl butyrate Chemical class CCCC(=O)OC1=CC=CC=C1 IGVPBCZDHMIOJH-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical group N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 229920002517 Poloxamer 338 Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- PWNMXPDKBYZCOO-UHFFFAOYSA-N Prulifloxacin Chemical compound C1=C2N3C(C)SC3=C(C(O)=O)C(=O)C2=CC(F)=C1N(CC1)CCN1CC=1OC(=O)OC=1C PWNMXPDKBYZCOO-UHFFFAOYSA-N 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- VYWWNRMSAPEJLS-MDWYKHENSA-N Rokitamycin Chemical compound C1[C@](OC(=O)CC)(C)[C@@H](OC(=O)CCC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](O)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C VYWWNRMSAPEJLS-MDWYKHENSA-N 0.000 description 1
- 206010040639 Sick sinus syndrome Diseases 0.000 description 1
- 208000007888 Sinus Tachycardia Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- MKFFGUZYVNDHIH-UHFFFAOYSA-N [2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]-propan-2-ylazanium;sulfate Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC(O)=CC(O)=C1.CC(C)NCC(O)C1=CC(O)=CC(O)=C1 MKFFGUZYVNDHIH-UHFFFAOYSA-N 0.000 description 1
- RRDRHWJDBOGQHN-JWCTVYNTSA-N [2-[(2s,5r,8s,11s,14r,17s,22s)-17-[(1r)-1-hydroxyethyl]-22-[[(2s)-2-[[(2s,3r)-3-hydroxy-2-[[(2s)-2-[6-methyloctanoyl(sulfomethyl)amino]-4-(sulfomethylamino)butanoyl]amino]butyl]amino]-4-(sulfomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15 Chemical compound CCC(C)CCCCC(=O)N(CS(O)(=O)=O)[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS(O)(=O)=O)NC1=O RRDRHWJDBOGQHN-JWCTVYNTSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010317 ablation therapy Methods 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960000919 alatrofloxacin Drugs 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 108010060162 alglucerase Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229950009484 amifloxacin Drugs 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000244 anti-pseudomonal effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125688 antiparkinson agent Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 238000010296 bead milling Methods 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000013153 catheter ablation Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960003972 cefacetrile Drugs 0.000 description 1
- RRYMAQUWDLIUPV-BXKDBHETSA-N cefacetrile Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC#N)[C@@H]12 RRYMAQUWDLIUPV-BXKDBHETSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- FUBBGQLTSCSAON-PBFPGSCMSA-N cefaloglycin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)C)C(O)=O)=CC=CC=C1 FUBBGQLTSCSAON-PBFPGSCMSA-N 0.000 description 1
- 229950004030 cefaloglycin Drugs 0.000 description 1
- 229960003866 cefaloridine Drugs 0.000 description 1
- CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960003012 cefamandole Drugs 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960004350 cefapirin Drugs 0.000 description 1
- 229960002420 cefatrizine Drugs 0.000 description 1
- ACXMTAJLYQCRGF-PBFPGSCMSA-N cefatrizine Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC1=CN=N[N]1 ACXMTAJLYQCRGF-PBFPGSCMSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960004489 cefonicid Drugs 0.000 description 1
- DYAIAHUQIPBDIP-AXAPSJFSSA-N cefonicid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004292 ceforanide Drugs 0.000 description 1
- SLAYUXIURFNXPG-CRAIPNDOSA-N ceforanide Chemical compound NCC1=CC=CC=C1CC(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)CC(O)=O)CS[C@@H]21 SLAYUXIURFNXPG-CRAIPNDOSA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960005495 cefotetan Drugs 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960002580 cefprozil Drugs 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- AVGYWQBCYZHHPN-CYJZLJNKSA-N cephalexin monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 AVGYWQBCYZHHPN-CYJZLJNKSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 229940049197 cerezyme Drugs 0.000 description 1
- CYETUYYEVKNSHZ-LGOOQLFJSA-N chembl1200498 Chemical compound CS(O)(=O)=O.C([C@@H]1[C@H]([C@@H]1C1)NC(=O)[C@H](C)NC(=O)[C@@H](N)C)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F CYETUYYEVKNSHZ-LGOOQLFJSA-N 0.000 description 1
- DDPFHDCZUJFNAT-PZPWKVFESA-N chembl2104402 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 DDPFHDCZUJFNAT-PZPWKVFESA-N 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229950001320 clinafloxacin Drugs 0.000 description 1
- QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940108538 colistimethate Drugs 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 108700028201 colistinmethanesulfonic acid Proteins 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- NKLGIWNNVDPGCA-ZDYKNUMJSA-N davercin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)O[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)C)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 NKLGIWNNVDPGCA-ZDYKNUMJSA-N 0.000 description 1
- 229950010035 davercin Drugs 0.000 description 1
- 125000005534 decanoate group Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 229920000359 diblock copolymer Polymers 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 229960004100 dirithromycin Drugs 0.000 description 1
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical group [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- JMGZBMRVDHKMKB-UHFFFAOYSA-L disodium;2-sulfobutanedioate Chemical compound [Na+].[Na+].OS(=O)(=O)C(C([O-])=O)CC([O-])=O JMGZBMRVDHKMKB-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 108700032313 elcatonin Proteins 0.000 description 1
- 229960000756 elcatonin Drugs 0.000 description 1
- 230000009177 electrical depolarization Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001903 ergotamine tartrate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960003306 fleroxacin Drugs 0.000 description 1
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 description 1
- 229960004273 floxacillin Drugs 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- XOEUHCONYHZURQ-HNUBZJOYSA-N flurithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@@](C)(F)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 XOEUHCONYHZURQ-HNUBZJOYSA-N 0.000 description 1
- 229960001398 flurithromycin Drugs 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000000174 gluconic acid Chemical class 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 229960000642 grepafloxacin Drugs 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 229960003884 hetacillin Drugs 0.000 description 1
- DXVUYOAEDJXBPY-NFFDBFGFSA-N hetacillin Chemical compound C1([C@@H]2C(=O)N(C(N2)(C)C)[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 DXVUYOAEDJXBPY-NFFDBFGFSA-N 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical class OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 239000008350 hydrogenated phosphatidyl choline Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000003752 hydrotrope Substances 0.000 description 1
- DNZMDASEFMLYBU-RNBXVSKKSA-N hydroxyethyl starch Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]1O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]1OCCO DNZMDASEFMLYBU-RNBXVSKKSA-N 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- 229940005535 hypnotics and sedatives Drugs 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 108010039650 imiglucerase Proteins 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- GSOSVVULSKVSLQ-JJVRHELESA-N imipenem hydrate Chemical compound O.C1C(SCCNC=N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 GSOSVVULSKVSLQ-JJVRHELESA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000003990 inverse gas chromatography Methods 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 229960001361 ipratropium bromide Drugs 0.000 description 1
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 1
- 229950003514 irloxacin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical class CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- 208000021803 junctional tachycardia Diseases 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229960000433 latamoxef Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000001459 lithography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 208000004731 long QT syndrome Diseases 0.000 description 1
- 229960001977 loracarbef Drugs 0.000 description 1
- JAPHQRWPEGVNBT-UTUOFQBUSA-N loracarbef Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C([O-])=O)=O)[NH3+])=CC=CC=C1 JAPHQRWPEGVNBT-UTUOFQBUSA-N 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 229940066294 lung surfactant Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940042006 metaproterenol sulfate Drugs 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical class COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229960002757 midecamycin Drugs 0.000 description 1
- KVZUWEFUEGGULL-GNEXTGJLSA-N mideplanin Chemical compound CC(C)CCCCCCC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)OC=2C(=CC(=CC=2)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@H]2C(N[C@H](C3=CC(O)=CC(O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C3C=3C(O)=CC=C(C=3)[C@@H](NC3=O)C(=O)N2)C(=O)NCCCN(C)C)=O)Cl)=C(OC=2C(=CC(C[C@H](C(N4)=O)NC(=O)[C@@H](N)C=5C=C(O6)C(O)=CC=5)=CC=2)Cl)C=C1[C@H]3NC(=O)[C@@H]4C1=CC6=CC(O)=C1 KVZUWEFUEGGULL-GNEXTGJLSA-N 0.000 description 1
- 229950000714 mideplanin Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960000931 miocamycin Drugs 0.000 description 1
- GQNZGCARKRHPOH-RQIKCTSVSA-N miocamycin Chemical compound C1[C@](OC(C)=O)(C)[C@@H](OC(=O)CC)[C@H](C)O[C@H]1O[C@H]1[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(C)=O)[C@H](C)C[C@@H]2CC=O)OC)O[C@@H]1C GQNZGCARKRHPOH-RQIKCTSVSA-N 0.000 description 1
- 208000006887 mitral valve stenosis Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001565 modulated differential scanning calorimetry Methods 0.000 description 1
- 229930189775 mogroside Natural products 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 239000002052 molecular layer Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940041009 monobactams Drugs 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 208000017972 multifocal atrial tachycardia Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 235000008486 nectar Nutrition 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical class CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229960002351 oleandomycin Drugs 0.000 description 1
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 1
- 235000019367 oleandomycin Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960002625 pazufloxacin Drugs 0.000 description 1
- 229960004236 pefloxacin Drugs 0.000 description 1
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 1
- 150000002961 penems Chemical class 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 229960004624 perflexane Drugs 0.000 description 1
- WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
- 229960001217 perflubron Drugs 0.000 description 1
- 229950011087 perflunafene Drugs 0.000 description 1
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 1
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical class OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 208000014321 polymorphic ventricular tachycardia Diseases 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical class CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical class OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 1
- 229960001224 prulifloxacin Drugs 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 238000012383 pulmonary drug delivery Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 229960001170 rokitamycin Drugs 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000005029 sieve analysis Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229960003177 sitafloxacin Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229960004954 sparfloxacin Drugs 0.000 description 1
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical class OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000003445 sucroses Chemical class 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 125000004964 sulfoalkyl group Chemical group 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- 229960004576 temafloxacin Drugs 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 229950008187 tosufloxacin Drugs 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 229960005041 troleandomycin Drugs 0.000 description 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- GDJZZWYLFXAGFH-UHFFFAOYSA-M xylenesulfonate group Chemical group C1(C(C=CC=C1)C)(C)S(=O)(=O)[O-] GDJZZWYLFXAGFH-UHFFFAOYSA-M 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- Cardiac arrhythmia (also dysrhythmia) is a term for any of a large and heterogeneous group of conditions in which there is abnormal electrical activity in the heart.
- the heart beat may be too fast or too slow and may be regular or irregular.
- Atrial arrhythmia therapy is a field with a high level of unmet clinical need.
- Many drugs used today have been on the market since the early 1980s and 1990s and are mostly inadequate due to either lack of efficacy or a side-effect profile that is often cardiac related, which necessitates extensive monitoring of the patient.
- Cardiac arrhythmias are associated with disabling symptoms like tightness around the chest, palpitations, feeling tired, shortness of breath, and sometimes chest pain. Arrhythmias frequently result in emergency room (ER) visits where intravenous drugs are administered, sometimes necessitating an extended stay in the hospital and in some cases also leading to unplanned invasive procedures.
- ER emergency room
- the present disclosure provides pharmaceutical compositions, comprising a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof, and cyclodextrin, wherein said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 5 :95 to about 95:5, and wherein said pharmaceutical composition is in a form of an inhalable dry powder.
- said cyclodextrin is selected from the group consisting of a- cyclodextrin, P-cyclodextrin, y-cyclodextrin, hydroxypropyl-P-cyclodextrin, hydroxyethyl-P- cyclodextrin, hydroxypropyl-y-cyclodextrin, hydroxyethyl-y-cyclodextrin, dihydroxypropyl-P- cyclodextrin, glucosyl-a-cyclodextrin, glucosyl-P-cyclodextrin, diglucosyl-P-cyclodextrin, maltosyl-a-cyclodextrin, maltosyl-P-cyclodextrin, maltotriosyl-P- cyclodextrin, maltotriosyl-y-cyclodextrin dimal
- the present disclosure provides pharmaceutical compositions, comprising a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof, and_hydroxypropyl-P-cyclodextrin, wherein said pharmaceutical composition is in a form of an inhalable dry powder.
- said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 5 :95 to about 95:5. In some embodiments, said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 10:90 to about 90: 10, from about 15:85 to about 85: 15, from about 20:80 to about 80:20, from about 25:75 to about 75:25, from about 30:70 to about 70:30, from about 35:65 to about 65:35, from about 40:60 to about 60:40, or from about 45:55 to about 55:45.
- said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio of about 50:50. In some embodiments, said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio of about 23 :77.
- said pharmaceutical composition further comprises a pharmaceutically acceptable excipient or carrier.
- the pharmaceutically acceptable excipient or carrier comprises lactose, mannitol, sorbitol, erythritol, raffinose, sucrose, xylitol, trehalose, dextrose, a cyclodextrin, maltitol, maltose, glucose, hydroxyapatite, or any combination thereof.
- the pharmaceutically acceptable excipient or carrier comprises porous particles, a crystallization inhibitor, a biodegradable polymer, ammonium bicarbonate, an amino acid, or any combination thereof.
- the crystallization inhibitor comprises polymers, polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), polysaccharide, hydroxypropyl methylcellulose (HPMC or Hypromellose), hydroxy ethyl cellulose (HEC), hydroxypropyl cellulose (HPC), polyethylene oxide, hydroxypropyl-P-cyclodextrin (HP- P-CD), sulfobutylether-P-cyclodextrin, hydroxypropyl methylcellulose acetate succinate (HPMC- AS-HF), polyethylene glycol (PEG), or any combination thereof.
- the pharmaceutically acceptable excipient or carrier comprises L-leucine or L-isoleucine.
- reconstitution of said pharmaceutical composition at a concentration of 9 mg/mL in water to 10 mg/mL affords a solution with a pH of about 5.0 to about 8.0. In some embodiments, reconstitution of said pharmaceutical composition at a concentration of 9 mg/mL in water to 10 mg/mL affords a solution with a pH of about 5.5 to about 7.0. In some embodiments, reconstitution of said pharmaceutical composition at a concentration of 9 mg/mL in water to 10 mg/mL affords a solution with a pH of about 6.7.
- said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof comprises flecainide acetate.
- said pharmaceutical composition further comprises an acid.
- said acid comprises acetic acid, aconitic acid, adipic acid, alginic acid, benzoic acid, caprylic acid, citric acid, cholic acid, formic acid, lactic acid, linoleic acid, malic acid, maleic acid, propionic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, tartaric acid, glutamic acid, hydrochloric acid, phosphoric acid, ascorbic acid, erythorbic acid, sorbic acid, thiodipropionic acid, or any combination thereof.
- said acid comprises acetic acid.
- said dry inhalable powder is formulated for administration via oral inhalation.
- said dry powder has a mass median aerodynamic diameter of about 0.3 pm to about 20 pm. In some embodiments, said dry powder has a mass median aerodynamic diameter of about 4.0 pm. In some embodiments, said dry powder has a mass median aerodynamic diameter of about 5.0 pm. In some embodiments, said dry powder has a mass median aerodynamic diameter of about 6.0 pm.
- said pharmaceutical composition has a glass transition temperature of about 15 °C to about 70 °C. In some embodiments, said pharmaceutical composition has a glass transition temperature of about 45.0 °C. In some embodiments, said pharmaceutical composition has a glass transition temperature of about 65.0 °C. In some embodiments, said glass transition temperature is measured by Differential Scanning Calorimetry (DSC).
- DSC Differential Scanning Calorimetry
- said pharmaceutical composition described herein is in the form of a unit dose, comprising about 50 mg to about 350 mg of said flecainide or said pharmaceutically acceptable salt thereof.
- said unit dose comprises from about 100 mg to about 150 mg of said flecainide or said pharmaceutically acceptable salt thereof.
- kits comprising a pharmaceutical composition described herein or a unit dose described herein and instructions for use of said pharmaceutical composition for treatment of a heart condition.
- said kit further comprising a container that contains said pharmaceutical composition.
- said container is selected from the group consisting of a capsule, blister pack, blister strip, reservoir, and cartridge.
- kits comprising a pharmaceutical composition that comprises a therapeutically effective amount of flecainide or pharmaceutically acceptable salt thereof, and a cyclodextrin, a receptacle containing said pharmaceutical composition, instructions for use of a dry powder inhaler for inhalation of a dose of said pharmaceutical composition in aerosol to a subject, wherein said pharmaceutical composition is in the form of an inhalable dry powder, and wherein said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 5:95 to about 95:5.
- kit comprises a unit dose of said pharmaceutical composition
- said unit dose comprises from about 50 mg to about 350 mg of said flecainide or said pharmaceutical acceptable salt thereof.
- the present disclosure provides systems, comprising a pharmaceutical composition described herein and a dry powder inhaler.
- said system further comprising instructions for use of said dry powder inhaler and said pharmaceutical composition for treatment of a heart condition.
- said heart condition comprises atrial arrhythmia.
- said instructions contain instructions for use of said dry powder inhaler to deliver said pharmaceutical composition in a unit dose that comprises from about 50 mg to about 350 mg of flecainide or said pharmaceutically acceptable salt thereof.
- the present disclosure provides systems, comprising a pharmaceutical composition that comprises a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof, and a cyclodextrin, a dry powder inhaler configured to deliver said pharmaceutical composition as an inhalable dry powder, instructions for use of said dry powder inhaler to deliver said pharmaceutical composition in a unit dose that comprises about 50 mg to about 350 mg amount of flecainide or said pharmaceutically acceptable salt thereof, wherein said pharmaceutical composition is in the form of an inhalable dry powder that has said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 5:95 to about 95:5.
- the present disclosure provides methods of treating a subject suffering from a heart condition, comprising administering to said subject via inhalation a pharmaceutical composition in the form of an inhalable dry powder, wherein said pharmaceutical composition comprises a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof, and a cyclodextrin, wherein said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 5 :95 to about 95:5.
- said cyclodextrin is selected from the group consisting of: a- cyclodextrin, P-cyclodextrin, y-cyclodextrin, hydroxypropyl-P-cyclodextrin, hydroxyethyl-P- cyclodextrin, hydroxypropyl-y-cyclodextrin, hydroxyethyl-y-cyclodextrin, dihydroxypropyl-P- cyclodextrin, glucosyl-a-cyclodextrin, glucosyl-P-cyclodextrin, diglucosyl-P-cyclodextrin, maltosyl-a-cyclodextrin, maltosyl-P-cyclodextrin, maltotriosyl-P- cyclodextrin, maltotriosyl-y-cyclodextrin dim
- said cyclodextrin comprises hydroxypropyl-P-cyclodextrin.
- said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof comprises from about 50 mg to about 350 mg of flecainide or said pharmaceutically acceptable salt thereof.
- said administration of said pharmaceutical composition is performed in up to six inhalation sessions. In some embodiments, said administration of said pharmaceutical composition is performed in one or two inhalation sessions. In some embodiments, said administration is performed via a dry powder inhaler.
- said heart condition comprises atrial arrhythmia. In some embodiments, said atrial arrhythmia comprises tachycardia. In some embodiments, comprising acute treatment after detection of said atrial arrhythmia. In some embodiments, said heart condition comprises atrial fibrillation. In some embodiments, said atrial fibrillation is recurrent atrial fibrillation. In some embodiments, said atrial fibrillation is paroxysmal atrial fibrillation.
- the present disclosure provides methods, comprising converting a solution containing flecainide to an inhalable dry powder, thereby producing a pharmaceutical composition described herein.
- said converting said solution containing flecainide to said inhalable dry powder comprises using spray drying, freeze drying, spray-freeze drying, emulsion spray drying, or an aerosol flow reactor method.
- said spray drying comprises spray drying at a solution flow rate of about 1.0 g/min to about 15.0 g/min, an atomization pressure of about 10 psi to about 100 psi, an inlet temperature of about 100 °C to about 200 °C, or an outlet temperature of about 40 °C to about 70 °C.
- said spray drying comprises spray drying a solution flow rate of about 1.0 g/min to about 15.0 g/min, an atomization pressure of about 10 psi to about 100 psi, an inlet temperature of about 100 °C to about 200 °C, and an outlet temperature of about 40 °C to about 70 °C.
- said solution containing flecainide further comprises a cyclodextrin.
- said cyclodextrin comprises hydroxypropyl-P-cyclodextrin.
- said solution containing flecainide further comprises an acid.
- said acid comprises acetic acid, aconitic acid, adipic acid, alginic acid, benzoic acid, caprylic acid, citric acid, cholic acid, formic acid, lactic acid (e.g., D-(-)-lactic acid or L-(+)-lactic acid), linoleic acid, malic acid, maleic acid, propionic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, tartaric acid, glutamic acid, hydrochloric acid, phosphoric acid, ascorbic acid, erythorbic acid, sorbic acid, thiodipropionic acid, or any combination thereof.
- said acid comprises acetic acid.
- said solution containing flecainide is prepared by dissolving flecainide or a pharmaceutically acceptable salt thereof, cyclodextrin, and pH buffer agents in water, thereby providing said solution containing flecainide.
- said cyclodextrin is selected from the group consisting of: a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, hydroxypropyl-P- cyclodextrin, hydroxyethyl-P-cyclodextrin, hydroxypropyl-y-cyclodextrin, hydroxyethyl-y- cyclodextrin, dihydroxypropyl-P-cyclodextrin, glucosyl-a-cyclodextrin, glucosyl-P-cyclodextrin, diglucosyl-P-cyclodextrin, maltosyl-a-cyclodextrin, maltosyl-P-cyclodextrin, mal
- said cyclodextrin comprises hydroxypropyl-P-cyclodextrin.
- said converting said solution containing flecainide further comprises heating said solution containing flecainide. In some embodiments, comprising heating said solution containing flecainide to about 40 °C. In some embodiments, said solution containing flecainide is cooled to 25 °C prior to spray drying. In some embodiments, said flecainide solution is diluted with water prior to spray drying. In some embodiments, pH of said solution containing flecainide is adjusted to about 6.0 using said a pH buffer agent prior to spay drying. In some embodiments, said pH buffer agent comprises sodium hydroxide.
- reconstitution of said inhalable dry powder pharmaceutical composition at a concentration of 9 mg/mL to 10 mg/mL in water affords a solution with a pH of about 5.0 to about 8.0. In some embodiments, reconstitution of said inhalable dry powder pharmaceutical composition at a concentration of 9 mg/mL to 10 mg/mL in water affords a solution with a pH of about 5.5 to about 7.0. In some embodiments, reconstitution of said inhalable dry powder pharmaceutical composition at a concentration of 9 mg/mL to 10 mg/mL in water affords a solution with a pH of about 6.7. In some embodiments, the inhalable dry powder pharmaceutical composition has a mass median aerodynamic diameter of about 0.3 pm to about 20 pm.
- said pharmaceutical composition has a glass transition temperature of about 15 °C to about 70 °C.
- said flecainide or said pharmaceutically acceptable salt thereof comprises flecainide acetate.
- said method further comprising packaging said pharmaceutical composition in unit dose form.
- said unit dose form further comprises a container selected from the group consisting of: a capsule, blister pack, blister strip, reservoir, and cartridge.
- FIG. 1 illustrates the particle size distribution of flecainide acetate powder.
- FIG. 2 illustrates X-ray powder diffraction (XRPD) data obtained from pure flecainide acetate drug and processed neat flecainide acetate.
- XRPD X-ray powder diffraction
- FIG. 3 illustrates XRPD data obtained from 20% w/w flecainide acetate, 48% w/w flecainide acetate, and 70% w/w flecainide acetate with leucine.
- FIG. 4 illustrates XRPD data obtained from neat flecainide acetate and non-powder forming formulations.
- FIG. 5 illustrates the particle size distribution flecainide acetate spray dried powders (Batch J - Batch N).
- FIG. 6 illustrates non-reversing heat flow signals observed via differential scanning calorimetry (DSC) analysis of flecainide acetate spray dried powders (Batch J - Batch N).
- FIG. 7 illustrates reversing heat flow signals observed via DSC analysis of flecainide acetate spray dried powders (Batch J - Batch N).
- FIG. 8 illustrates XRPD diffractograms of flecainide acetate spray dried powders (Batch J - Batch N).
- FIG. 9 illustrates the dynamic vapor sorption (DVS) isotherm profile of a 23/77 (w/w) flecainide acetate/HP-P-CD spray dried formulation prepared from a nebulization solution preparation (Batch J).
- DVS dynamic vapor sorption
- FIG. 10 illustrates the DVS isotherm profile of a 23/77 (w/w) flecainide acetate/HP-P-CD spray dried formulation prepared from a nebulization solution preparation at lower feed rate (Batch K).
- FIG. 11 illustrates the DVS isotherm profile of a 23/77 (w/w) flecainide acetate/HP-P-CD spray dried formulation (Batch M, direct solution preparation).
- FIG. 12 illustrates DVS isotherms of flecainide acetate spray dried powder Batches J, K, and M.
- FIG. 13 illustrates a DVS mass change profile of flecainide acetate spray dried powder Batch J.
- FIG. 14 illustrates a DVS mass change profile for flecainide acetate spray dried powder Batch K.
- FIG. 15 illustrates a DVS mass change profile for flecainide acetate spray dried powder Batch M.
- FIG. 16 illustrates particle size distributions of flecainide acetate spray powders stored at 40 °C / 75% RH in a closed container for 1 month.
- FIG. 17 illustrates reversing heat flow signals observed via DSC analysis of flecainide acetate spray dried powders stored in closed containers for 1 -month (Batches J, K, and M).
- FIG. 18 illustrates non-reversing heat flow signals observed via DSC analysis of flecainide acetate spray dried powders stored in closed containers for 1 month (Batches J, K, and M).
- FIG. 19 illustrates reversing heat flow signals observed via DSC analysis of flecainide acetate spray dried powders stored in open containers for 1 month.
- FIG. 20 illustrates non-reversing heat flow signals observed via DSC analysis of flecainide acetate spray dried powders stored in closed containers for 1 month.
- FIG. 21 illustrates an overlay of XRPD diffractograms of flecainide acetate spray dried powder Batches J-M after storage for 1 month.
- FIG. 22 illustrates total and reversing heat flow signals observed via DSC analysis of flecainide acetate spray dried powder Batch J.
- FIG. 23 illustrates total and reversing heat flow signals observed via DSC analysis of flecainide acetate spray dried powder Batch K.
- FIG. 24 illustrates total and reversing heat flow signals observed via DSC analysis of analysis of flecainide acetate spray dried powder Batch L.
- FIG. 25 illustrates total and reversing heat flow signals observed via DSC analysis of analysis of flecainide acetate spray dried powder Batch M.
- FIG. 26 illustrates total and reversing heat flow signals observed via DSC analysis of analysis of flecainide acetate spray dried powder Batch N.
- the present disclosure relates to a novel inhalable dry powder formulation comprising a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and a cyclodextrin for treatment of a heart condition (e.g., cardiac arrhythmic) in a subject in need thereof.
- a heart condition e.g., cardiac arrhythmic
- methods of treatment comprising administering a novel formulation comprising a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and a cyclodextrin for treatment of a heart condition (e.g., cardiac arrhythmic) in a subject in need thereof.
- the pharmaceutical composition is inhalable when delivered via a dry powder inhaler for the treatment of a heart condition e.g., atrial fibrillation (AF)) in a subject in need thereof.
- AF atrial fibrillation
- the pharmaceutical composition and the method of treatment provided herein are advantageous in offering a fast, efficient, and safe therapeutic solution to heart conditions, such as cardiac arrhythmia, including atrial arrhythmia.
- the present disclosure relates to inhalational administration of a pharmaceutical composition in the form of an inhalable dry powder that comprises flecainide or pharmaceutically acceptable salt thereof and a cyclodextrin or pharmaceutically acceptable salt thereof.
- the pharmaceutical composition or formulation provided herein enables delivery of a greater quantity of pharmaceutically active ingredient, e.g., flecainide, to the subject.
- the subject pharmaceutical composition or formulation has an increased weight ratio of flecainide or pharmaceutically acceptable salt thereof to cyclodextrin as compared to a corresponding flecainide formulation (e.g., flecainide to cyclodextrin weight ratio of 50/50 compared to a weight ratio of 20/80).
- the increased weight ratio of flecainide or pharmaceutically acceptable salt thereof increases the amount of flecainide administered via inhalation.
- the increased flecainide weight ratio to cyclodextrin shortens the inhalation duration as a given dose can be delivered at a higher speed as compared to a corresponding formulation with a lower weight of flecainide to cyclodextrin. Shortening the period of time required for a subject to completely inhale a target dose can improve subject compliance, which can further increase the delivery efficiency of the drug.
- the pharmaceutical composition or formulation provided herein reduces adverse cough of the subject while inhaling, has improved organoleptic properties, and improves overall patient experience of inhalation. In some embodiments, the improved overall inhalation experience results in better compliance with the full inhalation program. In some embodiments, more effective drug delivery is achieved when the subject has better inhalation compliance, and thus more drug is delivered.
- kits comprising the pharmaceutical composition or the unit dose provided herein and instructions for use of the pharmaceutical composition for treatment of a heart condition (e.g., cardiac arrhythmia, e.g., atrial arrhythmia).
- a heart condition e.g., cardiac arrhythmia, e.g., atrial arrhythmia
- the pharmaceutical composition comprises a anti arrhythmic pharmaceutical agent.
- the anti arrhythmic pharmaceutical agent is flecainide or therapeutically acceptable salt thereof.
- the pharmaceutically acceptable salt of flecainide is flecainide acetate.
- the anti arrhythmic pharmaceutical agent is a flecainide derivative (e.g., QX-FL, NU-FL) or pharmaceutically acceptable salt thereof.
- Flecainide is N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2- trifluoroethoxy)benzamide, which has the structure:
- a cyclodextrin is used as a solubility enhancer of a flecainide salt.
- Cyclodextrins are cyclic carbohydrates derived from starch. The unmodified cyclodextrins differ by the number of glucopyranose units joined together in the cylindrical structure. The parent cyclodextrins contain 6, 7, or 8 glucopyranose units and are referred to as a- , P-, and y-cyclodextrin respectively.
- Each cyclodextrin subunit can have secondary hydroxyl groups at the 2 and 3 positions and a primary hydroxyl group at the 6-position.
- the cyclodextrins can be pictured as hollow truncated cones with hydrophilic exterior surfaces and hydrophobic interior cavities. In aqueous solutions, these hydrophobic cavities can sequester hydrophobic organic compounds that can fit all or part of their structure into these cavities. This process, known as inclusion complexation, can result in increased apparent aqueous solubility and stability for the complexed drug.
- Non-limiting examples of a cyclodextrin suitable for inclusion in a pharmaceutical composition provided herein can include a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, derivatized a-cyclodextrins, derivatized P-cyclodextrins, and derivatized y-cyclodextrins.
- Nonlimiting examples of a cyclodextrin that can be used in the subject pharmaceutical composition include a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, hydroxypropyl-P-cyclodextrin, hydroxyethyl-P-cyclodextrin, hydroxypropyl -y-cyclodextrin, hydroxyethyl-y-cyclodextrin, dihydroxypropyl-P-cyclodextrin, glucosyl-a-cyclodextrin, glucosyl-P-cyclodextrin, diglucosyl-P- cyclodextrin, maltosyl-a-cyclodextrin, maltosyl-P-cyclodextrin, maltotriosyl-P-cyclodextrin, maltotriosyl-y-cyclodextrin dimaltosyl
- the pharmaceutical composition comprises hydroxypropyl- P-cyclodextrin (HPpCD).
- HPpCD hydroxypropyl- P-cyclodextrin
- the pharmaceutical composition comprises more than one species of cyclodextrin, such as, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different species of cyclodextrin.
- the pharmaceutical composition comprises HPpCD and one or more other cyclodextrins, such as, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more other different species of cyclodextrin.
- the cyclodextrin is selected from the group consisting of: a- cyclodextrin, P-cyclodextrin, y-cyclodextrin, derivatized a-cyclodextrins, derivatized P- cyclodextrins, and derivatized y-cyclodextrins.
- the cyclodextrin is selected from the group consisting of: a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, hydroxypropyl-P- cyclodextrin, hydroxyethyl-P-cyclodextrin, hydroxypropyl-y-cyclodextrin, hydroxyethyl-y- cyclodextrin, dihydroxypropyl-P-cyclodextrin, glucosyl-a-cyclodextrin, glucosyl-P-cyclodextrin, diglucosyl-P-cyclodextrin, maltosyl-a-cyclodextrin, maltosyl-P-cyclodextrin, maltosyl-y- cyclodextrin, maltotriosyl-P-cyclodextrin, maltotriosyl-y-cyclodextrin, dimaltosyl
- the concentration of the cyclodextrin contributes to the viscosity of the solution, which can reduce the nebulization efficiency (or rate) of the solution. For instance, in some cases, the higher the concentration of the cyclodextrin is, the higher viscosity of the solution is.
- the concentration of the cyclodextrin in the pharmaceutical composition is controlled so that the viscosity of the solution is not higher than a reference value, such as about 1.0, 1.1, 1.2, 1.3 cP, 1.4 cP, 1.5 cP, 1.6 cP, 1.7 cP, 1.8 cP, 1.9 cP, 2.0, 2.1 cP, 2.2 cP, 2.3 cP, 2.4 cP, 2.5 cP, 2.6 cP, 2.7 cP, 2.8 cP, 2.9 cP, 3.0 cP, 3.1 cP, 3.2 cP, 3.3 cP, 3.4 cP, 3.5 cP, 3.6 cP, 3.7 cP, 3.8 cP, 3.9 cP, 4.0 cP, 4.1 cP, 4.2 cP, 4.3 cP, 4.4 cP, 4.5 cP, 4.6 cP, 4.7 cP
- the pharmaceutical compositions described herein comprises a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and a cyclodextrin in weight ratio from about 5:95 to about 95:5.
- flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 15:85 to about 95:5. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 25:75 to about 95:5. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 35:65 to about 95:5. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 45:55 to about 95:5.
- flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 55:45 to about 95:5. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 65:35 to about 95:5. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 75:25 to about 95:5. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 85: 15 to about 95:5.
- flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95 to about 85: 15. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95 to about 75:25. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95 to about 65:35. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95 to about 55:45.
- flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95 to about 45:55. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95 to about 35:65. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95 to about 25:75. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95 to about 15:85.
- flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95, about 15:85, about 25:75, about 35:65, about 45:55, about 55:45, about 65:35, about 75:25, about 85: 15, or about 95:5.
- the presence of a cyclodextrin in the pharmaceutical composition can reduce the concentration of acid that is required to achieve a desirable concentration of flecainide salt according to some aspects of the present disclosure.
- the presence of a cyclodextrin e.g., HPpCD
- increases flecainide solubility e.g., through inclusion complexation that “dissolves” flecainide salt (e.g., flecainide acetate) inside the cavity of the cyclodextrin.
- the inclusion complexation can decopule the solubility of flecainide and the acidicity (the low pH) of the solution.
- cyclodextrin e.g., HPpCD
- the introduction of cyclodextrin can lead to reduction in the concentration of acid necessary to maintain sufficient flecainide solubility, and can synergistically lead to increased flecainide concentration in the solution, improved organoleptic properties, increased delivery speed, and improved delivery efficiency.
- the acid enhances solubility of flecainide.
- flecainide freebase has a low solubility, e.g., in water.
- certain salts of flecainide have higher solubility as compared to other salts of flecainide and flecainide freebase.
- flecainide acetate can have a higher solubility as compared to some other flecainide salts.
- the acid is provided in the pharmaceutical composition to provide the proton and anion for flecainide salt formation.
- acid is provided in the pharmaceutical composition to lower pH to promote solubility of the flecainide salt. In some cases, acid is provided in the pharmaceutical composition to provide the proton and anion for flecainide salt formation and sufficiently lower pH to ensure the solubility of the flecainide salt.
- a mixture of more than one acid increases flecainide solubility as compared to a single acid.
- the pharmaceutical composition comprises acetic acid as the single acid.
- the pharmaceutical composition comprises citric acid as the single acid.
- the pharmaceutical composition comprises a mixture of different acids.
- the pharmaceutical composition comprises lactic acid.
- the pharmaceutical composition comprises L-(+)-lactic acid.
- the pharmaceutical composition comprises D-(-)-lactic acid.
- the pharmaceutical composition comprises a mixture of D-(-)-lactic acid and L-(+)-lactic acid, i.e., the pharmaceutical composition comprises DL-lactic acid.
- the pharmaceutical composition comprises ascorbic acid.
- suitable organic or inorganic acid such as any GRAS (Generally Recognized As Safe) listed acid, e.g., acetic acid, aconitic acid, adipic acid, alginic acid, benzoic acid, caprylic acid, citric acid, cholic acid, formic acid, lactic acid (e.g., D-(- )-lactic acid or L-(+)-lactic acid), linoleic acid, malic acid, maleic acid, propionic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, tartaric acid, glutamic acid, hydrochloric acid, phosphoric acid, ascorbic acid, erythorbic acid, sorbic acid, or
- the pharmaceutical composition comprises a mixture of different acids, such as 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different acids.
- the pharmaceutical composition comprises one of the following: acetic acid and nitric acid; acetic acid and sulfuric acid; acetic acid and citric acid; acetic acid, nitric acid, and sulfuric acid; acetic acid, nitric acid, and citric acid; acetic acid, citric acid, and sulfuric acid; or acetic acid, nitric acid, citric acid, and sulfuric acid.
- the dry powder pharmaceutical composition is reconstituted in water.
- the process of reconstitution can involve dissolving the pharmaceutical composition described herein with high purity water, for instance, MilliQ water.
- 120 mg of dry powder pharmaceutical composition described herein is dissolved in 3 mL of water.
- the pharmaceutical composition has a reconstituted pH that is about 5.0 to about 8.0 when the pH is measured at room temperature, such as about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5,9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, about 7.9, or about 8.0 when the pH is measured at room temperature and at a concentration of about 9 mg/mL to about 10 mg/mL.
- the pharmaceutical composition is acidic when reconstituted, e.g., having a pH at most from about at least 5.0 to about at most 8.0.
- the pH of the pharmaceutical composition when reconstituted is at most 5.0, at most 5.1, at most 5.2, at most 5.3, at most 5.4. at most 5.5, at most 5.5, at most 5.6, at most 5.7, at most 5.8, at most 6.0, at most
- the pharmaceutical composition has a pH that is from about 5.5 and about 6.5 when the pH is measured at room temperature, such as from about 5.6 and about 6.4, from about 5.7 and about 6.3, from about 5.8 and about 6.2, or from about 5.9 and about 6.1 when the pH is measured at room temperature and flecainide acetate at a concentration of about 9 mg/mL to about 10 mg/mL.
- the pharmaceutical composition has a reconstituted pH of about 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 7.0, or 8.0 when the pH is measured at room temperature and at a concentration of about 9 mg/mL to about 10 mg/mL. In some examples, the pharmaceutical composition has a reconstituted pH of about 7.4 when the pH is measured at room temperature and at a concentration of about 9 mg/mL to about 10 mg/mL. [0080] Solutions can also comprise a buffer or a pH adjusting agent, typically a salt prepared from an organic acid or base.
- Representative buffers comprise organic acid salts of citric acid, lactic acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetic acid, or phthalic acid, Tris, tromethamine hydrochloride, or phosphate buffers.
- the buffers can include citrates, phosphates, phthalates, and lactates.
- buffers include, but are not limited to, acetate, tris, or citrate.
- acids include, but are not limited to, carboxylic acids.
- salts include, but are not limited to, sodium chloride, salts of carboxylic acids, (e.g., sodium citrate, sodium ascorbate, magnesium gluconate, sodium gluconate, tromethamine hydrochloride), ammonium carbonate, ammonium acetate, ammonium chloride, and the like.
- organic solids include, but are not limited to, camphor, and the like.
- the pharmaceutical composition of one or more embodiments of the present disclosure can also include a biocompatible, such as biodegradable polymer, copolymer, or blend or other combination thereof.
- useful polymers comprise polylactides, polylactide-glycolides, cyclodextrins, polyacrylates, methylcellulose, carboxymethylcellulose, polyvinyl alcohols, polyanhydrides, polylactams, polyvinyl pyrrolidones, polysaccharides (dextrans, starches, chitin, chitosan), hyaluronic acid, proteins, (albumin, collagen, gelatin).
- the delivery efficiency of the composition and/or the stability of the dispersions can be tailored to optimize the effectiveness of the anti arrhythmic pharmaceutical agent(s).
- formulations for treatment of a heart condition e.g., cardiac arrhythmia, e.g., atrial arrhythmia.
- the formulations can include the pharmaceutical compositions provided herein and a pharmaceutically acceptable carrier, excipient, diluent, or any other suitable component for the intended administration routes, such as oral or nasal inhalation.
- pharmaceutically acceptable excipients include, but are not limited to, lipids, metal ions, surfactants, amino acids, carbohydrates, buffers, salts, polymers, sweeteners, and the like, and combinations thereof.
- carbohydrates include, but are not limited to, monosaccharides, disaccharides, and polysaccharides.
- monosaccharides such as dextrose (anhydrous and monohydrate), galactose, mannitol, D-mannose, sorbitol, sorbose and the like
- disaccharides such as lactose, maltose, sucrose, trehalose, and the like
- trisaccharides such as raffinose and the like
- other carbohydrates such as starches (hydroxy ethyl starch), and maltodextrins.
- Non-limiting examples of lipids include phospholipids, glycolipids, ganglioside GM1, sphingomyelin, phosphatidic acid, cardiolipin; lipids bearing polymer chains such as polyethylene glycol, chitin, hyaluronic acid, or polyvinylpyrrolidone; lipids bearing sulfonated mono-, di-, and polysaccharides; fatty acids such as palmitic acid, stearic acid, and oleic acid; cholesterol, cholesterol esters, and cholesterol hemisuccinate.
- lipids include phospholipids, glycolipids, ganglioside GM1, sphingomyelin, phosphatidic acid, cardiolipin; lipids bearing polymer chains such as polyethylene glycol, chitin, hyaluronic acid, or polyvinylpyrrolidone; lipids bearing sulfonated mono-, di-, and polysaccharides; fatty acids such as palmitic
- the phospholipid comprises a saturated phospholipid, such as one or more phosphatidylcholines.
- exemplary acyl chain lengths are 16:0 and 18:0 e.g., palmitoyl and stearoyl).
- the phospholipid content can be determined by the active agent activity, the mode of delivery, and other factors.
- Phospholipids from both natural and synthetic sources can be used in varying amounts. When phospholipids are present, the amount is typically sufficient to coat the active agent(s) with at least a single molecular layer of phospholipid. In general, the phospholipid content ranges from about 5 wt% to about 99.9 wt%, such as about 20 wt% to about 80 wt%.
- compatible phospholipids can comprise those that have a gel to liquid crystal phase transition greater than about 40 °C, such as greater than about 60 °C, or greater than about 80 °C.
- the incorporated phospholipids can be relatively long chain (e.g., C16-C22) saturated lipids.
- Exemplary phospholipids useful in the present disclosure include, but are not limited to, phosphoglycerides such as dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, diarachidoylphosphatidylcholine, dibehenoylphosphatidylcholine, diphosphatidyl glycerols, short-chain phosphatidylcholines, hydrogenated phosphatidylcholine, E-100-3 (available from Lipoid KG, Ludwigshafen, Germany), long-chain saturated phosphatidylethanolamines, long- chain saturated phosphatidylserines, long-chain saturated phosphatidylglycerols, long-chain saturated phosphatidylinositols, phosphatidic acid, phosphatidylinositol, and sphingomyelin.
- phosphoglycerides such as dipalmitoylphosphatidylcholine, diste
- metal ions include, but are not limited to, divalent cations, including calcium, magnesium, zinc, iron, and the like.
- the pharmaceutical composition can also comprise a polyvalent cation, as disclosed in WO 01/85136 and WO 01/85137, which are incorporated herein by reference in their entireties.
- the polyvalent cation can be present in an amount effective to increase the melting temperature (T m ) of the phospholipid such that the pharmaceutical composition exhibits a T m which is greater than its storage temperature (T m ) by at least about 20 °C, such as at least about 40 °C.
- the molar ratio of polyvalent cation to phospholipid can be at least about 0.05: 1, such as about 0.05: 1 to about 2.0: 1 or about 0.25: 1 to about 1.0: 1. In some embodiments, the molar ratio of polyvalent cation to phospholipid is about 0.50: 1.
- the polyvalent cation is calcium, it can be in the form of calcium chloride. Although metal ion (e.g., calcium) is often included with phospholipid, none is required.
- the pharmaceutical composition can include one or more surfactants.
- one or more surfactants can be in the liquid phase with one or more being associated with solid particles or particles of the composition.
- associated with it is meant that the pharmaceutical compositions can incorporate, adsorb, absorb, be coated with, or be formed by the surfactant.
- surfactants include, but are not limited to, fluorinated and nonfluorinated compounds, such as saturated and unsaturated lipids, nonionic detergents, nonionic block copolymers, ionic surfactants, and combinations thereof. It should be emphasized that, in addition to the aforementioned surfactants, suitable fluorinated surfactants are compatible with the teachings herein and can be used to provide the desired preparations.
- nonionic detergents include, but are not limited to, sorbitan esters including sorbitan trioleate (SpanTM 85), sorbitan sesquioleate, sorbitan monooleate, sorbitan monolaurate, polyoxyethylene (20) sorbitan monolaurate, and polyoxyethylene (20) sorbitan monooleate, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene (2) ether, lauryl polyoxyethylene (4) ether, glycerol esters, and sucrose esters.
- sorbitan esters including sorbitan trioleate (SpanTM 85), sorbitan sesquioleate, sorbitan monooleate, sorbitan monolaurate, polyoxyethylene (20) sorbitan monolaurate, and polyoxyethylene (20) sorbitan monooleate, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene (2) ether, lauryl polyoxyethylene (4) ether, glycerol esters
- block copolymers include, but are not limited to, diblock and triblock copolymers of polyoxyethylene and poly oxypropylene, including pol oxamer 188 (PluronicTM F- 68), poloxamer 407 (PluronicTM F-127), and poloxamer 338.
- ionic surfactants include, but are not limited to, sodium sulfosuccinate, and fatty acid soaps.
- amino acids include, but are not limited to hydrophobic amino acids, for instance, L-leucin or L-isoleucin. Use of amino acids as pharmaceutically acceptable excipients is known in the art as disclosed in WO 95/31479, WO 96/32096, and WO 96/32149, which are incorporated herein by reference in their entireties.
- the pharmaceutical composition according to one or more embodiments of the disclosure may, if desired, contain a combination of anti arrhythmic pharmaceutical agent (e.g., flecainide salt) and one or more additional active agents.
- anti arrhythmic pharmaceutical agent e.g., flecainide salt
- additional active agents include, but are not limited to, agents that can be delivered through the lungs.
- Additional active agents can comprise, for example, hypnotics and sedatives, psychic energizers, tranquilizers, respiratory drugs, anticonvulsants, muscle relaxants, antiparkinson agents (dopamine antagonists), analgesics, anti-inflammatories, antianxiety drugs (anxiolytics), appetite suppressants, antimigraine agents, muscle contractants, additional anti-infectives (antivirals, antifungals, vaccines) antiarthritics, antimalarials, antiemetics, antiepileptics, cytokines, growth factors, anti-cancer agents, antithrombotic agents, antihypertensives, cardiovascular drugs, antiarrhythmics, antioxidants, anti-asthma agents, hormonal agents including contraceptives, sympathomimetics, diuretics, lipid regulating agents, anti androgenic agents, antiparasitic, anticoagulants, neoplasties, antineoplastics, hypoglycemics, nutritional agents and supplements, growth
- the additional active agent can fall into one of a number of structural classes, including but not limited to small molecules, peptides, polypeptides, proteins, polysaccharides, steroids, proteins capable of eliciting physiological effects, nucleotides, oligonucleotides, polynucleotides, fats, electrolytes, and the like.
- Examples of additional active agents suitable for use in this disclosure include but are not limited to one or more of calcitonin, amphotericin B, erythropoietin (EPO), Factor VIII, Factor IX, ceredase, cerezyme, cyclosporin, granulocyte colony stimulating factor (GCSF), thrombopoietin (TPO), alpha- 1 proteinase inhibitor, elcatonin, granulocyte macrophage colony stimulating factor (GMCSF), growth hormone, human growth hormone (HGH), growth hormone releasing hormone (GHRH), heparin, low molecular weight heparin (LMWH), interferon alpha, interferon beta, interferon gamma, interleukin- 1 receptor, interleukin-2, interleukin- 1 receptor antagonist, interleukin-3, interleukin-4, interleukin-6, luteinizing hormone releasing hormone (LHRH), factor IX, insulin, pro-insulin, insulin
- Additional active agents for use in the disclosure can further include nucleic acids, as bare nucleic acid molecules, vectors, associated viral particles, plasmid DNA or RNA or other nucleic acid constructions of a type suitable for transfection or transformation of cells, e.g., suitable for gene therapy including antisense.
- an active agent can comprise live attenuated or killed viruses suitable for use as vaccines.
- Other useful drugs include those listed within the Physician’s Desk Reference (most recent edition), which is incorporated herein by reference in its entirety.
- the agents can be provided in combination in a single species of pharmaceutical composition or individually in separate species of pharmaceutical compositions.
- compositions of one or more embodiments of the present disclosure can lack taste.
- taste masking agents are optionally included within the composition, the compositions in some embodiments do not include a taste masking agent other than a cyclodextrin and lack taste even without a taste masking agent.
- the pharmaceutical composition provided herein comprises a sweetener to improve the organoleptic properties of the composition.
- the sweetener can be a natural sweet substance, e.g. certain sugars, or an artificial sweetener.
- the presence of the sweetener in the pharmaceutical composition can improve the organoleptic properties of the composition.
- the presence of the sweetener in the pharmaceutical composition can improve the compliance of the subject.
- presence of the sweetener in the pharmaceutical composition increases the delivery efficiency of the composition.
- the presence of the sweetener in the pharmaceutical composition can enhance the therapeutic effects of the composition.
- Non-limiting examples of artificial sweeteners that can be used in the pharmaceutical composition include acesulfame potassium, aspartame, cyclamate, mogrosides, saccharin, stevia, sucralose, neotame, and sugar alcohols (e.g., erythritol, hydrogenated starch hydrolysates, isomalt, lactitol, maltitol, mannitol, sorbitol, and xylitol), such as those used in commercial products, like Sweet n’ low powder sweetener, Truvia powder sweetener, Equal (aspartame), Stevia powder sachet, Aspen Naturals liquid stevia, Now Better Stevia liquid sweetener, Sweet N’ Low liquid sweetener, Quick Sweet: Neotame liquid sweetener, or Splenda powder sachet, or pharmaceutically acceptable salts thereof.
- the pharmaceutical composition comprises saccharin.
- the pharmaceutical composition comprises a salt
- Natural sweet substances that can be used in the pharmaceutical composition include, but are not limited to, sucrose, agave, brown sugar, confectioner’s (powdered) sugar, com syrup, dextrose, fructose, fruit juice concentrate, glucose, high-fructose corn syrup, honey, invert sugar, lactose, malt sugar, maltose, maple syrup, molasses, nectars, raw sugar, and syrup.
- Sugars can increase the viscosity of the liquid solution, thus the concentration of any sugar added into the pharmaceutical composition, in some embodiments, is tightly controlled below a certain threshold value.
- pharmaceutically acceptable excipient or carrier comprises lactose, mannitol, sorbitol, erythritol, raffinose, sucrose, xylitol, trehalose, dextrose, cyclodextrins, maltitol, maltose, glucose, hydroxyapatite, or any combinations thereof.
- compositions can be desirable to add other pharmaceutically acceptable excipients to the pharmaceutical composition to improve particle rigidity, production yield, emitted dose and deposition, shelf-life, and patient acceptance.
- pharmaceutically acceptable excipients include, but are not limited to: coloring agents, taste masking agents, buffers, hygroscopic agents, antioxidants, and chemical stabilizers.
- various pharmaceutically acceptable excipients can be used to provide structure and form to the particle compositions (e.g., latex particles).
- the rigidifying components can be removed using a post-production technique such as selective solvent extraction.
- the pharmaceutical composition comprises crystallization inhibitors.
- Exemplary pharmaceutically acceptable crystallization inhibitors can be, but are not limited to, polymers, polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), polysaccharide, hydroxypropyl methylcellulose (HPMC or Hypromellose), hydroxyethyl cellulose (ELEC), hydroxypropyl cellulose (HPC), polyethylene oxide, hydroxypropyl-P-cyclodextrin (HP-P-CD), sulfobutylether-P-cyclodextrin, hydroxypropyl methylcellulose acetate succinate (HPMC-AS- HF), or polyethylene glycol (PEG).
- PVP polyvinyl pyrrolidone
- PVA polyvinyl alcohol
- HPMC or Hypromellose hydroxyethyl cellulose
- HP-P-CD hydroxypropyl cellulose
- HP-P-CD sulfobutylether-P-cyclod
- the distribution of aerosol particle of an inhalable can be expressed in terms of either: the mass median aerodynamic diameter (MMAD) — the size at which half of the mass of the aerosol is contained in smaller droplets and half in larger droplets; volumetric mean diameter (VMD); mass median diameter (MMD); the fine particle fraction (FPF) — the percentage of particles that are ⁇ 5 um in diameter.
- MMAD mass median aerodynamic diameter
- VMD volumetric mean diameter
- MMD mass median diameter
- FPF fine particle fraction
- Impaction occurs when the momentum of an inhaled particle is large enough that the particle does not follow the air stream and encounters a physiological surface.
- sedimentation occurs primarily in the deep lung when very small particles which have traveled with the inhaled air stream encounter physiological surfaces as a result of random diffusion within the air stream.
- Pulmonary drug delivery can be accomplished by inhalation of an aerosol through the mouth and throat. Particles having a mass median aerodynamic diameter (MMAD) of greater than about 5 microns generally do not reach the lung; instead, they tend to impact the back of the throat and are swallowed and possibly orally absorbed.
- MMAD mass median aerodynamic diameter
- Particles having diameters of about 1 to about 5 microns are small enough to reach the upper-to-mid-pulmonary region (conducting airways), but are too large to reach the alveoli. Smaller particles, z.e., about 0.5 to about 2 microns, are capable of reaching the alveolar region. Particles having diameters smaller than about 0.5 microns can also be deposited in the alveolar region by sedimentation, although very small particles can be exhaled. Measures of particle size can be referred to as volumetric mean diameter (VMD), mass median diameter (MMD), or MMAD. These measurements can be made by impaction (MMD and MMAD) or by laser (VMD).
- VMD volumetric mean diameter
- MMD mass median diameter
- MMAD MMAD
- Inhalable dry powder particle size can be expressed in terms of the mass median aerodynamic diameter (MMAD).
- Large particles e.g., MMAD-5 um
- Small particles e.g., MMAD-2 um
- intolerability e.g., cough and bronchospasm
- the geometric particle size distribution measurement of the dry powder pharmaceutical composition is characterized through standard methods such as cascade impaction, dynamic image analysis, static image analysis, laser diffraction, dynamic light scattering, sieve analysis, microscopic imaging (/. ⁇ ., optical microscopy, electron microscopy) to obtain average particle size, MMAD, VMD, FPF, and MMD.
- the preferable method of geometric particle size characterization is laser diffraction.
- the MMD values are determined by laser diffraction.
- the dry powders samples are added directly to the feeder funnel of the dry powder dispersion unit and are dispersed to primary particles via application of pressurized air (2 to 3 bar), with vacuum depression (suction) maximized for a given dispersion pressure.
- Dispersed particles are probed with a 632.8 nm laser beam that intersects the dispersed particles’ trajectory at right angles.
- Laser light scattered from the ensemble of particles is imaged onto a concentric array of photomultiplier detector elements using a reverse-Fourier lens assembly. Scattered light is acquired in time-slices of 5 ms.
- Particle size distributions are back-calculated from the scattered light spatial/intensity distribution using a proprietary algorithm.
- generation of a defined particle size with limited geometric standard deviation (GSD) can optimize deposition and tolerability.
- GSD geometric standard deviation
- Narrow GSD limits the number of particles outside the desired MMAD size range.
- an aerosol containing one or more compounds disclosed herein is provided having a MMAD from about 2 microns to about 5 microns with a GSD of less than or equal to about 2.5.
- an aerosol having an MMAD from about 2.8 microns to about 4.3 microns with a GSD less than or equal to 2 is provided. In another embodiment, an aerosol having an MMAD from about 2.5 microns to about 4.5 microns with a GSD less than or equal to 1.8 is provided.
- Dry powders can use dry powder inhaler devices (DPIs), which are capable of dispersing the drug substance effectively. Dry powder inhaler devices can use a variety of dosage containers (e.g., capsule, blister pack, blister strip, reservoir, cartridge).
- DPIs dry powder inhaler devices
- dosage containers e.g., capsule, blister pack, blister strip, reservoir, cartridge.
- a desired particle size and distribution can be obtained by choosing an appropriate device.
- the moisture content is typically less than about 15 wt %, such as less than about 10 wt %, less than about 5 wt %, less than about 2 wt %, less than about 1 wt %, or less than about 0.5 wt %.
- Such powders are described in WO95/24183, WO 96/32149, WO 99/16419, WO 99/16420, and WO 99/16422, which are incorporated herein by reference in their entireties.
- DPIs dry powder inhalers
- inhaler device formulation
- inhalation maneuver Preparing ideal DPI formulations requires control overall formulation characteristics at particulate and bulk level to ensure the drug delivery to lower airway regions.
- micronized drug particles less than 5 micron in size
- carrier particles larger carrier particles to address flowability and dose variability issues.
- concentration of drug in drug-carrier DPI formulations is low (e.g., 1 drug.: 67.5 carrier), but can vary depending on the aerosol dispersion properties of the formulation.
- drug particles will preferably adhere to the active binding sites (more adhesive areas) on the carrier surface and expected to separate from carrier surface upon inhalation.
- Drug re-dispersion is considered most important for getting drug particles into deep lung airway regions. Usually, only small amounts of drug reaches the lower airway regions due to strong drug-carrier adhesion. Indeed, drug re-dispersion is a function of balance between cohesive forces (between the drug particles) and the adhesive forces (between drug and carrier particles).
- patient inspiratory force should overcome drug-carrier adhesive forces which are dependent on physicochemical properties of both drug particles and carrier particles.
- the present disclosure provides a method of preparing an inhalable dry powder pharmaceutical composition that comprises an anti arrhythmic pharmaceutical agent and cyclodextrin.
- flecainide or pharmaceutically acceptable salt is dissolved in water thereby resulting in a flecainide solution.
- the flecainide solution further comprises an acid.
- the acid is glacial acetic acid.
- the flecainide solution or flecainide solution with acid further comprises cyclodextrin.
- the cyclodextrin is hydroxypropyl-P-cyclodextrin.
- the flecainide/cyclodextrin solution or flecainide/cyclodextrin/acid solution is heated to 40 °C. The steps above are not limited to any specific order.
- the heated flecainide/cyclodextrin solution or flecainide/cyclodextrin/acid solution is further cooled to 25 °C. In some embodiments, the flecainide/cyclodextrin solution or flecainide/cyclodextrin/acid solution is not heated.
- the pH of the flecainide/cyclodextrin solution or flecainide/cyclodextrin/acid solution is adjusted using a pH adjusting agent, thereby resulting in the pharmaceutical composition solution.
- the pH adjusting agent is acetic acid.
- the pH adjusting agent is sodium hydroxide.
- the pH adjusting agent is both acetic acid and sodium hydroxide. In some embodiments, the pH is adjusted to about 5.8 to about 6.0. In some embodiments, the pharmaceutical composition solution is spray-dried, thereby resulting in the inhalable dry powder pharmaceutical composition. In some embodiments, the pharmaceutical composition is diluted using water. In some embodiments, the pharmaceutical composition is diluted with water to form a 24.5 wt/wt% solution before the manufacturing process for inhalable dry powder pharmaceutical composition. In some embodiments, the pharmaceutical composition is diluted with water to form a 4 wt/wt% solution before the manufacturing process for inhalable dry powder pharmaceutical composition.
- the pharmaceutical composition described herein is formulated into a dry powder form through methods such as, but not limited to, microfabrication, rapid expansion templating, supercritical fluid, lithography, antisolvent particle formation (e.g., liquid antisolvent, vapor antisolvent), spray drying, spray-freeze drying, jet milling, bead milling, ball milling, pearl milling, or high-pressure homogenization.
- methods such as, but not limited to, microfabrication, rapid expansion templating, supercritical fluid, lithography, antisolvent particle formation (e.g., liquid antisolvent, vapor antisolvent), spray drying, spray-freeze drying, jet milling, bead milling, ball milling, pearl milling, or high-pressure homogenization.
- the composition can be formed by spray drying, spray-freeze-drying, aerosol flow reactor method, lyophilization, milling (e.g., wet milling, dry milling), and the like.
- spray drying spray-freeze-drying
- aerosol flow reactor method lyophilization
- milling e.g., wet milling, dry milling
- the aerosolized formulation create nucleation points for growth and the particle size can be tuned based on carrier gas and flow rate.
- the process involves first dissolving the drug material (e.g., flecainide or a pharmaceuticaly acceptable salt thereof) into a suitable solvent to produce a solution, which is then followed by atomising the solution as fine droplets into carrier gas.
- a heated laminar flow reactor tube can be used to evaporate the solvent, and solid drug nanoparticles (e.g., dry powder particles) are formed as a result.
- the method of producing the dry powder pharmaceutical composition disclosed herein is spray drying. [0113]
- the manufacturing process can have a variety of parameters adjusted.
- the solution flow rate is about 4.0 g/min to about 10.0 g/min.
- the nozzle is 2-fluid (Sprays System 1650LC/64AC), airless atomization, pressure, rotary/disk, or ultrasonic.
- the atomization pressure is about 20 psi to about 100 psi.
- the atomization G/L ratio is about 4.8 to about 4.9.
- the inlet temperature is about 80 °C to about 200 °C.
- the outlet temperature is about 35 °C to about 150 °C.
- the calculated relative humidity is about 5.2% to about 12.2%.
- the in-going batch size is about 9.6 g to about 24 g.
- the solids load are about 1% to about 10% of the entire load of material.
- the feed temperature of the spray drying process is about 15 °C to about 75 °C.
- the preparation to be spray dried or feed stock can be any solution, coarse suspension, slurry, or colloidal dispersion that can be atomized using the selected spray drying apparatus.
- the feedstock can comprise a suspension as described above.
- a dilute solution and/or one or more solvents can be utilized in the feedstock.
- the feed stock comprises a colloidal system such as an emulsion, reverse emulsion, microemulsion, multiple emulsion, particle dispersion, or slurry, n one version, the antiarrhythmic pharmaceutical agent and the matrix material are added to an aqueous feedstock to form a feedstock solution, suspension, or emulsion.
- the feedstock is then spray dried to produce dried particles comprising the matrix material and the antiarrhythmic pharmaceutical agent.
- Suitable spray-drying processes are known in the art, for example as disclosed in WO 99/16419 and U.S. Pat. Nos. 6,077.543; 6,051.256; 6,001,336; 5,985,248; and 5,976,574, which are incorporated herein by reference in their entireties.
- the first step in particle production typically comprises feedstock preparation. If a phospholipids-based particle is intended to act as a carrier for the antiarrhythmic pharmaceutical agent, the selected active agent(s) can be introduced into a liquid, such as water, to produce a concentrated suspension.
- the concentration of antiarrhythmic pharmaceutical agent and optional active agents typically depends on the amount of agent required in the final powder and the performance of the delivery device employed (e.g., the fine particle dose for a dry powder inhaler (DPI)).
- Any additional active agent(s) can be incorporated in a single feedstock preparation and spray dried to provide a single pharmaceutical composition species comprising a plurality of active agents.
- individual active agents could be added to separate stocks and spray dried separately to provide a plurality of pharmaceutical composition species with different compositions. These individual species could be added to the suspension medium or dry powder dispensing compartment in any desired proportion and placed in the aerosol delivery system.
- the pharmaceutical composition comprises anti arrhythmic pharmaceutical agent incorporated into a phospholipid matrix.
- the pharmaceutical composition can comprise phospholipid matrices that incorporate the active agent and that are in the form of particles that are hollow and/or porous microstructures, as described in the aforementioned WO 99/16419, WO 99/16420, WO 99/16422, WO01/85136, and WO 01/85137, which are incorporated herein by reference in their entireties.
- the hollow and/or porous microstructures are useful in delivering the anti arrhythmic pharmaceutical agent to the lungs because the density, size, and aerodynamic qualities of the hollow and/or porous microstructures facilitate transport into the deep lungs during inhalation.
- the phospholipid-based hollow and/or porous microstructures reduce the attraction forces between particles, making the pharmaceutical composition easier to deagglomerate during aerosolization and improving the flow properties of the pharmaceutical composition making it easier to process.
- the pharmaceutical composition is composed of hollow and/or porous microstructures having a bulk density less than about 1.0 g/cm, less than about 0.5 g/cm, less than about 0.3 g/cm, less than about 0.2 g/cm, or less than about 0.1 g/cm.
- the elimination of carrier particles will potentially reduce throat deposition and any gag effect or coughing, since large carrier particles, e.g., lactose particles, will impact the throat and upper air ways due to their size.
- the present disclosure involves high rugosity particles.
- the particles can have a rugosity of greater than 2.
- the rugosity can range from 2 to 15, such as 3 to 10.
- the pharmaceutical composition is in dry powder form and is contained within a unit dose receptacle which can be inserted into or near the aerosolization apparatus to aerosolize the unit dose of the pharmaceutical composition.
- This version is useful in that the dry powder form can be stably stored in its unit dose receptacle for a long period of time.
- pharmaceutical compositions of one or more embodiments of the present disclosure can be stable for at least 2 years. In some versions, no refrigeration is required to obtain stability.
- compositions disclosed herein can comprise a structural matrix that exhibits, defines or comprises voids, pores, defects, hollows, spaces, interstitial spaces, apertures, perforations or holes.
- the absolute shape (as opposed to the morphology) of the perforated microstructure is generally not critical and any overall configuration that provides the desired characteristics is contemplated as being within the scope of the disclosure. Accordingly, Some embodiments comprise approximately spherical shapes. However, collapsed, deformed or fractured particles are also compatible.
- the anti arrhythmic pharmaceutical agent is incorporated in a matrix that forms a discrete particle, and the pharmaceutical composition comprises a plurality of the discrete particles.
- the discrete particles can be sized so that they are effectively administered and/or so that they are available where needed.
- the particles are of a size that allows the particles to be aerosolized and delivered to a user's respiratory tract during the user's inhalation.
- the matrix material can comprise a hydrophobic or a partially hydrophobic material.
- the matrix material can comprise a lipid, such as a phospholipid, and/or a hydrophobic amino acid, such as leucine (e.g., L-leucine), isoleucine (e.g., L-isoleucine), or tri -leucine.
- leucine e.g., L-leucine
- isoleucine e.g., L-isoleucine
- tri -leucine tri -leucine.
- Examples of phospholipid matrices are described in WO 99/16419, WO 99/16420, WO 99/16422, WO 01/85136, and WO 01/85137 and in U.S. Pat. Nos. 5,874,064; 5,855,913: 5,985,309; 6,503,480; and 7,473,433, and in U.S. Published App. No. 2004.0156792, all of which are incorporated herein by reference in their entireties.
- hydrophobic amino acid matrices examples include hydrophobic amino acid matrices are described in U.S. Pat. Nos. 6,372, 258; 6,358,530; and 7,473.433, which are incorporated herein by reference in their entireties.
- the pharmaceutical composition can also comprise a polyvalent cation, as disclosed in WO 01/85136 and WO 01/85137, which are incorporated herein by reference in their entireties.
- release kinetics of the composition containing anti arrhythmic pharmaceutical agent(s) is controlled.
- the compositions of the present disclosure provide immediate release of the anti arrhythmic pharmaceutical agent(s).
- compositions of other embodiments of the present disclosure can be provided as non-homogeneous mixtures of active agent incorporated into a matrix material and unincorporated active agent in order to provide desirable release rates of anti arrhythmic pharmaceutical agent.
- anti arrhythmic pharmaceutical agents can be formulated using the emulsion-based manufacturing process (i.e. emulsion spray drying).
- a formulation described herein can have utility in immediate release applications when administered to the respiratory tract. Rapid release is facilitated by: (a) the high specific surface area of the low density porous powders; (b) the small size of the drug crystals that are incorporated therein, and; (c) the low surface energy of the particles.
- it can be desirable to engineer the particle matrix so that extended release of the active agent(s) is effected. This can be particularly desirable when the active agent(s) is rapidly cleared from the lungs or when sustained release is desired.
- the nature of the phase behavior of phospholipid molecules is influenced by the nature of their chemical structure and/or preparation methods in spray drying feedstock and drying conditions and other composition components utilized.
- the active agent(s) are never formally encapsulated in the phospholipid, and the fact that the phospholipid is initially present on the surface of the emulsion droplets as a monolayer (not a bilayer as in the case of liposomes).
- the spray-dried particles prepared by the emulsion-based manufacturing process of one or more embodiments of the present disclosure often have a high degree of disorder. Also, the spray-dried particles typically have low surface energies, where values as low as 20 mN/m have been observed for spray-dried DSPC particles (determined by inverse gas chromatography).
- SAXS Small angle X-ray scattering
- the pharmaceutical composition formation process can also include the additions of other composition components (e.g., small polymers such as Pluronic F-68; carbohydrates, salts, hydrotropes) to break the bilayer structure are also contemplated.
- other composition components e.g., small polymers such as Pluronic F-68; carbohydrates, salts, hydrotropes
- incorporation of the phospholipid in bilayer form can be used, especially if the active agents encapsulated therein.
- increasing the temperature of the phospholipid can provide benefit via incorporation of divalent counterions or cholesterol.
- increasing the interaction between the phospholipid and drug substance via the formation of ion-pairs negatively charged active steaylamine, positively charged active phosphatidylglycerol
- the active agent is amphiphilic, surfactant/surfactant interactions can also slow active dissolution.
- divalent counterions e.g., calcium or magnesium ions
- long- chain saturated phosphatidylcholines results in an interaction between the negatively charged phosphate portion of the zwitterionic headgroup and the positively charged metal ion. This results in a displacement of water of hydration and a condensation of the packing of the phospholipid lipid headgroup and acyl chains. Further, this results in an increase in the T m of the phospholipid.
- the decrease in headgroup hydration can have profound effects on the spreading properties of spray-dried phospholipid particles on contact with water.
- a fully hydrated phosphatidylcholine molecule will diffuse very slowly to a dispersed crystal via molecular diffusion through the water phase.
- the process is exceedingly slow because the solubility of the phospholipid in water is very low (about 10 mol/L for DPPC).
- Prior art attempts to overcome this phenomenon include homogenizing the crystals in the presence of the phospholipid. In this case, the high degree of shear and radius of curvature of the homogenized crystals facilitates coating of the phospholipid on the crystals.
- “dry” phospholipid powders according to one or more embodiments of this disclosure can spread rapidly when contacted with an aqueous phase, thereby coating dispersed crystals without the need to apply high energies.
- the surface tension of spray-dried DSPC/Ca mixtures at the air/water interface decreases to equilibrium values (about 20 mN/m) as fast as a measurement can be taken.
- liposomes of DSPC decrease the surface tension (about 50 mN/m) very little over a period of hours, and it is likely that this reduction is due to the presence of hydrolysis degradation products such as free fatty acids in the phospholipid.
- Single-tailed fatty acids can diffuse much more rapidly to the air/water interface than can the hydrophobic parent compound.
- the addition of calcium ions to phosphatidylcholines can facilitate the rapid encapsulation of crystalline drugs more rapidly and with lower applied energy.
- the pharmaceutical composition comprises low density particles achieved by co-spray-drying with a perfluorocarbon-in-water emulsion.
- perfluorocarbons include, but are not limited to, perfluorohexane, perfluorooctyl bromide, perfluorooctyl ethane, perfluorodecalin, perfluorooctyl ethane.
- the particles can be provided in a “dry” state.
- the particles will possess a moisture content that allows the powder to remain chemically and physically stable during storage at ambient or reduced temperature and remain dispersible.
- the moisture content of the particles is typically less than about 10 wt %, such as less than about 6 wt %, less than about 3 wt %, or less than about 1 wt %.
- the moisture content is, at least in part, dictated by the composition and is controlled by the process conditions employed, e.g., inlet temperature, feed concentration, pump rate, and blowing agent type, concentration and post drying.
- the pharmaceutical composition includes particle compositions that can comprise, or can be partially or completely coated with, charged species that prolong residence time at the point of contact or enhance penetration through mucosae.
- anionic charges are known to favor mucoadhesion while cationic charges can be used to associate the formed particle with negatively charged bioactive agents such as genetic material.
- the charges can be imparted through the association or incorporation of polyanionic or polycationic materials such as polyacrylic acids, polylysine, polylactic acid, and chitosan.
- the pharmaceutical composition comprises particles having a mass median diameter less than about 20 um, such as less than about 10 um, less than about 7 um, or less than about 5um.
- the particles can have a mass median aerodynamic diameter ranging from about 1 um to about 6 um, Such as about 1 ,5um to about 5um, or about 2 um to about 4 um. If the particles are too large, a larger percentage of the particles can not reach the lungs. If the particles are too small, a larger percentage of the particles can be exhaled.
- the dry powder pharmaceutical composition is stable for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 1 year, at least 2 years, at least 3 years, at least 4 years, or at least 5 years when stored in an open container at 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% relative humidity at a temperature of from about 0°C to about 50 °C, about 10 °C to about 40 °C, about 20 °C to about 40 °C, about 30 °C to about 40 °C, or about 20 °C to about 30 °C.
- the dry powder pharmaceutical composition is stable for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 1 year, at least 2 years, at least 3 years, at least 4 years, or at least 5 years when stored in a closed container at 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% relative humidity at a temperature of from about 0 °C to about 50 °C, about 10 °C to about 40 °C, about 20 °C to about 40 °C, about 30 °C to about 40 °C, or about 20 °C to about 30 °C. Stability can be determined by potency of the dry powder pharmaceutical composition described herein.
- the dry powder pharmaceutical described herein has an at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% potency after storage. In some embodiments, the dry powder pharmaceutical described herein has at least 90 % to about 100% potency after storage. Stability can be determined by the moisture content or water content by weight. In some embodiments, the water content of the dry powder pharmaceutical composition after storage is less than 15 wt %, less than 10 wt%, less than 5 wt %, or less than 1 wt % when storage in an open container. In some embodiments, the water content of the dry powder pharmaceutical composition after storage is less than 15 wt %, less than 10 wt%, less than 5 wt %, or less than 1 wt % when storage in an closed container.
- the methods, compositions, and kits provided herein can include administration of the pharmaceutical composition via inhalation, e.g., oral or nasal inhalation.
- cardiac arrhythmias the methods, compositions, and kits provided herein can treat include, but are not limited to, tachycardia, supraventricular tachycardia (SVT), paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (AF), paroxysmal atrial fibrillation (PAF), persistent atrial fibrillation, permanent atrial fibrillation, atrial flutter, paroxysmal atrial flutter, and lone atrial fibrillation.
- the methods, compositions, and kits provided herein find use in treating a subject suffering from atrial arrhythmia, e.g., atrial fibrillation.
- compositions according to some examples of the present disclosure can be used to treat and/or provide prophylaxis for a broad range of patients.
- a suitable patient for, receiving treatment and/or prophylaxis as described herein is any mammalian patient in need thereof, preferably such mammal is a human. Examples of subjects include, but are not limited to, pediatric patients, adult patients, and geriatric patients.
- the composition is intended only as a treatment for rapid resolution of symptoms and restoration of normal sinus rhythm, and is not taken as a preventative, e.g., when the patient is well, there is no need for drug- -this can increase the benefit-risk ratio of the therapy and overall safety due to the sporadic or intermittent dosing, and the focus on reducing disabling symptoms and restoring sinus rhythm only when needed.
- compositions disclosed herein can be more effective in subjects that include or lack certain physiological or demographic factors, such as, for example, age at clinical presentation, certain hemodynamic criteria, electrophysiological features, and prior treatments.
- a subject treated with a pharmaceutical composition of the disclosure suffers from an atrial fibrillation with an onset that occurred within 48 hours prior to the treating.
- a subject treated with a pharmaceutical composition of the disclosure suffers from an atrial fibrillation with an onset that occurred from 1 hour to 48 hours prior to the treating.
- a subject treated with a pharmaceutical composition of the disclosure suffers from recurrent atrial fibrillation.
- a subject treated with a pharmaceutical composition of the disclosure has undergone cardiac ablation no less than 3 months prior to the treating.
- a subject treated with a pharmaceutical composition of the disclosure has an ongoing prescription for an oral anti arrhythmic medication for atrial fibrillation.
- the oral anti arrhythmic medication is flecainide, or a pharmaceutically acceptable salt thereof.
- a subject treated with a pharmaceutical composition of the disclosure is over 17 years in age. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure is no more than 85 years in age. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure is from 18 years old to 85 years old. [0124] In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has a systolic blood pressure that is below 180 mmHg, below 175 mmHg, below 170 mmHg, below 165 mmHg, below 160 mmHg, below 155 mmHg, or below 150 mmHg at the time of the treating.
- the term “at the time of treating” means the measurement is taken from 1 min to 6 hr prior to the treating, for instance, when measured 1 min to 10 min, 1 min to 30 min, 1 min to 60 min, 1 min to 90 min, 1 min to 2 hr, 1 min to 3 hr, 1 min to 4 hr, 1 min to 5 hr, 10 min to 30 min, 10 min to 60 min, 30 min to 60 min, 30 min to 90 min, 30 min to 2 hr, 1 hr to 2 hr, or 2 hr to 3 hr prior to the treating.
- blood pressure e.g., systolic blood pressure or diastolic blood pressure
- heart rate e.g., ventricular rate
- the term “at the time of treating” means the measurement is taken from 1 min to 6 hr prior to the treating, for instance, when measured 1 min to 10 min, 1 min to 30 min, 1 min to 60 min, 1 min to 90 min, 1 min to 2 hr, 1 min to 3
- the physiological measurement for instance, the measurement of the systolic blood pressure or the ventricular rate of the subject provides a basis for an informed decision as to whether or not the subject is to be treated with the subject pharmaceutical composition and method.
- a subject treated with a pharmaceutical composition of the disclosure has a systolic blood pressure that is greater than 70 mmHg, greater than 75 mmHg, greater than 80 mmHg, greater than 85 mmHg, greater than 90 mmHg, greater than 95 mmHg, greater than 100 mmHg, greater than 105 mmHg, greater than 110 mmHg, greater than 115 mmHg, or greater than 120 mmHg at the time of the treating.
- a subject treated with a pharmaceutical composition of the disclosure has a systolic blood pressure that is from about 60 mmHg to about 180 mmHg, from about 65 mmHg to about 180 mmHg, from about 70 mmHg to about 180 mmHg, from about 75 mmHg to about 180 mmHg, from about 80 mmHg to about 180 mmHg, from about 85 mmHg to about 180 mmHg, from about 90 mmHg to about 180 mmHg, from about 95 mmHg to about 180 mmHg, from about 100 mmHg to about 180 mmHg, from about 105 mmHg to about 180 mmHg, from about 110 mmHg to about 180 mmHg, from about 115 mmHg to about 180 mmHg, from about 120 mmHg to about 180 mmHg, from about 70 mmHg to about 175 mmHg, from about 70 mmHg to
- a subject treated with a pharmaceutical composition of the disclosure has a ventricular rate that is at least about 50 BPM, at least about 55 BPM, at least about 60 BPM, at least about 65 BPM, at least about 70 BPM, at least about 75 BPM, at least about 80 BPM, at least about 85 BPM, at least about 90 BPM, at least about 95 BPM, or at least about 100 BPM at the time of treating.
- a subject treated with a pharmaceutical composition of the disclosure has a ventricular rate that is no greater than about 200 BPM, no greater than about 190 BPM, no greater than about 180 BPM, no greater than about 175 BPM, no greater than about 170 BPM, no greater than about 165 BPM, no greater than about 160 BPM, no greater than about 155 BPM, no greater than about 150 BPM, no greater than about 145 BPM, or no greater than about 140 BPM at the time of treating.
- a subject treated with a pharmaceutical composition of the disclosure has a ventricular rate that is from about 50 BPM to about 200 BPM, 50 BPM to about 180 BPM, from about 55 BPM to about 180 BPM, from about 60 BPM to about 180 BPM, from about 65 BPM to about 180 BPM, from about 70 BPM to about 180 BPM, from about 75 BPM to about 180 BPM, from about 80 BPM to about 180 BPM, about 85 BPM to about 180 BPM, about 95 BPM to about 180 BPM, about 100 BPM to about 180 BPM, from about 50 BPM to about 175 BPM, from about 50 BPM to about 170 BPM, from about 50 BPM to about 165 BPM, from about 50 BPM to about 160 BPM, from about 50 BPM to about 155 BPM, from about 70 BPM to about 175 BPM, about 70 BPM to about 170 BPM, about 70 BPM to about 165 BPM, about 70 BPM to about 160 BPM, about 70 BPM to about 155 BPM, from about 70 B
- a subject treated with a pharmaceutical composition of the disclosure has not been treated with anti arrhythmic drugs or electrical cardioversion since onset of an episode of atrial arrhythmia for which the pharmaceutical composition is being administered.
- a subject treated with a pharmaceutical composition of the disclosure does not exhibit acute decompensated heart failure at the time of treating.
- a subject treated with a pharmaceutical composition of the disclosure does not have heart failure with reduced ejection fraction or a history thereof.
- a subject treated with a pharmaceutical composition of the disclosure does not have myocardial ischemia or a history thereof.
- a subject treated with a pharmaceutical composition of the disclosure does not have myocardial infarction or a history thereof.
- a subject treated with a pharmaceutical composition of the disclosure has not exhibited myocardial infarction (MI) within 3 months prior to administration of the pharmaceutical composition.
- a subject treated with a pharmaceutical composition of the disclosure does not exhibit uncorrected severe aortic or mitral stenosis at the time of treating.
- a subject treated with a pharmaceutical composition of the disclosure does not exhibit hypertrophic cardiomyopathy with outflow tract obstruction at the time of treating.
- a subject treated with a pharmaceutical composition of the disclosure does not have persistent atrial fibrillation or a history thereof.
- a subject treated with a pharmaceutical composition of the disclosure does not exhibit atrial flutter at the time of treating.
- a subject treated with a pharmaceutical composition of the disclosure has not exhibited an episode of atrial flutter within 6 months prior to the treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit abnormal left ventricular ejection fraction at the time of treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit heart failure that is class 2 or greater as according to New York Heart Association Functional Classification at the time of treating.
- a subject treated with a pharmaceutical composition of the disclosure is hemodynamically stable, has a systolic blood pressure that is greater than about 90 mmHg, has ventricular rate from about 70 BPM to about 170 BPM at the time of treating, and does not have a condition or a history of a condition that is: myocardial infarction, myocardial ischemia, atrial stenosis, hypertrophic cardiomyopathy, and heart failure with reduced ejection fraction.
- a subject treated with a pharmaceutical composition of the disclosure does not have Long QT syndrome, Conduction disease (e.g., second- or third- degree heart block, bundle branch block), Sick sinus syndrome, Brugada Syndrome, Torsades de pointed (TdP), or a histories thereof.
- Conduction disease e.g., second- or third- degree heart block, bundle branch block
- Sick sinus syndrome e.g., Brugada Syndrome
- TdP Torsades de pointed
- a subject treated with a pharmaceutical composition of the disclosure does not exhibit at the time of treating an ECG-related feature that is: a QTc interval greater than 480 msec (estimated by the Fridericia's formula); a QRS duration greater than 105 ms; monomorphic or polymorphic ventricular tachycardias that are either sustained or not sustained; and excessive premature ventricular contractions greater than 20 multifocal PVC’s per hour (ventricular extrasystoles); or a predominantly paced heart rhythm.
- an ECG-related feature that is: a QTc interval greater than 480 msec (estimated by the Fridericia's formula); a QRS duration greater than 105 ms; monomorphic or polymorphic ventricular tachycardias that are either sustained or not sustained; and excessive premature ventricular contractions greater than 20 multifocal PVC’s per hour (ventricular extrasystoles); or a predominantly paced heart rhythm.
- a subject treated with a pharmaceutical composition of the disclosure does not exhibit severe renal impairment, wherein a eGFR of the subject is less than 30 mL/min/1.73 m2 at the time of treating.
- a subject treated with a pharmaceutical composition of the disclosure is not on dialysis at the time of treating.
- a subject treated with a pharmaceutical composition of the disclosure does not exhibit abnormal liver function at the time of treating.
- the abnormal liver function is hepatic disease or biochemical evidence of significant liver derangement.
- a subject treated with a pharmaceutical composition of the disclosure does not exhibit uncorrected hypokalemia at the time of treating.
- a subject treated with a pharmaceutical composition of the disclosure does not exhibit a serum potassium less than 3.6 mEq/L at the time of treating.
- a subject treated with a pharmaceutical composition of the disclosure does not exhibit an established pulmonary disease in need of inhalation medication at the time of treating.
- a subject treated with a pharmaceutical composition of the disclosure does not have a hypersensitivity to flecainide acetate or any of its active metabolites, or a history thereof.
- a subject treated with a pharmaceutical composition of the disclosure is not concomitantly administered a systemic drug that is an inhibitor of CYP 2D6.
- the inhibitor of CYP 2D6 is an antidepressant, a neuroleptic, or an antihistamine.
- the inhibitor of CYP 2D6 is propranolol or ritonavir.
- a subject treated with a pharmaceutical composition of the disclosure is not concomitantly administered a systemic drug that is a CYP 2D6 inducer.
- the CYP 2D6 inducer is phenytoin, phenobarbital, or carbamazepine.
- a subject treated with a pharmaceutical composition of the disclosure has not been treated with a Class I or a Class II anti arrhythmic drug within a week prior to administration of the pharmaceutical composition.
- a subject treated with a pharmaceutical composition of the disclosure with an ongoing episode of atrial fibrillation has not been treated with a Class I or a Class III anti arrhythmic drug since onset of the ongoing episode.
- a subject treated with a pharmaceutical composition of the disclosure is administered no more than 320 mg flecainide or a pharmaceutically acceptable salt thereof per day from any source.
- a subject treated with a pharmaceutical composition of the disclosure with an ongoing episode of atrial fibrillation has not been treated with electrical cardioversion since onset of the ongoing episode.
- a subject treated with a pharmaceutical composition of the disclosure has not been treated with amiodarone within 12 weeks prior to administration of the pharmaceutical composition. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has not been considered high risk for stroke based on screening coagulation panel. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit a CHA2DS2-VASc score greater than 2.
- a subject treated with a pharmaceutical composition of the disclosure does not exhibit a congenital heart disease at the time of treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit a history of refractory atrial fibrillation that has been pharmacologically or electrically cardioverted. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, or a non- cardiovascular cause at the time of treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit syncope at the time of treating.
- a subject treated with a pharmaceutical composition of the disclosure does not exhibit any serious or life threatening medical condition other than cardiac arrhythmia at the time of treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit an acute pathogenic infection at the time of treating. [0136] In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has not exhibited a drug or alcohol dependence within 12 months prior to administration of the pharmaceutical composition. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit a body mass index greater than 40 Kg/m 2 at the time of treating.
- the therapy provided herein can comprise or be suitable for inhalation, e.g., oral or nasal inhalation.
- inhalation e.g., oral or nasal inhalation.
- the pharmaceutical agent is inhaled by the patient through the mouth and absorbed by the lungs.
- nasal inhalation the pharmaceutical agent is inhaled by the patient through the nose and absorbed by the nasal mucous and/or the lungs.
- the inhalation route can avoid first-pass hepatic metabolism, hence dosing variability can be eliminated.
- the patient’s metabolic rates can not matter as the administration is independent of the metabolic paths experienced when a drug is administered via oral route through gastrointestinal tract, e.g., as tablets, pills, solution, or suspension.
- a fast onset of action, a potential improvement in efficacy, and/or a reduction in dose can be achieved with the fast absorption of drugs from the nasal mucosa and/or lungs.
- the therapy provided herein is provided to a subject for more than once on an as-needed basis.
- the present disclosure can involve a follow-up inhalation if no cardioversion occurs after an initial inhalation. In some instances, if no cardioversion occurs within 30 minutes of the initial inhalation, the follow-up dosage is higher or the same as the initial dosage.
- the time for onset of action can be short.
- the patient can have normal sinus rhythm within 20 minutes of initiating the administering, such as within 15 minutes, within 10 minutes, or within 5 minutes of initiating the administering.
- the rapid onset of action is advantageous because the longer a patient remains in arrhythmia (i.e. atrial fibrillation), the more difficult it will be to restore normal sinus rhythm.
- the method of the present disclosure allows the patient to avoid other therapies, such as ablation and/or electrical cardioversion.
- the method of the present disclosure is used in combination with other therapies, such as before or after electrical cardioversion and/or ablation therapy.
- the pharmaceutical composition can be administered to the patient on an as-needed basis.
- the unit dosage is about 50 mg to about 350 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 50 mg to about 350 mg of the anti arrhythmic pharmaceutical agent wherein the anti arrhythmic pharmaceutical agent is flecainide or a pharmaceutically acceptable salt thereof. In some embodiments, the unit dosage is about 100 mg to about 350 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 150 mg to about 350 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 200 mg to about 350 mg of the anti arrhythmic pharmaceutical agent.
- the unit dosage is about 250 mg to about 350 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 300 mg to about 350 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 50 mg to about 300 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 50 mg to about 250 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 50 mg to about 200 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 50 mg to about 150 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 50 mg to about 100 mg of the anti arrhythmic pharmaceutical agent.
- the unit dosage is about 100 mg to about 300 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 150 mg to about 250 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 100 mg to about 150 mg of the anti arrhythmic pharmaceutical agent.
- the unit dosage is about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, or about 350 mg of the antiarrhythmic pharmaceutical agent.
- the dosage necessary and the frequency of dosing of the antiarrhythmic pharmaceutical agent depend on the composition and weight ratio of the antiarrhythmic pharmaceutical agent to cyclodextin within the composition.
- the dose is less than about 10%, 20 %, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% of its normal intravenous dose.
- the dose is about 5% to about 10%, is about 10% to about 20%, is about 20% to about 30%, is about 30% to about 40%, is about 50% to about 60%, is about 60% to about 70%, is about 70% to about 80%, is about 80% to about 90%, or is about 90% to about 95% of the intravenous dose.
- the pharmaceutical composition of one or more embodiments of the present disclosure can have improved emitted dose efficiency.
- the emitted dose (ED) of the particles of the present disclosure can be greater than about 30%, such as greater than about 40%, greater than about 50%, greater than about 60%, or greater than about 70%.
- the dose of the antiarrhythmic agent e.g., flecainide salt, e.g., flecainide acetate, can be administered during a single inhalation or can be administered during several inhalation sessions.
- the fluctuations of antiarrhythmic pharmaceutical agent concentration can be reduced by administering the pharmaceutical composition more often or can be increased by administering the pharmaceutical composition less often. Therefore, the pharmaceutical composition provided herein can be administered from about four times daily to about once a month, such as about once daily to about once every two weeks, about once every two days to about once a week, and about once per week.
- the pharmaceutical compostion of the disclosure is administered via oral inhalation.
- “inhalation session” refers to a period starting from when the patient begins inhalation of the pharmaceutical composition and ending when the patient ceases inhalation of the pharmaceutical composition.
- the antiarrhythmic pharmaceutical agent is delivered over two or more inhalation sessions. In some cases, time between the two or more inhalation sessions is from about 0.1 to 10 minutes.
- the antiarrhythmic pharmaceutical agent is administered in the described dose in less than 60 minutes, less than 50 minutes, less than 40 minutes, less than 30 minutes, less than 20 minutes, less than 15 minutes, less than 10 minutes, less than 7 minutes, less than 5 minutes, in less than 3 minutes, in less than 2 minutes, or in less than 1 minute.
- each inhalation session is performed for about 0.5, 1, 1.2, 1.5, 1.8, 2, 2.2, 2.5, 2.8, 3, 3.2, 3.5, 3.8, 4, 4.2, 4.5, 4.8, or 5 minutes. In some cases, each inhalation session is performed for longer than 5 minutes. In some cases, each inhalation session is performed for up to 4.5 minutes.
- each inhalation session comprises at least 60 inhalation breaths, 50 inhalation breaths, 40 inhalation breaths, 30 inhalation breaths, 20 inhalation breaths, 10 inhalation breaths, 8 inhalation breaths, 6 inhalation breaths, 4 inhalation breaths, 3 inhalation breaths, 2 inhalation breaths or 1 inhalation breath.
- each inhalation session comprises no more than 100 inhalation breaths, 90 inhalation breaths, 80 inhalation breaths, 70 inhalation breaths, 60 inhalation breaths, 50 inhalation breaths, 40 inhalation breaths, 30 inhalation breaths, or 20 inhalation breaths.
- inhalation session of the anti arrhythmic pharmaceutical agent is performed with deep lung breath that lasts for longer than 1 second, 2 seconds, 3 seconds, or 4 seconds. In some cases, inhalation session of the anti arrhythmic pharmaceutical agent is performed with deep lung breath that lasts for about 1 second, 2 seconds, 3 seconds, or 4 seconds.
- the subject inhales an aerosolized pharmaceutical composition of the disclosure via tidal breathing.
- tidal breathing can refer to inhalation and exhalation during restful breathing.
- tidal breathing can include inhaling the arosolized pharmaceutical composition while breathing at a rate of 10 to 14 breaths a minute.
- the subject takes, or is instructed to take, a break between two inhalation sessions.
- the break between two inhalation session lasts for about 0.1 to 10 minutes, such as, 0.2 to 5, 1 to 5, 1.5 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 1.5, 1 to 2, 1 to 2.5, 1 to 3, 1 to 3.5 , 1 to 4, 1.5 to 2, 1.5 to 2.5, or 1.5 to 3 minutes.
- the subject takes, or is instructed to take, a break for about 1 minute between two inhalation sessions.
- the inhalation pattern for delivery of a single dose goes as follows: a first inhalation session for about 4 to 4.5 minutes, a break for about 1 minute, and a second inhalation session for about 4 to 4.5 minutes; a first inhalation session for about 4 to 4.5 minutes, a break for about 30 seconds, and a second inhalation session for about 4 to 4.5 minutes; a first inhalation session for about 4 to 4.5 minutes, a first break for about 1 minute, and a second inhalation session for about 4 to 4.5 minutes; a second break for about 1 minutes, and a third inhalation session for about 4 to 4.5 minutes; or a first inhalation session for about 4 to 4.5 minutes, a first break for about 30 seconds, and a second inhalation session for about 4 to 4.5 minutes; a second break for about 30 seconds, and a third inhalation session for about 4 to 4.5 minutes.
- the antiarrhythmic can be administered daily.
- the daily dosage of the flecainide acetate ranges from about 0.1 mg to about 600 mg, such as about 0.5 mg to about 500 mg, about 1 mg to about 400 mg, about 2 mg to about 300 mg, and about 3 mg to about 200 mg.
- the therapy provided herein is provided to a subject for more than once on an as-needed basis.
- the present disclosure can involve a follow-up inhalation if no cardioversion occurs after an initial inhalation. In some instances, if no cardioversion occurs within 30 minutes of the initial inhalation, the follow-up dosage is higher or the same as the initial dosage.
- the dosing can be guided by how the patient feels. Additionally or alternatively, dosing can be guided by using a portable/mobile ECG device. For instance, the dosing can be guided by using a Holter monitor.
- the pharmaceutical composition is administered prophylactically to a subject who is likely to develop an arrhythmia.
- a patient who has a history of arrhythmias can be prophylactically treated with a pharmaceutical composition comprising anti arrhythmic pharmaceutical agent to reduce the likelihood of developing an arrhythmia.
- the pharmaceutical composition can be administered to a patient in any regimen which is effective to prevent an arrhythmia.
- Illustrative prophylactic regimes include administering an anti arrhythmic pharmaceutical agent as described herein 1 to 21 times per week.
- patient receiving administration of pharmaceutical composition according to the method described herein needs to meet one or more of the following ECG criteria: P waves not seen on the ECG; fibrillatory waves are coarse; there are varying RR intervals; there are irregular-irregular QRS complexes; or there is an elevated ventricular rate.
- method of treatment disclosed herein comprises confirming a patient in atrial fibrillation episode via ECG.
- the method comprises confirming a patient having the following ECG features before administering the pharmaceutical composition as described herein: P waves not seen on the ECG; fibrillatory waves are coarse; there are varying RR intervals; there are irregular-irregular QRS complexes; and there is an elevated ventricular rate.
- a patient receiving administration of pharmaceutical composition according to the method described herein has a medical history that is current within predetermined time period and qualifies the patient to receive flecainide safely.
- the patient’s current AF episode has had a duration of less than 48 hours.
- total flecainide exposure the patient receives within past 24 hour period does not exceed 320 mg.
- the amount of the flecainide salt that is delivered to the subject can be from about 50 mg to about 300 mg, such as 50 mg to 60 mg, 50 mg to 70 mg, 50 mg to 80 mg, 50 mg to 90 mg, 50 mg to 100 mg, 50 mg to 110 mg, 50 mg to 120 mg, 50 mg to 130 mg, 50 mg to 140 mg, 50 mg to 150 mg, 50 mg to 160 mg, 50 mg to 170 mg, 50 mg to 180 mg, 50 mg to 190 mg, 50 mg to 200 mg, 50 mg to 210 mg, 50 mg to 220 mg, 50 mg to 230 mg, 50 mg to 240 mg, 50 mg to 250 mg, 50 mg to 260 mg, 50 mg to 270 mg, 50 mg to 280 mg, 50 mg to 290 mg, 70 mg to 80
- the amount of the flecainide salt that is delivered to the subject is at least about 50 mg, at least about 60 mg, at least about 70 mg, at least about 80 mg, at least about 90 mg, at least about 100 mg, at least about 110 mg, at least about 120 mg, at least about 130 mg, at least about 140 mg, at least about 150 mg, at least about 160 mg, at least about 170 mg, at least about 180 mg, at least about 190 mg, at least about 200 mg, at least about 210 mg, at least about 220 mg, at least about 230 mg, at least about 240 mg, at least about 250 mg, at least about 260 mg, at least about 270 mg, at least about 280 mg, or at least about 290 mg.
- arrhythmia e.g., atrial arrhythmia, e.g., atrial fibrillation
- the amount of the flecainide salt that is delivered to the subject is at most about 100 mg, at most about 110 mg, at most about 120 mg, at most about 130 mg, at most about 140 mg, at most about 150 mg, at most about 160 mg, at most about 170 mg, at most about 180 mg, at most about 190 mg, at most about 200 mg, at most about 210 mg, at most about 220 mg, at most about 230 mg, at most about 240 mg, at most about 250 mg, at most about 260 mg, at most about 270 mg, at most about 280 mg, or at most about 290 mg.
- arrhythmia e.g., atrial arrhythmia, e.g., atrial fibrillation
- the amount of the flecainide salt that is delivered to the subject is about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, or about 290 mg.
- This method of treatment results in a pulsatile pharmacokinetic profile and transient pharmacodynamic effect mimicking the effect of an IV.
- This method delivers high drug concentrations that are safe and effective to the heart, while the distribution to the rest of the body results in the drug being diluted to sub-therapeutic levels.
- This method is the shortest route of delivery to the heart next to intracardial injection. This provides the convenience of selfadministration like the “pill-in-the-pockef ’ approach, but the effectiveness and fast onset of action of an IV. Although the delivery of medications through the lung for systemic effect is not new, it was thought it wouldn’t be effective to the heart, because of the fast passage of drug through it.
- the anti arrhythmic pharmaceutical agent is a class I, class II, class III, or class IV anti arrhythmic. In some embodiments, the anti arrhythmic pharmaceutical agent is a class Ic, anti arrhythmic. In other embodiments, the anti arrhythmic pharmaceutical agent is flecainide or a pharmaceutically acceptable salt thereof.
- compositions and methods provided herein confer a reduced negative inotropic burden to the subject receiving inhalational delivery of the anti arrhythmic pharmaceutical agent, e.g., flecainide, as compared to receiving delivery of a corresponding dose of the same agent via a different route (e.g., oral or intravenous delivery).
- the anti arrhythmic pharmaceutical agent e.g., flecainide
- Certain antiarrhythmic drugs can have negative inotropic effect, which can limit their use for acute cardioversion of new- onset paroxysmal atrial fibrillation (AF).
- AF new- onset paroxysmal atrial fibrillation
- intravenous delivery of flecainide can exert negative inotropic burden to the subject’s heart, which can be measured by left ventricular (LV) contractility.
- LV left ventricular
- the negative inotropic burden of inhalational delivery of a therapeutically effective dose of anti arrhythmic pharmaceutical agent according to the methods described herein is lower than that of a corresponding therapeutically effective dose of the same agent delivered via a different route (e.g., oral or intravenous delivery).
- kits for treatment of heart conditions via inhalation can include one or more pharmaceutical agents, for instance, a salt of flecainide, or some additional active agent(s) as described herein.
- the kits include container for the pharmaceutical agents or compositions.
- unit doses of the pharmaceutical agents as discussed above are provided in the kits.
- the kits also include containers/receptacles for containing the pharmaceutical agents.
- compositions according to one or more embodiments of the disclosure may, if desired, contain a combination of anti arrhythmic pharmaceutical agent (e.g., flecainide salt) and one or more additional active agents.
- anti arrhythmic pharmaceutical agent e.g., flecainide salt
- the inhalable dry powder pharmaceutical composition described herein can be added into a suitable container, z.e., capsule, blister pack, blister strip, reservoir, and cartridge.
- additional pharmaceutically acceptable carrier or excipient, solubilizer, or other additional ingredients of the pharmaceutical composition e.g., cyclodextrin, e.g., HPpCD; e.g., acids, e.g., acetic acid, hydrochloric acid, nitric acid, or citric acid; e.g., saccharin, e.g., saccharin sodium
- cyclodextrin e.g., HPpCD
- acids e.g., acetic acid, hydrochloric acid, nitric acid, or citric acid
- saccharin e.g., saccharin sodium
- kits include separate containers/receptacles for containing the pharmaceutical composition as described herein. In some other cases, the kits include a single container for containing the pharmaceutical composition.
- the kits can further include instructions for methods of using the kit.
- the instructions can be presented in the form of a data sheet, a manual, on a piece of paper, printed on one or more containers or devices of the kit. Alternatively, the instructions can be provided in electronic form, for instance, available in a disc or online with a weblink available from the kit.
- the instructions for use of the kit can comprise instructions for use of the pharmaceutical composition and the aerosolization device (e.g., a dry powder inhaler) to treat any applicable indication, e.g., a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia.
- the instructions for use of the kit can comprise instructions for use of the pharmaceutical composition and the aerosolization device (e.g., a dry powder inhaler ) to treat atrial fibrillation.
- the kits include a nose clip.
- a nose clip can be used to hinder passage of air through a nose of a subject during inhalation and increase the proportion of a total inhaled volume that is the aerosol issued by the a dry powder inhaler .
- Unit doses of the pharmaceutical compositions can be placed in a container.
- containers include, but are not limited to, capsule, blister pack, blister strip, reservoir, cartridge, or container closure systems made of metal, polymer (e.g., plastic, elastomer), glass, or the like.
- the container can be inserted into an aerosolization device.
- the container can be of a suitable shape, size, and material to contain the pharmaceutical composition and to provide the pharmaceutical composition in a usable condition.
- the capsule or blister can comprise a wall which comprises a material that does not adversely react with the pharmaceutical composition.
- the wall can comprise a material that allows the capsule to be opened to allow the pharmaceutical composition to be aerosolized.
- the wall comprises one or more of gelatin, hydroxypropyl methylcellulose (HPMC), polyethyleneglycol-compounded HPMC, hydroxyproplycellulose, agar, aluminum foil, or the like.
- the DPI are pre-filled with doses of the pharmaceutical composition. In some embodiments, the DPI are pre-filled with a single dose. In some embodiments, the DPI are pre-filled with multiple doses. In some cases, the DPI is disposable after usage. In some cases, the DPI or aerolization device does not contain a capsule for the pharmaceutical compsotion, while the device itself has a compartment or compartments for filling and/or refilling of the pharmaceutical composition. In some cases, the DPI uses a capsule comprising the pharmaceutical composition. In some cases, the DPI or aerolization device requires inhalation of the patient to aerolize the pharmaceutical composition.
- heart condition can refer to a condition where heart has an abnormal function and/or structure, for example, heart is beating in an irregular rhythm, experiencing arrhythmia, atrial fibrillation, and/or tachycardia, there is myocardial infarction, and/or coronary heart disease.
- atrial arrhythmia can refer to an arrhythmia that affects at least one atrium and does not include bradycardia. For instance, atrial arrhythmia can originate in and affect at least one atrium.
- tachycardia can refer to an arrhythmia in which the heart beat is too fast.
- tachycardia can involve a resting heart rate of over 100 beats per minute, such as greater than 110, greater than 120, or greater than 130 beats minute.
- tachycardia can comprise sinus tachycardia, atrial fibrillation, atrial flutter, AV nodal reentrant tachycardia, accessory pathway mediated tachycardia, atrial tachycardia, multifocal atrial tachycardia, junctional tachycardia, ventricular tachycardia, supraventricular tachycardia, or any combination thereof.
- the phrase “heart rhythm arrhythmia” can refer to an arrhythmia in which the heart beat is irregular.
- the term “atrial fibrillation” can refer to an abnormal heart rhythm characterized by rapid and irregular beating of the atria.
- cardiac arrhythmia can refer to a process by which an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia is converted to a normal sinus rhythm. Cardioversion can be induced by electricity, drugs, or both.
- an anti arrhythmic agent can include not only a single active agent but also a combination or mixture of two or more different active agents.
- the term “pharmaceutically acceptable solvate” can refer to a solvate that retains one or more of the biological activities and/or properties of the anti arrhythmic pharmaceutical agent and that is not biologically or otherwise undesirable.
- pharmaceutically acceptable solvates include, but are not limited to, anti arrhythmic pharmaceutical agents in combination with water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, ethanolamine, or combinations thereof.
- salt is equivalent to the term “pharmaceutically acceptable salt,” and can refer to those salts that retain one or more of the biological activities and properties of the free acids and bases and that are not biologically or otherwise undesirable.
- pharmaceutically acceptable salts include, but are not limited to, sulfates, pyrosulfates, bi sulfates, sulfites, bi sulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, mal onates, succinates, suberates, sebacates, fumarates, maleates, butyne- 1,4-dioates, hexyn
- atrial arrhythmia can refer to an arrhythmia that affects at least one atrium and does not include bradycardia. For instance, atrial arrhythmia can originate in and affect at least one atrium.
- tachycardia can mean an arrhythmia in which the heart beat is too fast, e.g., faster than normal.
- tachycardia can involve a resting heart rate of over 100 beats per minute, such as greater than 110, greater than 120, or greater than 130 beats minute.
- heart rhythm arrhythmia can refer to an arrhythmia in which the heart beat is irregular.
- the amount of an agent as described herein in the coronary circulation of the heart can be measured by extracting a sample from any vascular region of the coronary circulation of the heart (e.g., arteries, veins, including coronary sinus) by using a cannula.
- the amount of the agent in the sample can then be determined by known means, such as bioanalytical techniques that employ analytical equipment such as LC-MS/MS.
- the amount of the agent in the blood in the heart can be measured for any particular time.
- treating and “treatment” can refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, reduction in likelihood of the occurrence of symptoms and/or underlying cause, and/or remediation of damage.
- “treating” a patient with an active agent as provided herein can include prevention of a particular condition, disease, or disorder in a susceptible individual as well as treatment of a clinically symptomatic individual.
- nominal amount can refer to the amount contained within the unit dose receptacle(s) that are administered.
- an effective amount can refer to an amount covering both therapeutically effective amounts and prophylactically effective amounts.
- a “therapeutically effective amount” of an active agent can refer to an amount that is effective to achieve a desired therapeutic result.
- a therapeutically effective amount of a given active agent can vary with respect to factors such as the type and severity of the disorder or disease being treated and the age, gender, and weight of the patient.
- “inhalation” e.g., “oral inhalation” or “nasal inhalation” refers to inhalation delivery of a therapeutically effective amount of a pharmaceutical agent contained in one unit dose receptacle, which, in some instance, can require one or more breaths, like 1, 2, 3, 4, 5, 6, 7, 8, 9, or more breaths.
- the term “therapeutically effective amount” can include a “prophylactically effective amount,” e.g., an amount of active agent that is effective to prevent the onset or recurrence of a particular condition, disease, or disorder in a susceptible individual.
- minimum effective amount can mean the minimum amount of a pharmaceutical agent necessary to achieve an effective amount.
- mass median diameter can refer to the median diameter of a plurality of particles, typically in a polydisperse particle population, e.g., consisting of a range of particle sizes.
- geometric diameter can refer to the diameter of a single particle, as determined by microscopy, unless the context indicates otherwise.
- MMAD mass median aerodynamic diameter
- the “aerodynamic diameter” can be the diameter of a unit density sphere having the same settling velocity, generally in air, as a powder and is therefore a useful way to characterize an aerosolized powder or other dispersed particle or particle formulation in terms of its settling behavior.
- the aerodynamic diameter encompasses particle or particle shape, density, and physical size of the particle or particle.
- MMAD refers to the median of the aerodynamic particle or particle size distribution of aerosolized particles determined by cascade impaction, unless the context indicates otherwise.
- a “pharmaceutically acceptable” component is meant a component that is not biologically or otherwise undesirable, e.g., the component can be incorporated into a pharmaceutical formulation of the disclosure and administered to a patient as described herein without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the formulation in which it is contained.
- pharmaceutically acceptable refers to an excipient, it can imply that the component has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug Administration.
- P wave can represent the wave generated by the electrical depolarization of the atria (right and left) and is usually 0.08 to 0.1 seconds (80-100 ms) in duration.
- active dry powder inhaler refers to an inhalation device that does not rely solely on a patient’s inspiratory effort to disperse and aerosolize a pharmaceutical composition contained within the device in a reservoir or in a unit dose form and does include inhaler devices that comprise a means for providing energy to disperse and aerosolize the drug composition, Such as pressurized gas and vibrating or rotating elements.
- room temperature can refer to a temperature that is from 18 °C to 25 °C.
- Example 1 Vacuum dried de-constituted Flecainide acetate pH study
- This example illustrates the change in pH of flecainide acetate when dried for certain vacuum dried formulations.
- a 10 mL solution with 20 mg/mL of flecainide acetate with varying amounts of acids were prepared as shown in Table 1.
- a 1 mL aliquot from each sample was dried for 12 hours in vacuum.
- the dried flecainide acetate test samples were then reconstituted in 1 mL water to the original concentration.
- the pH was measured to verify any acid loss.
- This example demonstrates preparation of certain spray dried flecainide powders. Different pre-formulated powders were made via spray drying in order to determine the effects of several variables on the final product characteristics as shown in Table 2.
- Feedstock was prepared with the composition quantities and pH targets shown in Table 3 prior to spray drying.
- DI water deionized water
- All components were readily soluble in water.
- the pH of the feedstock solution was adjusted by either adding acetic acid or citric acid for the feedstock.
- This example characterizes certain test formulations of Flecainide acetate powder prepared in Example 2.
- the bulk powder was reconstituted in DI water at the same concentration as the original feedstock.
- the pH of the reconstituted solution was measured and compared to that of the original feedstock.
- the solubility of the dry powder during reconstitution was also observed.
- the pH was measured using an Orion Star Al l i from Thermo Scientific. Flecainide acetate powder density study.
- Dry powder density was determined by bulk density and puck density. Bulk density was determined by adding a known mass of dry powder into a tared Eppendorf tube and filled up to 0.5 cubic centimeter. The weight of the powder was measured on Mettler Toledo, AT261 balance. Bulk powder density was calculated as the powder weight over the volume. Puck density was determined by using a capsule filler tool with a cavity volume of 832 p in 3 (0.0136 cm 3 ) with a vacuum pressure of 80 ⁇ 1 kPa and 1.5 to 1.7 L/min flow. The puck was extracted from the cavity and weighed on a Mettler Toledo AT261 balance. Puck density was calculated as the puck weight over the volume of the cavity.
- Powder crystallinity using X-ray diffraction was performed on selected samples to determine the crystallinity of the pre-formulated Flecainide acetate powder. The analysis was performed on a X'pert Pro (PANalytical).
- Table 6 shows the observations as well as powder reconstitution results for all the preformulation spray drying campaigns. Table 6 displays some test compositions or batches that were were spray dried using identical spray drying process conditions.
- a test composition of neat flecainide acetate powder without excipients was coarse and appeared crystalline.
- Another test composition, Batch C with similar formulation to Batch A but using only citric acid to adjust feedstock pH, did not yield any dry powder during spray drying.
- Two different test compositions, Batches B and D, containing >50%w/w flecainide acetate with trileucine did not yield any dry powder regardless of the amount of trileucine in the formulation or the type of acid used to adjust the feedstock pH.
- Powder from another two test compositions, Batches E and F appeared visually fine. Batches E and F were prepared from a feedstock with a pH under 5, andcontained less than 50%w/w flecainide acetate with leucine.
- FIG. 2 compares the pure drug and the neat flecainide acetate (Batch A).
- the formulated flecainide acetate powder at various drug loading values with leucine as excipient (Batches E, F, and G) exhibited amorphous XRPD profiles.
- Spray drying feasibility was conducted on a custom laboratory scale dryer with 35 kg/hr drying gas capacity for five example compositions, Batches J-N.
- Table 10 summarizes the manufacturing conditions for the Batches J - Batch N.
- Batch J - Batch L varied solution flow rate in order to evaluate the impact of relative humidity on yield.
- Atomization gas-to-liquid (G/L) ratio for the three batches was matched in order to target similar particle sizes. No significant difference in yield was observed between the lowest and highest humidity conditions.
- the lower yield on Batch J compared to Batch K and Batch L is likely due to start-up losses.
- Changing solution preparation method in Batch M did not negatively impact process yield.
- Increased active loading in Batch N resulted in a low yield ( ⁇ 30 %), and likely decreased the over glass transition temperature (Tg) of the formulation below the outlet temperature of the dryer, resulting in sticking and particle fusion.
- Table 10 Manufacturing summary in water, water content by Karl Fisher, particle size distribution by laser diffraction, particle morphology by scanning electron microscopy, thermal transitions by differential scanning calorimetry and physical state by X-ray powder diffraction. Results are summarized in Table 11.
- Formulations manufactured according to the Method #1 (Table 9) exhibited pH values that differed from water by 0.5.
- Formulation Batch N prepared according toMethod #2, exhibited a larger pH difference of 1.0.
- compositions were evaluated for moisture uptake as a function of environmental humidity conditions.
- the three samples selected each containined 23/77 Flecainide Acetate/HP-P-CD, but were prepared under different process conditions (formulations Batch J, Batch K, and Batch L).
- the dynamic vapor sorption (DVS) technique was employed at 25 °C to evaluate the sorption and desorption of water.
- Each analysis initiated at ambient conditions (40 % RH) to avoid changes to the material during the initial desorption and sorption.
- any loss in mass at a given relative humidity can be an indication of amorphous content recrystallizing.
- No negative change in mass during the sorption cycle was observed for the standard spray drying condition and solution preparation (Batch J, FIG. 13), while a change was observed with a slower feed rate (4 g/min, Batch K, FIG. 14) or solution preparation (direct to concentration, Batch M, FIG. 15).
- Residual solvent was not measured in the initial sample because the spray solution was just water. However, residual solvent was evaluated on the 1-month stability samples to determine if any volatile material was present. A small amount of an unknown solvent was detected that was not part of the standard suite solvents assayed by gas chromatography (MeOH, EtOH, acetone, IP A, ACN, DCM, EtOAc, THF, and heptane).
- Thermal transitions were evaluated by modulated differential scanning calorimetry using hermetically sealed sample pans. Three broad glass transition temperatures were observed at varying temperatures (Table 25). The first glass transition temperature was lower in the open samples, likely due to the uptake of water on stability (>10 wt %). Thermograms are shown for closed, reversing (FIG. 17); closed, non-reversing (FIG. 18); open, reversing (FIG. 19); open, non-reversing (FIG. 20).
- This example summarizes aerosol performance of three exmemplary flecainide dry powder compositions.
- the three engineered powders of spray dried flecainide acetate were characterized for aerosol performance by measuring the aerosol powder release kinetics from inhaler/capsule by laser photometry and aerodynamic particle size by Next Generation Impactor (NGI).
- NKI Next Generation Impactor
- Powders were puck filled in hypromellose size 3 capsules at a target powder mass of 50 mg and tested in the Plastiape RS01 family of Dry Powder Inhalers, medium (0.10R) and high (0.16R) flow resistance models.
- Table 28 summarizes capsule filling parameters used for manufacturing the capsules in this study. Empty hypromellose size 3 capsules were preconditioned overnight at 10 to 15%RH before filling. Mean fill mass for each powder batch is summarized below. Filled capsules were pouched and stored inside a vacuum box maintained at ⁇ 30% RH (ambient temperature). Capsules were used within 14 days after manufacturing.
- Table 28 Capsule filling parameters and estimated bulk powder density.
- Table 29 and Table 30 summarize the capsule emptying study results for RS01 medium and high flow resistance devices, respectively, and a 50 mg powder mass per capsule. Two pressure drops where evaluated for each inhaler and powder lot. For the medium resistance device, aerosol powder clearance volume was ⁇ 1.2 liters for 2 and 4 kPa inspiratory efforts, suggesting an adult with tidal volume >1.5L can empty the 50 mg capsule in a single inhalation breath. However, longer emptying volumes were observed for the high flow resistance inhaler, suggesting a second inhalation may be required.
- Mean MMAD was 3.9 pm and 3.2 pm for Lot B and Lot D powders, respectively, which is comparable in performance to the corresponding result for each powder with the RS01 medium flow resistance device (Table 32).
- Aerosol powder release kinetics from the inhaler/capsule by laser photometry show faster capsule emptying for RS01 medium than high flow resistance device for all 3 powder lots and at both 2 and 4 kPa tested pressure drops. Therefore, patients that are able to generate inhaled volume of >1.5 L can receive the dose from a 50 mg capsule powder mass in a single inhalation maneuver
- Aerosol performance for RS01 medium and high flow resistance devices tested at 4 kPa pressure drop were comparable (Table 35 and FIG. 34).
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Pharmaceutical compositions comprising an antiarrhythmic agent for treatment of a heart condition via inhalation are disclosed. Methods of treating a heart condition disclosed herein include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Dry powder drug product and kits are also disclosed.
Description
ANTIARRHYTHMIC FORMULATION
CROSS REFERENCE
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 63/146,155, filed February 5, 2021, which is incorporated herein by reference in its entirety.
BACKGROUND
[0002] Cardiac arrhythmia (also dysrhythmia) is a term for any of a large and heterogeneous group of conditions in which there is abnormal electrical activity in the heart. The heart beat may be too fast or too slow and may be regular or irregular.
[0003] Atrial arrhythmia therapy is a field with a high level of unmet clinical need. Many drugs used today have been on the market since the early 1980s and 1990s and are mostly inadequate due to either lack of efficacy or a side-effect profile that is often cardiac related, which necessitates extensive monitoring of the patient.
[0004] Cardiac arrhythmias are associated with disabling symptoms like tightness around the chest, palpitations, feeling tired, shortness of breath, and sometimes chest pain. Arrhythmias frequently result in emergency room (ER) visits where intravenous drugs are administered, sometimes necessitating an extended stay in the hospital and in some cases also leading to unplanned invasive procedures.
[0005] There remains a need for improved compositions and methods for treating heart conditions. Accordingly, there also remains a need for methods of making these compositions.
SUMMARY
[0006] In certain aspects, the present disclosure provides pharmaceutical compositions, comprising a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof, and cyclodextrin, wherein said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 5 :95 to about 95:5, and wherein said pharmaceutical composition is in a form of an inhalable dry powder.
[0007] In some embodiments, said cyclodextrin is selected from the group consisting of a- cyclodextrin, P-cyclodextrin, y-cyclodextrin, hydroxypropyl-P-cyclodextrin, hydroxyethyl-P- cyclodextrin, hydroxypropyl-y-cyclodextrin, hydroxyethyl-y-cyclodextrin, dihydroxypropyl-P- cyclodextrin, glucosyl-a-cyclodextrin, glucosyl-P-cyclodextrin, diglucosyl-P-cyclodextrin, maltosyl-a-cyclodextrin, maltosyl-P-cyclodextrin, maltosyl-y-cyclodextrin, maltotriosyl-P- cyclodextrin, maltotriosyl-y-cyclodextrin dimaltosyl-P-cyclodextrin, succinyl-P-cyclodextrin, 6A-
amino-6A-deoxy-N-(3-hydroxypropyl)-P-cyclodextrin, sulfobutylether-P-cyclodextrin, sulfobutylether-y-cyclodextrin, sulfoalkylether-P-cyclodextrin, and sulfoalkylether-y- cyclodextrin. In some embodiments, said cyclodextrin comprises hydroxypropyl-P-cyclodextrin.
[0008] In certain aspects, the present disclosure provides pharmaceutical compositions, comprising a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof, and_hydroxypropyl-P-cyclodextrin, wherein said pharmaceutical composition is in a form of an inhalable dry powder.
[0009] In some embodiments, said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 5 :95 to about 95:5. In some embodiments, said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 10:90 to about 90: 10, from about 15:85 to about 85: 15, from about 20:80 to about 80:20, from about 25:75 to about 75:25, from about 30:70 to about 70:30, from about 35:65 to about 65:35, from about 40:60 to about 60:40, or from about 45:55 to about 55:45. In some embodiments, said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio of about 50:50. In some embodiments, said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio of about 23 :77.
[0010] In some embodiments, said pharmaceutical composition further comprises a pharmaceutically acceptable excipient or carrier. In some embodiments, the pharmaceutically acceptable excipient or carrier comprises lactose, mannitol, sorbitol, erythritol, raffinose, sucrose, xylitol, trehalose, dextrose, a cyclodextrin, maltitol, maltose, glucose, hydroxyapatite, or any combination thereof. In some embodiments, the pharmaceutically acceptable excipient or carrier comprises porous particles, a crystallization inhibitor, a biodegradable polymer, ammonium bicarbonate, an amino acid, or any combination thereof. In some embodiments, the crystallization inhibitor comprises polymers, polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), polysaccharide, hydroxypropyl methylcellulose (HPMC or Hypromellose), hydroxy ethyl cellulose (HEC), hydroxypropyl cellulose (HPC), polyethylene oxide, hydroxypropyl-P-cyclodextrin (HP- P-CD), sulfobutylether-P-cyclodextrin, hydroxypropyl methylcellulose acetate succinate (HPMC- AS-HF), polyethylene glycol (PEG), or any combination thereof. In some embodiments, the pharmaceutically acceptable excipient or carrier comprises L-leucine or L-isoleucine.
[0011] In some embodiments, reconstitution of said pharmaceutical composition at a concentration of 9 mg/mL in water to 10 mg/mL affords a solution with a pH of about 5.0 to about 8.0. In some embodiments, reconstitution of said pharmaceutical composition at a concentration of 9 mg/mL in water to 10 mg/mL affords a solution with a pH of about 5.5 to about 7.0. In some
embodiments, reconstitution of said pharmaceutical composition at a concentration of 9 mg/mL in water to 10 mg/mL affords a solution with a pH of about 6.7.
[0012] In some embodiments, said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof comprises flecainide acetate. In some embodiments, said pharmaceutical composition further comprises an acid. In some embodiments, said acid comprises acetic acid, aconitic acid, adipic acid, alginic acid, benzoic acid, caprylic acid, citric acid, cholic acid, formic acid, lactic acid, linoleic acid, malic acid, maleic acid, propionic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, tartaric acid, glutamic acid, hydrochloric acid, phosphoric acid, ascorbic acid, erythorbic acid, sorbic acid, thiodipropionic acid, or any combination thereof. In some embodiments, said acid comprises acetic acid.
[0013] In some embodiments, said dry inhalable powder is formulated for administration via oral inhalation. In some embodiments, said dry powder has a mass median aerodynamic diameter of about 0.3 pm to about 20 pm. In some embodiments, said dry powder has a mass median aerodynamic diameter of about 4.0 pm. In some embodiments, said dry powder has a mass median aerodynamic diameter of about 5.0 pm. In some embodiments, said dry powder has a mass median aerodynamic diameter of about 6.0 pm. In some embodiments, said pharmaceutical composition has a glass transition temperature of about 15 °C to about 70 °C. In some embodiments, said pharmaceutical composition has a glass transition temperature of about 45.0 °C. In some embodiments, said pharmaceutical composition has a glass transition temperature of about 65.0 °C. In some embodiments, said glass transition temperature is measured by Differential Scanning Calorimetry (DSC).
[0014] In some embodiments, said pharmaceutical composition described herein is in the form of a unit dose, comprising about 50 mg to about 350 mg of said flecainide or said pharmaceutically acceptable salt thereof. In some embodiments, said unit dose comprises from about 100 mg to about 150 mg of said flecainide or said pharmaceutically acceptable salt thereof.
[0015] In certain aspects, the present disclosure provides kits, comprising a pharmaceutical composition described herein or a unit dose described herein and instructions for use of said pharmaceutical composition for treatment of a heart condition.
[0016] In some embodiments, said kit further comprising a container that contains said pharmaceutical composition. In some embodiments, wherein said container is selected from the group consisting of a capsule, blister pack, blister strip, reservoir, and cartridge.
[0017] In certain aspects, the present disclosure provides kits, comprising a pharmaceutical composition that comprises a therapeutically effective amount of flecainide or pharmaceutically acceptable salt thereof, and a cyclodextrin, a receptacle containing said pharmaceutical composition, instructions for use of a dry powder inhaler for inhalation of a dose of said
pharmaceutical composition in aerosol to a subject, wherein said pharmaceutical composition is in the form of an inhalable dry powder, and wherein said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 5:95 to about 95:5.
[0018] In some embodiments, wherein said kit comprises a unit dose of said pharmaceutical composition, and wherein said unit dose comprises from about 50 mg to about 350 mg of said flecainide or said pharmaceutical acceptable salt thereof.
[0019] In certain aspects, the present disclosure provides systems, comprising a pharmaceutical composition described herein and a dry powder inhaler.
[0020] In some embodiments, said system further comprising instructions for use of said dry powder inhaler and said pharmaceutical composition for treatment of a heart condition. In some embodiments, said heart condition comprises atrial arrhythmia. In some embodiments, said instructions contain instructions for use of said dry powder inhaler to deliver said pharmaceutical composition in a unit dose that comprises from about 50 mg to about 350 mg of flecainide or said pharmaceutically acceptable salt thereof.
[0021] In certain aspects, the present disclosure provides systems, comprising a pharmaceutical composition that comprises a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof, and a cyclodextrin, a dry powder inhaler configured to deliver said pharmaceutical composition as an inhalable dry powder, instructions for use of said dry powder inhaler to deliver said pharmaceutical composition in a unit dose that comprises about 50 mg to about 350 mg amount of flecainide or said pharmaceutically acceptable salt thereof, wherein said pharmaceutical composition is in the form of an inhalable dry powder that has said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 5:95 to about 95:5.
[0022] In certain aspects, the present disclosure provides methods of treating a subject suffering from a heart condition, comprising administering to said subject via inhalation a pharmaceutical composition in the form of an inhalable dry powder, wherein said pharmaceutical composition comprises a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof, and a cyclodextrin, wherein said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 5 :95 to about 95:5.
[0023] In some embodiments, said cyclodextrin is selected from the group consisting of: a- cyclodextrin, P-cyclodextrin, y-cyclodextrin, hydroxypropyl-P-cyclodextrin, hydroxyethyl-P- cyclodextrin, hydroxypropyl-y-cyclodextrin, hydroxyethyl-y-cyclodextrin, dihydroxypropyl-P- cyclodextrin, glucosyl-a-cyclodextrin, glucosyl-P-cyclodextrin, diglucosyl-P-cyclodextrin,
maltosyl-a-cyclodextrin, maltosyl-P-cyclodextrin, maltosyl-y-cyclodextrin, maltotriosyl-P- cyclodextrin, maltotriosyl-y-cyclodextrin dimaltosyl-P-cyclodextrin, succinyl-P-cyclodextrin, 6A- amino-6A-deoxy-N-(3-hydroxypropyl)-P-cyclodextrin, sulfobutylether-P-cyclodextrin, sulfobutylether-y-cyclodextrin, sulfoalkylether-P-cyclodextrin, and sulfoalkylether-y- cyclodextrin. In some embodiments, said cyclodextrin comprises hydroxypropyl-P-cyclodextrin. In some embodiments, said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof comprises from about 50 mg to about 350 mg of flecainide or said pharmaceutically acceptable salt thereof. In some embodiments, said administration of said pharmaceutical composition is performed in up to six inhalation sessions. In some embodiments, said administration of said pharmaceutical composition is performed in one or two inhalation sessions. In some embodiments, said administration is performed via a dry powder inhaler. In some embodiments, said heart condition comprises atrial arrhythmia. In some embodiments, said atrial arrhythmia comprises tachycardia. In some embodiments, comprising acute treatment after detection of said atrial arrhythmia. In some embodiments, said heart condition comprises atrial fibrillation. In some embodiments, said atrial fibrillation is recurrent atrial fibrillation. In some embodiments, said atrial fibrillation is paroxysmal atrial fibrillation.
[0024] In certain aspects, the present disclosure provides methods, comprising converting a solution containing flecainide to an inhalable dry powder, thereby producing a pharmaceutical composition described herein.
[0025] In some embodiments, said converting said solution containing flecainide to said inhalable dry powder comprises using spray drying, freeze drying, spray-freeze drying, emulsion spray drying, or an aerosol flow reactor method. In some embodiments, said spray drying comprises spray drying at a solution flow rate of about 1.0 g/min to about 15.0 g/min, an atomization pressure of about 10 psi to about 100 psi, an inlet temperature of about 100 °C to about 200 °C, or an outlet temperature of about 40 °C to about 70 °C. In some embodiments, said spray drying comprises spray drying a solution flow rate of about 1.0 g/min to about 15.0 g/min, an atomization pressure of about 10 psi to about 100 psi, an inlet temperature of about 100 °C to about 200 °C, and an outlet temperature of about 40 °C to about 70 °C. In some embodiments, said solution containing flecainide further comprises a cyclodextrin. In some embodiments, said cyclodextrin comprises hydroxypropyl-P-cyclodextrin. In some embodiments, said solution containing flecainide further comprises an acid. In some embodiments, said acid comprises acetic acid, aconitic acid, adipic acid, alginic acid, benzoic acid, caprylic acid, citric acid, cholic acid, formic acid, lactic acid (e.g., D-(-)-lactic acid or L-(+)-lactic acid), linoleic acid, malic acid, maleic acid, propionic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, tartaric acid, glutamic acid, hydrochloric acid, phosphoric acid, ascorbic acid, erythorbic acid, sorbic acid, thiodipropionic acid, or any
combination thereof. In some embodiments, said acid comprises acetic acid. In some embodiments, said solution containing flecainide is prepared by dissolving flecainide or a pharmaceutically acceptable salt thereof, cyclodextrin, and pH buffer agents in water, thereby providing said solution containing flecainide. In some embodiments, said cyclodextrin is selected from the group consisting of: a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, hydroxypropyl-P- cyclodextrin, hydroxyethyl-P-cyclodextrin, hydroxypropyl-y-cyclodextrin, hydroxyethyl-y- cyclodextrin, dihydroxypropyl-P-cyclodextrin, glucosyl-a-cyclodextrin, glucosyl-P-cyclodextrin, diglucosyl-P-cyclodextrin, maltosyl-a-cyclodextrin, maltosyl-P-cyclodextrin, maltosyl-y- cyclodextrin, maltotriosyl-P-cyclodextrin, maltotriosyl-y-cyclodextrin dimaltosyl-P-cyclodextrin, succinyl-P-cyclodextrin, 6A-amino-6A-deoxy-N-(3-hydroxypropyl)-P-cyclodextrin, sulfobutylether-P-cyclodextrin, sulfobutylether-y-cyclodextrin, sulfoalkylether-P-cyclodextrin, and sulfoalkylether-y-cyclodextrin. In some embodiments, said cyclodextrin comprises hydroxypropyl-P-cyclodextrin. In some embodiments, said converting said solution containing flecainide further comprises heating said solution containing flecainide. In some embodiments, comprising heating said solution containing flecainide to about 40 °C. In some embodiments, said solution containing flecainide is cooled to 25 °C prior to spray drying. In some embodiments, said flecainide solution is diluted with water prior to spray drying. In some embodiments, pH of said solution containing flecainide is adjusted to about 6.0 using said a pH buffer agent prior to spay drying. In some embodiments, said pH buffer agent comprises sodium hydroxide. In some embodiments, reconstitution of said inhalable dry powder pharmaceutical composition at a concentration of 9 mg/mL to 10 mg/mL in water affords a solution with a pH of about 5.0 to about 8.0. In some embodiments, reconstitution of said inhalable dry powder pharmaceutical composition at a concentration of 9 mg/mL to 10 mg/mL in water affords a solution with a pH of about 5.5 to about 7.0. In some embodiments, reconstitution of said inhalable dry powder pharmaceutical composition at a concentration of 9 mg/mL to 10 mg/mL in water affords a solution with a pH of about 6.7. In some embodiments, the inhalable dry powder pharmaceutical composition has a mass median aerodynamic diameter of about 0.3 pm to about 20 pm. In some embodiments, said pharmaceutical composition has a glass transition temperature of about 15 °C to about 70 °C. In some embodiments, said flecainide or said pharmaceutically acceptable salt thereof comprises flecainide acetate. In some embodiments, said method further comprising packaging said pharmaceutical composition in unit dose form. In some embodiments, said unit dose form further comprises a container selected from the group consisting of: a capsule, blister pack, blister strip, reservoir, and cartridge.
INCORPORATION BY REFERENCE
[0026] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
BRIEF DESCRIPTION OF THE DRAWINGS
[0027] The novel features of the disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:
[0028] FIG. 1 illustrates the particle size distribution of flecainide acetate powder.
[0029] FIG. 2 illustrates X-ray powder diffraction (XRPD) data obtained from pure flecainide acetate drug and processed neat flecainide acetate.
[0030] FIG. 3 illustrates XRPD data obtained from 20% w/w flecainide acetate, 48% w/w flecainide acetate, and 70% w/w flecainide acetate with leucine.
[0031] FIG. 4 illustrates XRPD data obtained from neat flecainide acetate and non-powder forming formulations.
[0032] FIG. 5 illustrates the particle size distribution flecainide acetate spray dried powders (Batch J - Batch N).
[0033] FIG. 6 illustrates non-reversing heat flow signals observed via differential scanning calorimetry (DSC) analysis of flecainide acetate spray dried powders (Batch J - Batch N).
[0034] FIG. 7 illustrates reversing heat flow signals observed via DSC analysis of flecainide acetate spray dried powders (Batch J - Batch N).
[0035] FIG. 8 illustrates XRPD diffractograms of flecainide acetate spray dried powders (Batch J - Batch N).
[0036] FIG. 9 illustrates the dynamic vapor sorption (DVS) isotherm profile of a 23/77 (w/w) flecainide acetate/HP-P-CD spray dried formulation prepared from a nebulization solution preparation (Batch J).
[0037] FIG. 10 illustrates the DVS isotherm profile of a 23/77 (w/w) flecainide acetate/HP-P-CD spray dried formulation prepared from a nebulization solution preparation at lower feed rate (Batch K).
[0038] FIG. 11 illustrates the DVS isotherm profile of a 23/77 (w/w) flecainide acetate/HP-P-CD spray dried formulation (Batch M, direct solution preparation).
[0039] FIG. 12 illustrates DVS isotherms of flecainide acetate spray dried powder Batches J, K, and M.
[0040] FIG. 13 illustrates a DVS mass change profile of flecainide acetate spray dried powder Batch J.
[0041] FIG. 14 illustrates a DVS mass change profile for flecainide acetate spray dried powder Batch K.
[0042] FIG. 15 illustrates a DVS mass change profile for flecainide acetate spray dried powder Batch M.
[0043] FIG. 16 illustrates particle size distributions of flecainide acetate spray powders stored at 40 °C / 75% RH in a closed container for 1 month.
[0044] FIG. 17 illustrates reversing heat flow signals observed via DSC analysis of flecainide acetate spray dried powders stored in closed containers for 1 -month (Batches J, K, and M).
[0045] FIG. 18 illustrates non-reversing heat flow signals observed via DSC analysis of flecainide acetate spray dried powders stored in closed containers for 1 month (Batches J, K, and M).
[0046] FIG. 19 illustrates reversing heat flow signals observed via DSC analysis of flecainide acetate spray dried powders stored in open containers for 1 month.
[0047] FIG. 20 illustrates non-reversing heat flow signals observed via DSC analysis of flecainide acetate spray dried powders stored in closed containers for 1 month.
[0048] FIG. 21 illustrates an overlay of XRPD diffractograms of flecainide acetate spray dried powder Batches J-M after storage for 1 month.
[0049] FIG. 22 illustrates total and reversing heat flow signals observed via DSC analysis of flecainide acetate spray dried powder Batch J.
[0050] FIG. 23 illustrates total and reversing heat flow signals observed via DSC analysis of flecainide acetate spray dried powder Batch K.
[0051] FIG. 24 illustrates total and reversing heat flow signals observed via DSC analysis of analysis of flecainide acetate spray dried powder Batch L.
[0052] FIG. 25 illustrates total and reversing heat flow signals observed via DSC analysis of analysis of flecainide acetate spray dried powder Batch M.
[0053] FIG. 26 illustrates total and reversing heat flow signals observed via DSC analysis of analysis of flecainide acetate spray dried powder Batch N.
[0054] FIG. 27 shows aerodynamic particle size distribution for T=0M (0 month) powders tested in RS01 medium flow resistance (0.10R) and 50 mg capsule powder mass. Mean of three replicates with standard deviation.
[0055] FIG. 28 shows aerodynamic particle size distribution for T=0M powders tested in RS01 high flow resistance (0.16R) and 50 mg capsule powder mass. Mean of three replicates with standard deviation.
[0056] FIG. 29 shows aerodynamic particle size distribution for T=1M (1 month) powders tested in RS01 medium flow resistance (0.10R) and 50 mg capsule powder fill mass. Mean of three replicates with standard deviation.
[0057] FIG. 30 shows aerosol clearance volume by laser photometry for powder batch Lot B (T=0M) using two different flow resistance inhaler devices and tested at 2 kPa (n=3); 0.10R (Left) and 0.16R (Right).
[0058] FIG. 31 shows aerosol clearance volume by laser photometry for powder batch Lot D (T=0M) using two different flow resistance inhaler devices and tested at 2 kPa (n=3); 0.10R (Left) and 0.16R (Right).
[0059] FIG. 32 shows aerosol clearance volume by laser photometry for powder batch Lot B (T=0M) using two different flow resistance inhaler devices and tested at 4 kPa (n=3); 0.10R (Left) and 0.16R (Right).
[0060] FIG. 33 shows aerosol clearance volume by laser photometry for powder lot Lot D (T=0M) using two different flow resistance inhaler devices and tested at 4 kPa (n=3); 0.1 OR (Left) and 0.16R (Right).
[0061] FIG. 34 is an APSD cumulative plot for T=0M two powder batches (Lot B & Lot D) and evaluated in two flow resistance devices (0.10 and 0.16R) at 4 kPa pressure drop. Mean of 3 replicates and standard deviation.
[0062] FIG. 35 is an APSD cumulative plot for T=0M and T=1M for powder lots (Lot A, Lot B, & Lot D) tested with medium flow resistance device (0.10R) at 4 kPa pressure drop. Mean of 3 replicates and standard deviation.
[0063] FIG. 36 is a drug mass distribution plot comparing T=0M and T=1M for powder batch (Lot A) tested with medium flow resistance device (0.1 OR) at 4 kPa pressure drop. Mean of 3 replicates with standard deviation.
[0064] FIG. 37 is a drug mass distribution plot comparing T=0M and T=1M for powder batch (Lot B) tested with medium flow resistance device (0.10R) at 4 kPa pressure drop. Mean of 3 replicates with standard deviation.
[0065] FIG. 38 is a drug mass distribution plot comparing T=0M and T=1M for powder batch (Lot D) tested with medium flow resistance device (0.1 OR) at 4 kPa pressure drop. Mean of 3 replicates with standard deviation.
DETAILED DESCRIPTION
[0066] In some aspects, the present disclosure relates to a novel inhalable dry powder formulation comprising a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt
thereof and a cyclodextrin for treatment of a heart condition (e.g., cardiac arrhythmic) in a subject in need thereof. In some aspects, provided herein are methods of treatment comprising administering a novel formulation comprising a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and a cyclodextrin for treatment of a heart condition (e.g., cardiac arrhythmic) in a subject in need thereof. In some embodiments, the pharmaceutical composition is inhalable when delivered via a dry powder inhaler for the treatment of a heart condition e.g., atrial fibrillation (AF)) in a subject in need thereof.
PMARMACEUTICAL COMPOSITION
[0067] In some embodiments, the pharmaceutical composition and the method of treatment provided herein are advantageous in offering a fast, efficient, and safe therapeutic solution to heart conditions, such as cardiac arrhythmia, including atrial arrhythmia. In some embodiments, the present disclosure relates to inhalational administration of a pharmaceutical composition in the form of an inhalable dry powder that comprises flecainide or pharmaceutically acceptable salt thereof and a cyclodextrin or pharmaceutically acceptable salt thereof.
[0068] In some embodiments, the pharmaceutical composition or formulation provided herein enables delivery of a greater quantity of pharmaceutically active ingredient, e.g., flecainide, to the subject. In some embodiments, the subject pharmaceutical composition or formulation has an increased weight ratio of flecainide or pharmaceutically acceptable salt thereof to cyclodextrin as compared to a corresponding flecainide formulation (e.g., flecainide to cyclodextrin weight ratio of 50/50 compared to a weight ratio of 20/80). In some cases, the increased weight ratio of flecainide or pharmaceutically acceptable salt thereof increases the amount of flecainide administered via inhalation. In some embodiments, the increased flecainide weight ratio to cyclodextrin shortens the inhalation duration as a given dose can be delivered at a higher speed as compared to a corresponding formulation with a lower weight of flecainide to cyclodextrin. Shortening the period of time required for a subject to completely inhale a target dose can improve subject compliance, which can further increase the delivery efficiency of the drug. In some embodiments, the pharmaceutical composition or formulation provided herein reduces adverse cough of the subject while inhaling, has improved organoleptic properties, and improves overall patient experience of inhalation. In some embodiments, the improved overall inhalation experience results in better compliance with the full inhalation program. In some embodiments, more effective drug delivery is achieved when the subject has better inhalation compliance, and thus more drug is delivered.
[0069] In one aspect of the present disclosure, provided herein is a unit dose of a pharmaceutical composition provided herein. In some embodiments, the unit dose comprises about 50 mg to about
350 mg of the salt of flecainide. In another aspect, provided herein are kits comprising the pharmaceutical composition or the unit dose provided herein and instructions for use of the pharmaceutical composition for treatment of a heart condition (e.g., cardiac arrhythmia, e.g., atrial arrhythmia).
FLECAINIDE
[0070] In some aspects of the present disclosure, the pharmaceutical composition comprises a anti arrhythmic pharmaceutical agent. In some embodiments, the anti arrhythmic pharmaceutical agent is flecainide or therapeutically acceptable salt thereof. In some embodiments, the pharmaceutically acceptable salt of flecainide is flecainide acetate. In some embodiments, the anti arrhythmic pharmaceutical agent is a flecainide derivative (e.g., QX-FL, NU-FL) or pharmaceutically acceptable salt thereof. Flecainide is N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2- trifluoroethoxy)benzamide, which has the structure:
CYCLODEXTRIN
[0071] In some aspects of the present disclosure, a cyclodextrin is used as a solubility enhancer of a flecainide salt. Cyclodextrins are cyclic carbohydrates derived from starch. The unmodified cyclodextrins differ by the number of glucopyranose units joined together in the cylindrical structure. The parent cyclodextrins contain 6, 7, or 8 glucopyranose units and are referred to as a- , P-, and y-cyclodextrin respectively. Each cyclodextrin subunit can have secondary hydroxyl groups at the 2 and 3 positions and a primary hydroxyl group at the 6-position. The cyclodextrins can be pictured as hollow truncated cones with hydrophilic exterior surfaces and hydrophobic interior cavities. In aqueous solutions, these hydrophobic cavities can sequester hydrophobic organic compounds that can fit all or part of their structure into these cavities. This process, known as inclusion complexation, can result in increased apparent aqueous solubility and stability for the complexed drug.
[0072] Non-limiting examples of a cyclodextrin suitable for inclusion in a pharmaceutical composition provided herein can include a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, derivatized a-cyclodextrins, derivatized P-cyclodextrins, and derivatized y-cyclodextrins. Nonlimiting examples of a cyclodextrin that can be used in the subject pharmaceutical composition include a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, hydroxypropyl-P-cyclodextrin,
hydroxyethyl-P-cyclodextrin, hydroxypropyl -y-cyclodextrin, hydroxyethyl-y-cyclodextrin, dihydroxypropyl-P-cyclodextrin, glucosyl-a-cyclodextrin, glucosyl-P-cyclodextrin, diglucosyl-P- cyclodextrin, maltosyl-a-cyclodextrin, maltosyl-P-cyclodextrin, maltosyl-y-cyclodextrin, maltotriosyl-P-cyclodextrin, maltotriosyl-y-cyclodextrin dimaltosyl-P-cyclodextrin, succinyl-P- cyclodextrin, 6A-amino-6A-deoxy-N-(3-hydroxypropyl)-P-cyclodextrin, sulfobutylether-P- cyclodextrin, sulfobutylether-y-cyclodextrin, sulfoalkylether-P-cyclodextrin, and sulfoalkylether- y-cyclodextrin. In some embodiments, the pharmaceutical composition comprises hydroxypropyl- P-cyclodextrin (HPpCD). In some embodiments, the pharmaceutical composition comprises more than one species of cyclodextrin, such as, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different species of cyclodextrin. In some embodiments, the pharmaceutical composition comprises HPpCD and one or more other cyclodextrins, such as, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more other different species of cyclodextrin. In some cases, the cyclodextrin is selected from the group consisting of: a- cyclodextrin, P-cyclodextrin, y-cyclodextrin, derivatized a-cyclodextrins, derivatized P- cyclodextrins, and derivatized y-cyclodextrins. In some cases, the cyclodextrin is selected from the group consisting of: a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, hydroxypropyl-P- cyclodextrin, hydroxyethyl-P-cyclodextrin, hydroxypropyl-y-cyclodextrin, hydroxyethyl-y- cyclodextrin, dihydroxypropyl-P-cyclodextrin, glucosyl-a-cyclodextrin, glucosyl-P-cyclodextrin, diglucosyl-P-cyclodextrin, maltosyl-a-cyclodextrin, maltosyl-P-cyclodextrin, maltosyl-y- cyclodextrin, maltotriosyl-P-cyclodextrin, maltotriosyl-y-cyclodextrin, dimaltosyl-P-cyclodextrin, succinyl-P-cyclodextrin, 6A-amino-6A-deoxy-N-(3-hydroxypropyl)-P-cyclodextrin, sulfobutylether-P-cyclodextrin, sulfobutylether-y-cyclodextrin, sulfoalkylether-P-cyclodextrin, and sulfoalkyl ether-y-cy cl odextrin .
[0073] In some embodiments, the concentration of the cyclodextrin contributes to the viscosity of the solution, which can reduce the nebulization efficiency (or rate) of the solution. For instance, in some cases, the higher the concentration of the cyclodextrin is, the higher viscosity of the solution is. In some cases, the concentration of the cyclodextrin in the pharmaceutical composition is controlled so that the viscosity of the solution is not higher than a reference value, such as about 1.0, 1.1, 1.2, 1.3 cP, 1.4 cP, 1.5 cP, 1.6 cP, 1.7 cP, 1.8 cP, 1.9 cP, 2.0, 2.1 cP, 2.2 cP, 2.3 cP, 2.4 cP, 2.5 cP, 2.6 cP, 2.7 cP, 2.8 cP, 2.9 cP, 3.0 cP, 3.1 cP, 3.2 cP, 3.3 cP, 3.4 cP, 3.5 cP, 3.6 cP, 3.7 cP, 3.8 cP, 3.9 cP, 4.0 cP, 4.1 cP, 4.2 cP, 4.3 cP, 4.4 cP, 4.5 cP, 4.6 cP, 4.7 cP, 4.8 cP, 4.9 cP, 5.0 cP, 6.0 cP, 7.0 cP, 8.0 cP, 9.0 cP, 10.0 cP. In some cases, the concentration of the cyclodextrin in the pharmaceutical composition is at most about 2%, 5%, 8%, 10%, 12%, 15%, 18%, 20%, 20.5%,
21%, 21.5%, 22%, 22.5%, 23%, 23.5%, 24%, 24.5%, 25%, 25.5%, 26%, 26.5%, 27%, 27.5%, 28%, 28.5%, 29%, 29.5%, 30%, 31%, 32%, 33%, 34%, 35%, 38%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, or 80% (w/v) of the solution.
[0074] In some embodiments, the pharmaceutical compositions described herein comprises a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and a cyclodextrin in weight ratio from about 5:95 to about 95:5. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 15:85 to about 95:5. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 25:75 to about 95:5. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 35:65 to about 95:5. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 45:55 to about 95:5. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 55:45 to about 95:5. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 65:35 to about 95:5. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 75:25 to about 95:5. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 85: 15 to about 95:5. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95 to about 85: 15. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95 to about 75:25. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95 to about 65:35. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95 to about 55:45. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95 to about 45:55. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95 to about 35:65. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95 to about 25:75. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95 to about 15:85. In some embodiments, flecainide or a pharmaceutically acceptable salt thereof and the cyclodextrin is in a weight ratio about 5:95, about 15:85, about 25:75, about 35:65, about 45:55, about 55:45, about 65:35, about 75:25, about 85: 15, or about 95:5.
[0075] Without wishing to be bound by a certain theory, the presence of a cyclodextrin in the pharmaceutical composition can reduce the concentration of acid that is required to achieve a desirable concentration of flecainide salt according to some aspects of the present disclosure. In some embodiments, the presence of a cyclodextrin (e.g., HPpCD) increases flecainide solubility, e.g., through inclusion complexation that “dissolves” flecainide salt (e.g., flecainide acetate) inside
the cavity of the cyclodextrin. The inclusion complexation, on the other hand, can decopule the solubility of flecainide and the acidicity (the low pH) of the solution. As a result, the introduction of cyclodextrin (e.g., HPpCD) can lead to reduction in the concentration of acid necessary to maintain sufficient flecainide solubility, and can synergistically lead to increased flecainide concentration in the solution, improved organoleptic properties, increased delivery speed, and improved delivery efficiency.
ACIDS
[0076] Some aspects of the present disclosure relate to use of one or more acids in the pharmaceutical composition. In some cases, the acid enhances solubility of flecainide. In some cases, flecainide freebase has a low solubility, e.g., in water. In some cases, certain salts of flecainide have higher solubility as compared to other salts of flecainide and flecainide freebase. For instance, flecainide acetate can have a higher solubility as compared to some other flecainide salts. Without wishing to be bound to a certain theory, in some cases, the acid is provided in the pharmaceutical composition to provide the proton and anion for flecainide salt formation. In some cases, acid is provided in the pharmaceutical composition to lower pH to promote solubility of the flecainide salt. In some cases, acid is provided in the pharmaceutical composition to provide the proton and anion for flecainide salt formation and sufficiently lower pH to ensure the solubility of the flecainide salt.
[0077] In some cases, a mixture of more than one acid increases flecainide solubility as compared to a single acid. In some instances, the pharmaceutical composition comprises acetic acid as the single acid. In some instances, the pharmaceutical composition comprises citric acid as the single acid. In some cases, the pharmaceutical composition comprises a mixture of different acids. In some cases, the pharmaceutical composition comprises lactic acid. In some cases, the pharmaceutical composition comprises L-(+)-lactic acid. In some cases, the pharmaceutical composition comprises D-(-)-lactic acid. In some cases, the pharmaceutical composition comprises a mixture of D-(-)-lactic acid and L-(+)-lactic acid, i.e., the pharmaceutical composition comprises DL-lactic acid. In some cases, there are equal amounts of D-(-)-lactic acid and L-(+)-lactic acid in the pharmaceutical composition. In some cases, the pharmaceutical composition comprises ascorbic acid. Non-limiting examples of the acids that can be used in the subject pharmaceutical compositions and methods of treatment include any suitable organic or inorganic acid, such as any GRAS (Generally Recognized As Safe) listed acid, e.g., acetic acid, aconitic acid, adipic acid, alginic acid, benzoic acid, caprylic acid, citric acid, cholic acid, formic acid, lactic acid (e.g., D-(- )-lactic acid or L-(+)-lactic acid), linoleic acid, malic acid, maleic acid, propionic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, tartaric acid, glutamic acid, hydrochloric acid, phosphoric
acid, ascorbic acid, erythorbic acid, sorbic acid, or thiodipropionic acid, or any other acid that is not listed in GRAS but is pharmaceutically acceptable in the subject pharmaceutical composition. [0078] In some cases, the pharmaceutical composition comprises a mixture of different acids, such as 2, 3, 4, 5, 6, 7, 8, 9, 10 or more different acids. In some cases, the pharmaceutical composition comprises one of the following: acetic acid and nitric acid; acetic acid and sulfuric acid; acetic acid and citric acid; acetic acid, nitric acid, and sulfuric acid; acetic acid, nitric acid, and citric acid; acetic acid, citric acid, and sulfuric acid; or acetic acid, nitric acid, citric acid, and sulfuric acid.
[0079] In some embodiments, the dry powder pharmaceutical composition is reconstituted in water. The process of reconstitution can involve dissolving the pharmaceutical composition described herein with high purity water, for instance, MilliQ water. In some embodiments, 120 mg of dry powder pharmaceutical composition described herein is dissolved in 3 mL of water. In some embodiments, the pharmaceutical composition has a reconstituted pH that is about 5.0 to about 8.0 when the pH is measured at room temperature, such as about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5,9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, about 7.8, about 7.9, or about 8.0 when the pH is measured at room temperature and at a concentration of about 9 mg/mL to about 10 mg/mL. In some cases, the pharmaceutical composition is acidic when reconstituted, e.g., having a pH at most from about at least 5.0 to about at most 8.0. In some embodiments, the pH of the pharmaceutical composition when reconstituted is at most 5.0, at most 5.1, at most 5.2, at most 5.3, at most 5.4. at most 5.5, at most 5.5, at most 5.6, at most 5.7, at most 5.8, at most 6.0, at most
6.1, at most 6.2, at most 6.3, at most 6.4, at most 6.5, at most 6.6, at most 6.7, at most 6.8, at most
6.9, at most 7.0, at most 7.1, at most 7.2, at most 7.3, at most 7.4, at most 7.5, at most 7.6, at most
7.7, at most 7.8, at most 7.9, or at most 8.0 when the pH is measured at room temperature and at a concentration of about 9 mg/mL to about 10 mg/mL. In some cases, the pharmaceutical composition has a pH that is from about 5.5 and about 6.5 when the pH is measured at room temperature, such as from about 5.6 and about 6.4, from about 5.7 and about 6.3, from about 5.8 and about 6.2, or from about 5.9 and about 6.1 when the pH is measured at room temperature and flecainide acetate at a concentration of about 9 mg/mL to about 10 mg/mL. In some instances, the pharmaceutical composition has a reconstituted pH of about 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 7.0, or 8.0 when the pH is measured at room temperature and at a concentration of about 9 mg/mL to about 10 mg/mL. In some examples, the pharmaceutical composition has a reconstituted pH of about 7.4 when the pH is measured at room temperature and at a concentration of about 9 mg/mL to about 10 mg/mL.
[0080] Solutions can also comprise a buffer or a pH adjusting agent, typically a salt prepared from an organic acid or base. Representative buffers comprise organic acid salts of citric acid, lactic acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetic acid, or phthalic acid, Tris, tromethamine hydrochloride, or phosphate buffers. Thus, the buffers can include citrates, phosphates, phthalates, and lactates. Examples of buffers include, but are not limited to, acetate, tris, or citrate. Examples of acids include, but are not limited to, carboxylic acids. Examples of salts include, but are not limited to, sodium chloride, salts of carboxylic acids, (e.g., sodium citrate, sodium ascorbate, magnesium gluconate, sodium gluconate, tromethamine hydrochloride), ammonium carbonate, ammonium acetate, ammonium chloride, and the like. Examples of organic solids include, but are not limited to, camphor, and the like. The pharmaceutical composition of one or more embodiments of the present disclosure can also include a biocompatible, such as biodegradable polymer, copolymer, or blend or other combination thereof. In this respect useful polymers comprise polylactides, polylactide-glycolides, cyclodextrins, polyacrylates, methylcellulose, carboxymethylcellulose, polyvinyl alcohols, polyanhydrides, polylactams, polyvinyl pyrrolidones, polysaccharides (dextrans, starches, chitin, chitosan), hyaluronic acid, proteins, (albumin, collagen, gelatin). Those skilled in the art will appreciate that, by selecting the appropriate polymers, the delivery efficiency of the composition and/or the stability of the dispersions can be tailored to optimize the effectiveness of the anti arrhythmic pharmaceutical agent(s).
PHARMACEUTICALLY ACCEPTABALE EXCIPIENTS
[0081] In one aspect, provided herein are formulations for treatment of a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia. The formulations can include the pharmaceutical compositions provided herein and a pharmaceutically acceptable carrier, excipient, diluent, or any other suitable component for the intended administration routes, such as oral or nasal inhalation. Examples of pharmaceutically acceptable excipients include, but are not limited to, lipids, metal ions, surfactants, amino acids, carbohydrates, buffers, salts, polymers, sweeteners, and the like, and combinations thereof.
[0082] Examples of carbohydrates include, but are not limited to, monosaccharides, disaccharides, and polysaccharides. For example, monosaccharides such as dextrose (anhydrous and monohydrate), galactose, mannitol, D-mannose, sorbitol, sorbose and the like; disaccharides such as lactose, maltose, sucrose, trehalose, and the like; trisaccharides such as raffinose and the like; and other carbohydrates such as starches (hydroxy ethyl starch), and maltodextrins.
[0083] Non-limiting examples of lipids include phospholipids, glycolipids, ganglioside GM1, sphingomyelin, phosphatidic acid, cardiolipin; lipids bearing polymer chains such as polyethylene
glycol, chitin, hyaluronic acid, or polyvinylpyrrolidone; lipids bearing sulfonated mono-, di-, and polysaccharides; fatty acids such as palmitic acid, stearic acid, and oleic acid; cholesterol, cholesterol esters, and cholesterol hemisuccinate.
[0084] In some cases, the phospholipid comprises a saturated phospholipid, such as one or more phosphatidylcholines. Exemplary acyl chain lengths are 16:0 and 18:0 e.g., palmitoyl and stearoyl). The phospholipid content can be determined by the active agent activity, the mode of delivery, and other factors.
[0085] Phospholipids from both natural and synthetic sources can be used in varying amounts. When phospholipids are present, the amount is typically sufficient to coat the active agent(s) with at least a single molecular layer of phospholipid. In general, the phospholipid content ranges from about 5 wt% to about 99.9 wt%, such as about 20 wt% to about 80 wt%.
[0086] Generally, compatible phospholipids can comprise those that have a gel to liquid crystal phase transition greater than about 40 °C, such as greater than about 60 °C, or greater than about 80 °C. The incorporated phospholipids can be relatively long chain (e.g., C16-C22) saturated lipids. Exemplary phospholipids useful in the present disclosure include, but are not limited to, phosphoglycerides such as dipalmitoylphosphatidylcholine, distearoylphosphatidylcholine, diarachidoylphosphatidylcholine, dibehenoylphosphatidylcholine, diphosphatidyl glycerols, short-chain phosphatidylcholines, hydrogenated phosphatidylcholine, E-100-3 (available from Lipoid KG, Ludwigshafen, Germany), long-chain saturated phosphatidylethanolamines, long- chain saturated phosphatidylserines, long-chain saturated phosphatidylglycerols, long-chain saturated phosphatidylinositols, phosphatidic acid, phosphatidylinositol, and sphingomyelin.
[0087] Examples of metal ions include, but are not limited to, divalent cations, including calcium, magnesium, zinc, iron, and the like. For instance, when phospholipids are used, the pharmaceutical composition can also comprise a polyvalent cation, as disclosed in WO 01/85136 and WO 01/85137, which are incorporated herein by reference in their entireties. The polyvalent cation can be present in an amount effective to increase the melting temperature (Tm) of the phospholipid such that the pharmaceutical composition exhibits a Tm which is greater than its storage temperature (Tm) by at least about 20 °C, such as at least about 40 °C. The molar ratio of polyvalent cation to phospholipid can be at least about 0.05: 1, such as about 0.05: 1 to about 2.0: 1 or about 0.25: 1 to about 1.0: 1. In some embodiments, the molar ratio of polyvalent cation to phospholipid is about 0.50: 1. When the polyvalent cation is calcium, it can be in the form of calcium chloride. Although metal ion (e.g., calcium) is often included with phospholipid, none is required.
[0088] The pharmaceutical composition can include one or more surfactants. For instance, one or more surfactants can be in the liquid phase with one or more being associated with solid particles or particles of the composition. By “associated with” it is meant that the pharmaceutical
compositions can incorporate, adsorb, absorb, be coated with, or be formed by the surfactant. Surfactants include, but are not limited to, fluorinated and nonfluorinated compounds, such as saturated and unsaturated lipids, nonionic detergents, nonionic block copolymers, ionic surfactants, and combinations thereof. It should be emphasized that, in addition to the aforementioned surfactants, suitable fluorinated surfactants are compatible with the teachings herein and can be used to provide the desired preparations.
[0089] Examples of nonionic detergents include, but are not limited to, sorbitan esters including sorbitan trioleate (Span™ 85), sorbitan sesquioleate, sorbitan monooleate, sorbitan monolaurate, polyoxyethylene (20) sorbitan monolaurate, and polyoxyethylene (20) sorbitan monooleate, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene (2) ether, lauryl polyoxyethylene (4) ether, glycerol esters, and sucrose esters. Other suitable nonionic detergents can be easily identified using McCutcheon’s Emulsifiers and Detergents (McPublishing Co., Glen Rock, N.J.), which is incorporated herein by reference in its entirety.
[0090] Examples of block copolymers include, but are not limited to, diblock and triblock copolymers of polyoxyethylene and poly oxypropylene, including pol oxamer 188 (Pluronic™ F- 68), poloxamer 407 (Pluronic™ F-127), and poloxamer 338. Examples of ionic surfactants include, but are not limited to, sodium sulfosuccinate, and fatty acid soaps. Examples of amino acids include, but are not limited to hydrophobic amino acids, for instance, L-leucin or L-isoleucin. Use of amino acids as pharmaceutically acceptable excipients is known in the art as disclosed in WO 95/31479, WO 96/32096, and WO 96/32149, which are incorporated herein by reference in their entireties.
[0091] The pharmaceutical composition according to one or more embodiments of the disclosure may, if desired, contain a combination of anti arrhythmic pharmaceutical agent (e.g., flecainide salt) and one or more additional active agents. Examples of additional active agents include, but are not limited to, agents that can be delivered through the lungs.
[0092] Additional active agents can comprise, for example, hypnotics and sedatives, psychic energizers, tranquilizers, respiratory drugs, anticonvulsants, muscle relaxants, antiparkinson agents (dopamine antagonists), analgesics, anti-inflammatories, antianxiety drugs (anxiolytics), appetite suppressants, antimigraine agents, muscle contractants, additional anti-infectives (antivirals, antifungals, vaccines) antiarthritics, antimalarials, antiemetics, antiepileptics, cytokines, growth factors, anti-cancer agents, antithrombotic agents, antihypertensives, cardiovascular drugs, antiarrhythmics, antioxidants, anti-asthma agents, hormonal agents including contraceptives, sympathomimetics, diuretics, lipid regulating agents, anti androgenic agents, antiparasitic, anticoagulants, neoplasties, antineoplastics, hypoglycemics, nutritional agents and supplements, growth supplements, antienteritis agents, vaccines, antibodies, diagnostic
agents, and contrasting agents. The additional active agent, when administered by inhalation, can act locally or systemically.
[0093] The additional active agent can fall into one of a number of structural classes, including but not limited to small molecules, peptides, polypeptides, proteins, polysaccharides, steroids, proteins capable of eliciting physiological effects, nucleotides, oligonucleotides, polynucleotides, fats, electrolytes, and the like.
[0094] Examples of additional active agents suitable for use in this disclosure include but are not limited to one or more of calcitonin, amphotericin B, erythropoietin (EPO), Factor VIII, Factor IX, ceredase, cerezyme, cyclosporin, granulocyte colony stimulating factor (GCSF), thrombopoietin (TPO), alpha- 1 proteinase inhibitor, elcatonin, granulocyte macrophage colony stimulating factor (GMCSF), growth hormone, human growth hormone (HGH), growth hormone releasing hormone (GHRH), heparin, low molecular weight heparin (LMWH), interferon alpha, interferon beta, interferon gamma, interleukin- 1 receptor, interleukin-2, interleukin- 1 receptor antagonist, interleukin-3, interleukin-4, interleukin-6, luteinizing hormone releasing hormone (LHRH), factor IX, insulin, pro-insulin, insulin analogues (e.g., mono-acylated insulin as described in U.S. Pat. No. 5,922,675, which is incorporated herein by reference in its entirety), amylin, C-peptide, somatostatin, somatostatin analogs including octreotide, vasopressin, follicle stimulating hormone (FSH), insulin-like growth factor (IGF), insulintropin, macrophage colony stimulating factor (M- CSF), nerve growth factor (NGF), tissue growth factors, keratinocyte growth factor (KGF), glial growth factor (GGF), tumor necrosis factor (TNF), endothelial growth factors, parathyroid hormone (PTH), glucagon-like peptide thymosin alpha 1, Ilb/IIa inhibitor, alpha- 1 antitrypsin, phosphodiesterase (PDE) compounds, VLA-4 inhibitors, bisphosponates, respiratory syncytial virus antibody, cystic fibrosis transmembrane regulator (CFFR) gene, deoxyribonuclease (DNase), bactericidal/permeability increasing protein (BPI), anti-CMV antibody, 13-cis retinoic acid, oleandomycin, troleandomycin, roxithromycin, clarithromycin, davercin, azithromycin, flurithromycin, dirithromycin, josamycin, spiromycin, midecamycin, leucomycin, miocamycin, rokitamycin, andazithromycin, and swinolide A; fluoroquinolones such as ciprofloxacin, ofloxacin, levofloxacin, trovafloxacin, alatrofloxacin, moxifloxicin, norfloxacin, enoxacin, grepafloxacin, gatifloxacin, lomefloxacin, sparfloxacin, temafloxacin, pefloxacin, amifloxacin, fleroxacin, tosufloxacin, prulifloxacin, irloxacin, pazufloxacin, clinafloxacin, and sitafloxacin, teicoplanin, rampolanin, mideplanin, colistin, daptomycin, gramicidin, colistimethate, polymixins such as polymixin B, capreomycin, bacitracin, penems; penicillins including penicllinase-sensitive agents like penicillin G, penicillin V, penicillinase-resistant agents like methicillin, oxacillin, cioxacillin, dicloxacillin, floxacillin, nafcillin; gram negative microorganism active agents like ampicillin, amoxicillin, and hetacillin, cillin, and galampicillin; antipseudomonal penicillins like
carbenicillin, ticarcillin, azlocillin, mezlocillin, and piperacillin; cephalosporins like cefpodoxime, cefprozil, ceftbuten, ceftizoxime, ceftriaxone, cephalothin, cephapirin, cephalexin, cephradrine, cefoxitin, cefamandole, cefazolin, cephaloridine, cefaclor, cefadroxil, cephaloglycin, cefuroxime, ceforanide, cefotaxime, cefatrizine, cephacetrile, cefepime, cefixime, cefonicid, cefoperazone, cefotetan, cefinetazole, ceftazidime, loracarbef, and moxalactam, monobactams like aztreonam; and carbapenems such as imipenem, meropenem, pentamidine isethiouate, lidocaine, metaproterenol sulfate, beclomethasone diprepionate, triamcinolone acetamide, budesonide acetonide, fluticasone, ipratropium bromide, flunisolide, cromolyn sodium, ergotamine tartrate and where applicable, analogues, agonists, antagonists, inhibitors, and pharmaceutically acceptable salt forms of the above. In reference to peptides and proteins, the disclosure is intended to encompass synthetic, native, glycosylated, unglycosylated, pegylated forms, and biologically active fragments, derivatives, and analogs thereof.
[0095] Additional active agents for use in the disclosure can further include nucleic acids, as bare nucleic acid molecules, vectors, associated viral particles, plasmid DNA or RNA or other nucleic acid constructions of a type suitable for transfection or transformation of cells, e.g., suitable for gene therapy including antisense. Further, an active agent can comprise live attenuated or killed viruses suitable for use as vaccines. Other useful drugs include those listed within the Physician’s Desk Reference (most recent edition), which is incorporated herein by reference in its entirety.
[0096] When a combination of active agents is used, the agents can be provided in combination in a single species of pharmaceutical composition or individually in separate species of pharmaceutical compositions.
[0097] The pharmaceutical compositions of one or more embodiments of the present disclosure can lack taste. In this regard, although taste masking agents are optionally included within the composition, the compositions in some embodiments do not include a taste masking agent other than a cyclodextrin and lack taste even without a taste masking agent.
[0098] In some embodiments, the pharmaceutical composition provided herein comprises a sweetener to improve the organoleptic properties of the composition. The sweetener can be a natural sweet substance, e.g. certain sugars, or an artificial sweetener. Without wishing to be bound to a certain theory, the presence of the sweetener in the pharmaceutical composition can improve the organoleptic properties of the composition. In some cases, the presence of the sweetener in the pharmaceutical composition can improve the compliance of the subject. In some embodiments, presence of the sweetener in the pharmaceutical composition increases the delivery efficiency of the composition. In some embodiments, the presence of the sweetener in the pharmaceutical composition can enhance the therapeutic effects of the composition.
[0099] Non-limiting examples of artificial sweeteners that can be used in the pharmaceutical composition include acesulfame potassium, aspartame, cyclamate, mogrosides, saccharin, stevia, sucralose, neotame, and sugar alcohols (e.g., erythritol, hydrogenated starch hydrolysates, isomalt, lactitol, maltitol, mannitol, sorbitol, and xylitol), such as those used in commercial products, like Sweet n’ low powder sweetener, Truvia powder sweetener, Equal (aspartame), Stevia powder sachet, Aspen Naturals liquid stevia, Now Better Stevia liquid sweetener, Sweet N’ Low liquid sweetener, Quick Sweet: Neotame liquid sweetener, or Splenda powder sachet, or pharmaceutically acceptable salts thereof. In some embodiments, the pharmaceutical composition comprises saccharin. In some embodiments, the pharmaceutical composition comprises a salt of saccharin. In some embodiments, the pharmaceutical composition comprises saccharin sodium.
[0100] Natural sweet substances that can be used in the pharmaceutical composition include, but are not limited to, sucrose, agave, brown sugar, confectioner’s (powdered) sugar, com syrup, dextrose, fructose, fruit juice concentrate, glucose, high-fructose corn syrup, honey, invert sugar, lactose, malt sugar, maltose, maple syrup, molasses, nectars, raw sugar, and syrup. Sugars can increase the viscosity of the liquid solution, thus the concentration of any sugar added into the pharmaceutical composition, in some embodiments, is tightly controlled below a certain threshold value.
[0101] In some embodiments, pharmaceutically acceptable excipient or carrier comprises lactose, mannitol, sorbitol, erythritol, raffinose, sucrose, xylitol, trehalose, dextrose, cyclodextrins, maltitol, maltose, glucose, hydroxyapatite, or any combinations thereof.
[0102] Besides the above mentioned pharmaceutically acceptable excipients, it can be desirable to add other pharmaceutically acceptable excipients to the pharmaceutical composition to improve particle rigidity, production yield, emitted dose and deposition, shelf-life, and patient acceptance. Such optional pharmaceutically acceptable excipients include, but are not limited to: coloring agents, taste masking agents, buffers, hygroscopic agents, antioxidants, and chemical stabilizers. Further, various pharmaceutically acceptable excipients can be used to provide structure and form to the particle compositions (e.g., latex particles). In this regard, it will be appreciated that the rigidifying components can be removed using a post-production technique such as selective solvent extraction.
[0103] In some embodiments, the pharmaceutical composition comprises crystallization inhibitors. Exemplary pharmaceutically acceptable crystallization inhibitors can be, but are not limited to, polymers, polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), polysaccharide, hydroxypropyl methylcellulose (HPMC or Hypromellose), hydroxyethyl cellulose (ELEC), hydroxypropyl cellulose (HPC), polyethylene oxide, hydroxypropyl-P-cyclodextrin (HP-P-CD),
sulfobutylether-P-cyclodextrin, hydroxypropyl methylcellulose acetate succinate (HPMC-AS- HF), or polyethylene glycol (PEG).
DRY POWDER
PARTICLES
[0104] The distribution of aerosol particle of an inhalable can be expressed in terms of either: the mass median aerodynamic diameter (MMAD) — the size at which half of the mass of the aerosol is contained in smaller droplets and half in larger droplets; volumetric mean diameter (VMD); mass median diameter (MMD); the fine particle fraction (FPF) — the percentage of particles that are <5 um in diameter. These measures have been used for comparisons of the in vitro performance of different inhaler device and drug combinations. In general, the higher the fine particle fraction, the higher the proportion of the emitted dose that is likely to deposit the lung. Generally, inhaled particles are subject to deposition by one of two mechanisms: impaction, which usually predominates for larger particles, and sedimentation, which is prevalent for smaller particles. Impaction occurs when the momentum of an inhaled particle is large enough that the particle does not follow the air stream and encounters a physiological surface. In contrast, sedimentation occurs primarily in the deep lung when very small particles which have traveled with the inhaled air stream encounter physiological surfaces as a result of random diffusion within the air stream. For pulmonary administration, the upper airways are avoided in favor of the middle and lower airways. Pulmonary drug delivery can be accomplished by inhalation of an aerosol through the mouth and throat. Particles having a mass median aerodynamic diameter (MMAD) of greater than about 5 microns generally do not reach the lung; instead, they tend to impact the back of the throat and are swallowed and possibly orally absorbed. Particles having diameters of about 1 to about 5 microns are small enough to reach the upper-to-mid-pulmonary region (conducting airways), but are too large to reach the alveoli. Smaller particles, z.e., about 0.5 to about 2 microns, are capable of reaching the alveolar region. Particles having diameters smaller than about 0.5 microns can also be deposited in the alveolar region by sedimentation, although very small particles can be exhaled. Measures of particle size can be referred to as volumetric mean diameter (VMD), mass median diameter (MMD), or MMAD. These measurements can be made by impaction (MMD and MMAD) or by laser (VMD). Inhalable dry powder particle size can be expressed in terms of the mass median aerodynamic diameter (MMAD). Large particles (e.g., MMAD-5 um) can deposit in the upper airway because they are too large to navigate the curvature of the upper airway. Small particles (e.g., MMAD-2 um) can be poorly deposited in the lower airways and thus become exhaled, providing additional opportunity for upper airway deposition. Hence, intolerability (e.g.,
cough and bronchospasm) can occur from upper airway deposition from both inhalation impaction of large particles and settling of small particles during repeated inhalation and expiration.
[0105] In some embodiments, described herein, the geometric particle size distribution measurement of the dry powder pharmaceutical composition is characterized through standard methods such as cascade impaction, dynamic image analysis, static image analysis, laser diffraction, dynamic light scattering, sieve analysis, microscopic imaging (/.< ., optical microscopy, electron microscopy) to obtain average particle size, MMAD, VMD, FPF, and MMD. In some embodiments, the preferable method of geometric particle size characterization is laser diffraction. In some embodiments, the MMD values are determined by laser diffraction. In some embodiments, the dry powders samples are added directly to the feeder funnel of the dry powder dispersion unit and are dispersed to primary particles via application of pressurized air (2 to 3 bar), with vacuum depression (suction) maximized for a given dispersion pressure. Dispersed particles are probed with a 632.8 nm laser beam that intersects the dispersed particles’ trajectory at right angles. Laser light scattered from the ensemble of particles is imaged onto a concentric array of photomultiplier detector elements using a reverse-Fourier lens assembly. Scattered light is acquired in time-slices of 5 ms. Particle size distributions are back-calculated from the scattered light spatial/intensity distribution using a proprietary algorithm.
[0106] Thus, in one embodiment, an optimum particle size is used e.g., MMAD=2-5 um) in order to maximize deposition at a mid-lung and to minimize intolerability associated with upper airway deposition. Moreover, generation of a defined particle size with limited geometric standard deviation (GSD) can optimize deposition and tolerability. Narrow GSD limits the number of particles outside the desired MMAD size range. In one embodiment, an aerosol containing one or more compounds disclosed herein is provided having a MMAD from about 2 microns to about 5 microns with a GSD of less than or equal to about 2.5. In another embodiment, an aerosol having an MMAD from about 2.8 microns to about 4.3 microns with a GSD less than or equal to 2 is provided. In another embodiment, an aerosol having an MMAD from about 2.5 microns to about 4.5 microns with a GSD less than or equal to 1.8 is provided.
DRY POWDER INHALER
[0107] Dry powders can use dry powder inhaler devices (DPIs), which are capable of dispersing the drug substance effectively. Dry powder inhaler devices can use a variety of dosage containers (e.g., capsule, blister pack, blister strip, reservoir, cartridge).
[0108] A desired particle size and distribution can be obtained by choosing an appropriate device. For dry powders, the moisture content is typically less than about 15 wt %, such as less than about 10 wt %, less than about 5 wt %, less than about 2 wt %, less than about 1 wt %, or less than about
0.5 wt %. Such powders are described in WO95/24183, WO 96/32149, WO 99/16419, WO 99/16420, and WO 99/16422, which are incorporated herein by reference in their entireties.
[0109] Efficient drug delivery to the lungs through dry powder inhalers (DPIs) is dependent on several factors including inhaler device, formulation, and inhalation maneuver. Preparing ideal DPI formulations requires control overall formulation characteristics at particulate and bulk level to ensure the drug delivery to lower airway regions. In DPI formulations, it is customary to blend micronized drug particles (less than 5 micron in size) with larger carrier particles to address flowability and dose variability issues. The typical concentration of drug in drug-carrier DPI formulations is low (e.g., 1 drug.: 67.5 carrier), but can vary depending on the aerosol dispersion properties of the formulation. Therefore, during drug-carrier mixing, drug particles will preferably adhere to the active binding sites (more adhesive areas) on the carrier surface and expected to separate from carrier surface upon inhalation. Drug re-dispersion is considered most important for getting drug particles into deep lung airway regions. Usually, only small amounts of drug reaches the lower airway regions due to strong drug-carrier adhesion. Indeed, drug re-dispersion is a function of balance between cohesive forces (between the drug particles) and the adhesive forces (between drug and carrier particles). In order to aerosolize drug particles, patient inspiratory force should overcome drug-carrier adhesive forces which are dependent on physicochemical properties of both drug particles and carrier particles. Consequently, it can be desirable to control the characteristics of carrier particles in terms of size, morphology, crystal form, surface energy. It has been reported that the differences in carrier particle size is likely to have significant impact on DPI aerosolization performance. The presence of fine particles on carrier surface can decrease the drugcarrier contact area and consequently drug-carrier adhesion forces leading to improved DPI performance. Better aerosolization performance was observed when the carrier tap density was higher, whereas no correlation was found between carrier flowability and DPI performance. Carriers with reduced dispersive surface energy produced higher fine particle fraction (FPF) of the drug upon aerosolization. Carrier particles with higher elongation ratio or increased surface roughness showed favorable inhalation properties.
PREPARATIONS
[0110] In some aspects, the present disclosure provides a method of preparing an inhalable dry powder pharmaceutical composition that comprises an anti arrhythmic pharmaceutical agent and cyclodextrin.
[oni] In some embodiments, flecainide or pharmaceutically acceptable salt is dissolved in water thereby resulting in a flecainide solution. In some embodiments, the flecainide solution further comprises an acid. In some embodiments, the acid is glacial acetic acid. In some embodiments,
the flecainide solution or flecainide solution with acid further comprises cyclodextrin. In some embodiments, the cyclodextrin is hydroxypropyl-P-cyclodextrin. In some embodiments, the flecainide/cyclodextrin solution or flecainide/cyclodextrin/acid solution is heated to 40 °C. The steps above are not limited to any specific order. In some embodiments, the heated flecainide/cyclodextrin solution or flecainide/cyclodextrin/acid solution is further cooled to 25 °C. In some embodiments, the flecainide/cyclodextrin solution or flecainide/cyclodextrin/acid solution is not heated. In some embodiments, the pH of the flecainide/cyclodextrin solution or flecainide/cyclodextrin/acid solution is adjusted using a pH adjusting agent, thereby resulting in the pharmaceutical composition solution. In some embodiments, the pH adjusting agent is acetic acid. In some embodiments, the pH adjusting agent is sodium hydroxide. In some embodiments, the pH adjusting agent is both acetic acid and sodium hydroxide. In some embodiments, the pH is adjusted to about 5.8 to about 6.0. In some embodiments, the pharmaceutical composition solution is spray-dried, thereby resulting in the inhalable dry powder pharmaceutical composition. In some embodiments, the pharmaceutical composition is diluted using water. In some embodiments, the pharmaceutical composition is diluted with water to form a 24.5 wt/wt% solution before the manufacturing process for inhalable dry powder pharmaceutical composition. In some embodiments, the pharmaceutical composition is diluted with water to form a 4 wt/wt% solution before the manufacturing process for inhalable dry powder pharmaceutical composition. In some embodiments, the pharmaceutical composition described herein is formulated into a dry powder form through methods such as, but not limited to, microfabrication, rapid expansion templating, supercritical fluid, lithography, antisolvent particle formation (e.g., liquid antisolvent, vapor antisolvent), spray drying, spray-freeze drying, jet milling, bead milling, ball milling, pearl milling, or high-pressure homogenization.
[0112] For dry powders, the composition can be formed by spray drying, spray-freeze-drying, aerosol flow reactor method, lyophilization, milling (e.g., wet milling, dry milling), and the like. In methods involving rapid freezing of the pharmaceutical composition liquid during the process of spray can lead to sublimation of frozen water and leading to the dry powder particles. In methods involving flow reactors, the aerosolized formulation create nucleation points for growth and the particle size can be tuned based on carrier gas and flow rate. In aerosol flow reactor method of manufacturing, the process involves first dissolving the drug material (e.g., flecainide or a pharmaceuticaly acceptable salt thereof) into a suitable solvent to produce a solution, which is then followed by atomising the solution as fine droplets into carrier gas. A heated laminar flow reactor tube can be used to evaporate the solvent, and solid drug nanoparticles (e.g., dry powder particles) are formed as a result. In some embodiments, the method of producing the dry powder pharmaceutical composition disclosed herein is spray drying.
[0113] In spray drying, the manufacturing process can have a variety of parameters adjusted. In some embodiments, the solution flow rate is about 4.0 g/min to about 10.0 g/min. In some embodiments, the nozzle is 2-fluid (Sprays System 1650LC/64AC), airless atomization, pressure, rotary/disk, or ultrasonic. In some embodiments, the atomization pressure is about 20 psi to about 100 psi. In some embodiments, the atomization G/L ratio is about 4.8 to about 4.9. In some embodiments, the inlet temperature is about 80 °C to about 200 °C. In some embodiments, the outlet temperature is about 35 °C to about 150 °C. In some embodiments, the calculated relative humidity is about 5.2% to about 12.2%. In some embodiments, the in-going batch size is about 9.6 g to about 24 g. In some embodiments, the solids load are about 1% to about 10% of the entire load of material. In some embodiments, the feed temperature of the spray drying process is about 15 °C to about 75 °C.
[0114] In spray drying, the preparation to be spray dried or feed stock can be any solution, coarse suspension, slurry, or colloidal dispersion that can be atomized using the selected spray drying apparatus. In the case of insoluble agents, the feedstock can comprise a suspension as described above. Alternatively, a dilute solution and/or one or more solvents can be utilized in the feedstock. In one or more embodiments, the feed stock comprises a colloidal system such as an emulsion, reverse emulsion, microemulsion, multiple emulsion, particle dispersion, or slurry, n one version, the antiarrhythmic pharmaceutical agent and the matrix material are added to an aqueous feedstock to form a feedstock solution, suspension, or emulsion. The feedstock is then spray dried to produce dried particles comprising the matrix material and the antiarrhythmic pharmaceutical agent. Suitable spray-drying processes are known in the art, for example as disclosed in WO 99/16419 and U.S. Pat. Nos. 6,077.543; 6,051.256; 6,001,336; 5,985,248; and 5,976,574, which are incorporated herein by reference in their entireties. Whatever components are selected, the first step in particle production typically comprises feedstock preparation. If a phospholipids-based particle is intended to act as a carrier for the antiarrhythmic pharmaceutical agent, the selected active agent(s) can be introduced into a liquid, such as water, to produce a concentrated suspension. The concentration of antiarrhythmic pharmaceutical agent and optional active agents typically depends on the amount of agent required in the final powder and the performance of the delivery device employed (e.g., the fine particle dose for a dry powder inhaler (DPI)). Any additional active agent(s) can be incorporated in a single feedstock preparation and spray dried to provide a single pharmaceutical composition species comprising a plurality of active agents. Conversely, individual active agents could be added to separate stocks and spray dried separately to provide a plurality of pharmaceutical composition species with different compositions. These individual species could be added to the suspension medium or dry powder dispensing compartment in any desired proportion and placed in the aerosol delivery system.
[0115] In one version, the pharmaceutical composition comprises anti arrhythmic pharmaceutical agent incorporated into a phospholipid matrix. The pharmaceutical composition can comprise phospholipid matrices that incorporate the active agent and that are in the form of particles that are hollow and/or porous microstructures, as described in the aforementioned WO 99/16419, WO 99/16420, WO 99/16422, WO01/85136, and WO 01/85137, which are incorporated herein by reference in their entireties. The hollow and/or porous microstructures are useful in delivering the anti arrhythmic pharmaceutical agent to the lungs because the density, size, and aerodynamic qualities of the hollow and/or porous microstructures facilitate transport into the deep lungs during inhalation. In addition, the phospholipid-based hollow and/or porous microstructures reduce the attraction forces between particles, making the pharmaceutical composition easier to deagglomerate during aerosolization and improving the flow properties of the pharmaceutical composition making it easier to process. In one version, the pharmaceutical composition is composed of hollow and/or porous microstructures having a bulk density less than about 1.0 g/cm, less than about 0.5 g/cm, less than about 0.3 g/cm, less than about 0.2 g/cm, or less than about 0.1 g/cm. Moreover, the elimination of carrier particles will potentially reduce throat deposition and any gag effect or coughing, since large carrier particles, e.g., lactose particles, will impact the throat and upper air ways due to their size. In some aspects, the present disclosure involves high rugosity particles. For instance, the particles can have a rugosity of greater than 2. Such as greater than 3, or greater than 4, and the rugosity can range from 2 to 15, such as 3 to 10. In one version, the pharmaceutical composition is in dry powder form and is contained within a unit dose receptacle which can be inserted into or near the aerosolization apparatus to aerosolize the unit dose of the pharmaceutical composition. This version is useful in that the dry powder form can be stably stored in its unit dose receptacle for a long period of time. In some examples, pharmaceutical compositions of one or more embodiments of the present disclosure can be stable for at least 2 years. In some versions, no refrigeration is required to obtain stability. In other versions, reduced temperatures, e.g., at 2-8 °C., can be used to prolong stable storage. It will be appreciated that the pharmaceutical compositions disclosed herein can comprise a structural matrix that exhibits, defines or comprises voids, pores, defects, hollows, spaces, interstitial spaces, apertures, perforations or holes. The absolute shape (as opposed to the morphology) of the perforated microstructure is generally not critical and any overall configuration that provides the desired characteristics is contemplated as being within the scope of the disclosure. Accordingly, Some embodiments comprise approximately spherical shapes. However, collapsed, deformed or fractured particles are also compatible. In one version, the anti arrhythmic pharmaceutical agent is incorporated in a matrix that forms a discrete particle, and the pharmaceutical composition comprises a plurality of the discrete particles. The discrete particles can be sized so that they are
effectively administered and/or so that they are available where needed. For example, for an aerosolizable pharmaceutical composition, the particles are of a size that allows the particles to be aerosolized and delivered to a user's respiratory tract during the user's inhalation. The matrix material can comprise a hydrophobic or a partially hydrophobic material. For example, the matrix material can comprise a lipid, such as a phospholipid, and/or a hydrophobic amino acid, such as leucine (e.g., L-leucine), isoleucine (e.g., L-isoleucine), or tri -leucine. Examples of phospholipid matrices are described in WO 99/16419, WO 99/16420, WO 99/16422, WO 01/85136, and WO 01/85137 and in U.S. Pat. Nos. 5,874,064; 5,855,913: 5,985,309; 6,503,480; and 7,473,433, and in U.S. Published App. No. 2004.0156792, all of which are incorporated herein by reference in their entireties. Examples of hydrophobic amino acid matrices are described in U.S. Pat. Nos. 6,372, 258; 6,358,530; and 7,473.433, which are incorporated herein by reference in their entireties. When phospholipids are utilized as the matrix material, the pharmaceutical composition can also comprise a polyvalent cation, as disclosed in WO 01/85136 and WO 01/85137, which are incorporated herein by reference in their entireties. According to another embodiment, release kinetics of the composition containing anti arrhythmic pharmaceutical agent(s) is controlled. According to one or more embodiments, the compositions of the present disclosure provide immediate release of the anti arrhythmic pharmaceutical agent(s). Alternatively, the compositions of other embodiments of the present disclosure can be provided as non-homogeneous mixtures of active agent incorporated into a matrix material and unincorporated active agent in order to provide desirable release rates of anti arrhythmic pharmaceutical agent. According to this embodiment, anti arrhythmic pharmaceutical agents can be formulated using the emulsion-based manufacturing process (i.e. emulsion spray drying).
[0116] In one or more embodiments of the present disclosure, a formulation described herein can have utility in immediate release applications when administered to the respiratory tract. Rapid release is facilitated by: (a) the high specific surface area of the low density porous powders; (b) the small size of the drug crystals that are incorporated therein, and; (c) the low surface energy of the particles. Alternatively, it can be desirable to engineer the particle matrix so that extended release of the active agent(s) is effected. This can be particularly desirable when the active agent(s) is rapidly cleared from the lungs or when sustained release is desired. For example, the nature of the phase behavior of phospholipid molecules is influenced by the nature of their chemical structure and/or preparation methods in spray drying feedstock and drying conditions and other composition components utilized. In the case of spray-drying of active agent(s) solubilized within a small unilamellar vesicle (SUV) or multilamellar vesicle (MLV), the active agent(s) are encapsulated within multiple bilayers and are released over an extended time. In contrast, spraydrying of a feedstock comprised of emulsion droplets and dispersed or dissolved active agent(s) in
accordance with the teachings herein leads to a phospholipid matrix with less long-range order, thereby facilitating rapid release. While not being bound to any particular theory, it is believed that this is due in part to the fact that the active agent(s) are never formally encapsulated in the phospholipid, and the fact that the phospholipid is initially present on the surface of the emulsion droplets as a monolayer (not a bilayer as in the case of liposomes). The spray-dried particles prepared by the emulsion-based manufacturing process of one or more embodiments of the present disclosure often have a high degree of disorder. Also, the spray-dried particles typically have low surface energies, where values as low as 20 mN/m have been observed for spray-dried DSPC particles (determined by inverse gas chromatography). Small angle X-ray scattering (SAXS) studies conducted with spray-dried phospholipid particles have also shown a high degree of disorder for the lipid, with scattering peaks smeared out, and length scales extending in some instances only beyond a few nearest neighbors. It should be noted that a matrix having a high gel to liquid crystal phase transition temperature is not sufficient in itself to achieve sustained release of the active agent(s). Having sufficient order for the bilayer structures is also important for achieving sustained release. To facilitate rapid release, an emulsion-system of high porosity (high surface area), and minimal interaction between the drug substance and phospholipid can be used. The pharmaceutical composition formation process can also include the additions of other composition components (e.g., small polymers such as Pluronic F-68; carbohydrates, salts, hydrotropes) to break the bilayer structure are also contemplated. To achieve a sustained release, incorporation of the phospholipid in bilayer form can be used, especially if the active agents encapsulated therein. In this case increasing the temperature of the phospholipid can provide benefit via incorporation of divalent counterions or cholesterol. As well, increasing the interaction between the phospholipid and drug substance via the formation of ion-pairs (negatively charged active steaylamine, positively charged active phosphatidylglycerol) would tend to decrease the dissolution rate. If the active agent is amphiphilic, surfactant/surfactant interactions can also slow active dissolution. The addition of divalent counterions e.g., calcium or magnesium ions) to long- chain saturated phosphatidylcholines results in an interaction between the negatively charged phosphate portion of the zwitterionic headgroup and the positively charged metal ion. This results in a displacement of water of hydration and a condensation of the packing of the phospholipid lipid headgroup and acyl chains. Further, this results in an increase in the Tm of the phospholipid. The decrease in headgroup hydration can have profound effects on the spreading properties of spray-dried phospholipid particles on contact with water. A fully hydrated phosphatidylcholine molecule will diffuse very slowly to a dispersed crystal via molecular diffusion through the water phase. The process is exceedingly slow because the solubility of the phospholipid in water is very low (about 10 mol/L for DPPC). Prior art attempts to overcome this phenomenon include
homogenizing the crystals in the presence of the phospholipid. In this case, the high degree of shear and radius of curvature of the homogenized crystals facilitates coating of the phospholipid on the crystals. In contrast, “dry” phospholipid powders according to one or more embodiments of this disclosure can spread rapidly when contacted with an aqueous phase, thereby coating dispersed crystals without the need to apply high energies. For example, upon reconstitution, the surface tension of spray-dried DSPC/Ca mixtures at the air/water interface decreases to equilibrium values (about 20 mN/m) as fast as a measurement can be taken. In contrast, liposomes of DSPC decrease the surface tension (about 50 mN/m) very little over a period of hours, and it is likely that this reduction is due to the presence of hydrolysis degradation products such as free fatty acids in the phospholipid. Single-tailed fatty acids can diffuse much more rapidly to the air/water interface than can the hydrophobic parent compound. Hence, the addition of calcium ions to phosphatidylcholines can facilitate the rapid encapsulation of crystalline drugs more rapidly and with lower applied energy. In another version, the pharmaceutical composition comprises low density particles achieved by co-spray-drying with a perfluorocarbon-in-water emulsion. Examples of perfluorocarbons include, but are not limited to, perfluorohexane, perfluorooctyl bromide, perfluorooctyl ethane, perfluorodecalin, perfluorooctyl ethane. In accordance with the teachings herein the particles can be provided in a “dry” state.
[0117] That is, in one or more embodiments, the particles will possess a moisture content that allows the powder to remain chemically and physically stable during storage at ambient or reduced temperature and remain dispersible. In this regard, there is little or no change in primary particle size, content, purity, and aerodynamic particle size distribution. As such, the moisture content of the particles is typically less than about 10 wt %, such as less than about 6 wt %, less than about 3 wt %, or less than about 1 wt %. The moisture content is, at least in part, dictated by the composition and is controlled by the process conditions employed, e.g., inlet temperature, feed concentration, pump rate, and blowing agent type, concentration and post drying. Reduction inbound water leads to significant improvements in the dispersibility and flowability of phospholipid-based powders, leading to the potential for highly efficient delivery of powdered lung surfactants or particle composition comprising active agent dispersed in the phospholipid. The improved dispersibility allows simple passive DPI devices to be used to effectively deliver these powders. Yet another version of the pharmaceutical composition includes particle compositions that can comprise, or can be partially or completely coated with, charged species that prolong residence time at the point of contact or enhance penetration through mucosae. For example, anionic charges are known to favor mucoadhesion while cationic charges can be used to associate the formed particle with negatively charged bioactive agents such as genetic material.
The charges can be imparted through the association or incorporation of polyanionic or polycationic materials such as polyacrylic acids, polylysine, polylactic acid, and chitosan.
[0118] In some versions, the pharmaceutical composition comprises particles having a mass median diameter less than about 20 um, such as less than about 10 um, less than about 7 um, or less than about 5um. The particles can have a mass median aerodynamic diameter ranging from about 1 um to about 6 um, Such as about 1 ,5um to about 5um, or about 2 um to about 4 um. If the particles are too large, a larger percentage of the particles can not reach the lungs. If the particles are too small, a larger percentage of the particles can be exhaled.
[0119] In some embodiments, the dry powder pharmaceutical composition is stable for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 1 year, at least 2 years, at least 3 years, at least 4 years, or at least 5 years when stored in an open container at 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% relative humidity at a temperature of from about 0°C to about 50 °C, about 10 °C to about 40 °C, about 20 °C to about 40 °C, about 30 °C to about 40 °C, or about 20 °C to about 30 °C. In some embodiments, the dry powder pharmaceutical composition is stable for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 1 year, at least 2 years, at least 3 years, at least 4 years, or at least 5 years when stored in a closed container at 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% relative humidity at a temperature of from about 0 °C to about 50 °C, about 10 °C to about 40 °C, about 20 °C to about 40 °C, about 30 °C to about 40 °C, or about 20 °C to about 30 °C. Stability can be determined by potency of the dry powder pharmaceutical composition described herein. In some embodiments, the dry powder pharmaceutical described herein has an at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% potency after storage. In some embodiments, the dry powder pharmaceutical described herein has at least 90 % to about 100% potency after storage. Stability can be determined by the moisture content or water content by weight. In some embodiments, the water content of the dry powder pharmaceutical composition after storage is less than 15 wt %, less than 10 wt%, less than 5 wt %, or less than 1 wt % when storage in an open container. In some embodiments, the water content of the dry powder pharmaceutical composition after storage is less than 15 wt %, less than 10 wt%, less than 5 wt %, or less than 1 wt % when storage in an closed container.
METHODS OF TREATMENT
CARDIAC CONDITIONS
[0120] The methods, compositions, and kits provided herein can include administration of the pharmaceutical composition via inhalation, e.g., oral or nasal inhalation. Examples of cardiac arrhythmias the methods, compositions, and kits provided herein can treat include, but are not
limited to, tachycardia, supraventricular tachycardia (SVT), paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation (AF), paroxysmal atrial fibrillation (PAF), persistent atrial fibrillation, permanent atrial fibrillation, atrial flutter, paroxysmal atrial flutter, and lone atrial fibrillation. In some cases, the methods, compositions, and kits provided herein find use in treating a subject suffering from atrial arrhythmia, e.g., atrial fibrillation.
[0121] Thus, the pharmaceutical compositions according to some examples of the present disclosure can be used to treat and/or provide prophylaxis for a broad range of patients. A suitable patient for, receiving treatment and/or prophylaxis as described herein is any mammalian patient in need thereof, preferably such mammal is a human. Examples of subjects include, but are not limited to, pediatric patients, adult patients, and geriatric patients. In some cases, the composition is intended only as a treatment for rapid resolution of symptoms and restoration of normal sinus rhythm, and is not taken as a preventative, e.g., when the patient is well, there is no need for drug- -this can increase the benefit-risk ratio of the therapy and overall safety due to the sporadic or intermittent dosing, and the focus on reducing disabling symptoms and restoring sinus rhythm only when needed.
[0122] Pharmaceutical compositions disclosed herein can be more effective in subjects that include or lack certain physiological or demographic factors, such as, for example, age at clinical presentation, certain hemodynamic criteria, electrophysiological features, and prior treatments. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure suffers from an atrial fibrillation with an onset that occurred within 48 hours prior to the treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure suffers from an atrial fibrillation with an onset that occurred from 1 hour to 48 hours prior to the treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure suffers from recurrent atrial fibrillation. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has undergone cardiac ablation no less than 3 months prior to the treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has an ongoing prescription for an oral anti arrhythmic medication for atrial fibrillation. In some embodiments, the oral anti arrhythmic medication is flecainide, or a pharmaceutically acceptable salt thereof.
[0123] In some embodiments, a subject treated with a pharmaceutical composition of the disclosure is over 17 years in age. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure is no more than 85 years in age. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure is from 18 years old to 85 years old. [0124] In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has a systolic blood pressure that is below 180 mmHg, below 175 mmHg, below 170
mmHg, below 165 mmHg, below 160 mmHg, below 155 mmHg, or below 150 mmHg at the time of the treating. In some cases, when referring to a physiological measurement of the subject, for instance, blood pressure, e.g., systolic blood pressure or diastolic blood pressure, or heart rate, e.g., ventricular rate, the term “at the time of treating” means the measurement is taken from 1 min to 6 hr prior to the treating, for instance, when measured 1 min to 10 min, 1 min to 30 min, 1 min to 60 min, 1 min to 90 min, 1 min to 2 hr, 1 min to 3 hr, 1 min to 4 hr, 1 min to 5 hr, 10 min to 30 min, 10 min to 60 min, 30 min to 60 min, 30 min to 90 min, 30 min to 2 hr, 1 hr to 2 hr, or 2 hr to 3 hr prior to the treating. In some cases, the physiological measurement, for instance, the measurement of the systolic blood pressure or the ventricular rate of the subject provides a basis for an informed decision as to whether or not the subject is to be treated with the subject pharmaceutical composition and method. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has a systolic blood pressure that is greater than 70 mmHg, greater than 75 mmHg, greater than 80 mmHg, greater than 85 mmHg, greater than 90 mmHg, greater than 95 mmHg, greater than 100 mmHg, greater than 105 mmHg, greater than 110 mmHg, greater than 115 mmHg, or greater than 120 mmHg at the time of the treating.
[0125] In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has a systolic blood pressure that is from about 60 mmHg to about 180 mmHg, from about 65 mmHg to about 180 mmHg, from about 70 mmHg to about 180 mmHg, from about 75 mmHg to about 180 mmHg, from about 80 mmHg to about 180 mmHg, from about 85 mmHg to about 180 mmHg, from about 90 mmHg to about 180 mmHg, from about 95 mmHg to about 180 mmHg, from about 100 mmHg to about 180 mmHg, from about 105 mmHg to about 180 mmHg, from about 110 mmHg to about 180 mmHg, from about 115 mmHg to about 180 mmHg, from about 120 mmHg to about 180 mmHg, from about 70 mmHg to about 175 mmHg, from about 70 mmHg to about 170 mmHg, from about 70 mmHg to about 165 mmHg, from about 70 mmHg to about 160 mmHg, from about 70 mmHg to about 155 mmHg, from about 70 mmHg to about 150 mmHg, from about 80 mmHg to about 165 mmHg, from about 90 mmHg to about 165 mmHg, from about 100 mmHg to about 165 mmHg, from about 70 mmHg to about 160 mmHg, from about 70 mmHg to about 160 mmHg, from about 75 mmHg to about 160 mmHg, from about 80 mmHg to about 160 mmHg, from about 85 mmHg to about 160 mmHg, from about 90 mmHg to about 160 mmHg, from about 95 mmHg to about 160 mmHg, from about 100 mmHg to about 160 mmHg, from about 70 mmHg to about 155 mmHg, from about 75 mmHg to about 155 mmHg, or from about 80 mmHg to about 155 mmHg at the time of treating.
[0126] In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has a ventricular rate that is at least about 50 BPM, at least about 55 BPM, at least about 60 BPM, at least about 65 BPM, at least about 70 BPM, at least about 75 BPM, at least about 80
BPM, at least about 85 BPM, at least about 90 BPM, at least about 95 BPM, or at least about 100 BPM at the time of treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has a ventricular rate that is no greater than about 200 BPM, no greater than about 190 BPM, no greater than about 180 BPM, no greater than about 175 BPM, no greater than about 170 BPM, no greater than about 165 BPM, no greater than about 160 BPM, no greater than about 155 BPM, no greater than about 150 BPM, no greater than about 145 BPM, or no greater than about 140 BPM at the time of treating.
[0127] In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has a ventricular rate that is from about 50 BPM to about 200 BPM, 50 BPM to about 180 BPM, from about 55 BPM to about 180 BPM, from about 60 BPM to about 180 BPM, from about 65 BPM to about 180 BPM, from about 70 BPM to about 180 BPM, from about 75 BPM to about 180 BPM, from about 80 BPM to about 180 BPM, about 85 BPM to about 180 BPM, about 95 BPM to about 180 BPM, about 100 BPM to about 180 BPM, from about 50 BPM to about 175 BPM, from about 50 BPM to about 170 BPM, from about 50 BPM to about 165 BPM, from about 50 BPM to about 160 BPM, from about 50 BPM to about 155 BPM, from about 70 BPM to about 175 BPM, about 70 BPM to about 170 BPM, about 70 BPM to about 165 BPM, about 70 BPM to about 160 BPM, about 70 BPM to about 155 BPM, about 75 BPM to about 180 BPM, about 75 BPM to about 175 BPM, about 75 BPM to about 170 BPM, about 75 BPM to about 165 BPM, about 75 BPM to about 160 BPM, about 75 BPM to about 155 BPM, about 80 BPM to about 175 BPM, about 80 BPM to about 170 BPM, about 80 BPM to about 165 BPM, about 80 BPM to about 160 BPM, about 80 BPM to about 155 BPM, about 80 BPM to about 150BPM, about 80 BPM to about 145 BPM, about 85 BPM to about 155 BPM, about 90 BPM to about 155 BPM, about 95 BPM to about 155 BPM, or about 100 BPM to about 155 BPM at the time of treating.
[0128] In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has not been treated with anti arrhythmic drugs or electrical cardioversion since onset of an episode of atrial arrhythmia for which the pharmaceutical composition is being administered. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit acute decompensated heart failure at the time of treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not have heart failure with reduced ejection fraction or a history thereof. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not have myocardial ischemia or a history thereof. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not have myocardial infarction or a history thereof. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has not exhibited myocardial infarction (MI) within 3 months prior to administration of the pharmaceutical composition. In
some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit uncorrected severe aortic or mitral stenosis at the time of treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit hypertrophic cardiomyopathy with outflow tract obstruction at the time of treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not have persistent atrial fibrillation or a history thereof. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit atrial flutter at the time of treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has not exhibited an episode of atrial flutter within 6 months prior to the treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit abnormal left ventricular ejection fraction at the time of treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit heart failure that is class 2 or greater as according to New York Heart Association Functional Classification at the time of treating.
[0129] In some embodiments, a subject treated with a pharmaceutical composition of the disclosure is hemodynamically stable, has a systolic blood pressure that is greater than about 90 mmHg, has ventricular rate from about 70 BPM to about 170 BPM at the time of treating, and does not have a condition or a history of a condition that is: myocardial infarction, myocardial ischemia, atrial stenosis, hypertrophic cardiomyopathy, and heart failure with reduced ejection fraction.
[0130] In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not have Long QT syndrome, Conduction disease (e.g., second- or third- degree heart block, bundle branch block), Sick sinus syndrome, Brugada Syndrome, Torsades de pointed (TdP), or a histories thereof. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit at the time of treating an ECG-related feature that is: a QTc interval greater than 480 msec (estimated by the Fridericia's formula); a QRS duration greater than 105 ms; monomorphic or polymorphic ventricular tachycardias that are either sustained or not sustained; and excessive premature ventricular contractions greater than 20 multifocal PVC’s per hour (ventricular extrasystoles); or a predominantly paced heart rhythm.
[0131] In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit severe renal impairment, wherein a eGFR of the subject is less than 30 mL/min/1.73 m2 at the time of treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure is not on dialysis at the time of treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit abnormal liver function at the time of treating. In some embodiments, the abnormal liver
function is hepatic disease or biochemical evidence of significant liver derangement. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit uncorrected hypokalemia at the time of treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit a serum potassium less than 3.6 mEq/L at the time of treating.
[0132] In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit an established pulmonary disease in need of inhalation medication at the time of treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not have a hypersensitivity to flecainide acetate or any of its active metabolites, or a history thereof. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure is not concomitantly administered a systemic drug that is an inhibitor of CYP 2D6. In some embodiments, the inhibitor of CYP 2D6 is an antidepressant, a neuroleptic, or an antihistamine. In some embodiments, the inhibitor of CYP 2D6 is propranolol or ritonavir. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure is not concomitantly administered a systemic drug that is a CYP 2D6 inducer. In some embodiments, the CYP 2D6 inducer is phenytoin, phenobarbital, or carbamazepine.
[0133] In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has not been treated with a Class I or a Class II anti arrhythmic drug within a week prior to administration of the pharmaceutical composition. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure with an ongoing episode of atrial fibrillation has not been treated with a Class I or a Class III anti arrhythmic drug since onset of the ongoing episode. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure is administered no more than 320 mg flecainide or a pharmaceutically acceptable salt thereof per day from any source. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure with an ongoing episode of atrial fibrillation has not been treated with electrical cardioversion since onset of the ongoing episode. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has not been treated with amiodarone within 12 weeks prior to administration of the pharmaceutical composition. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has not been considered high risk for stroke based on screening coagulation panel. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit a CHA2DS2-VASc score greater than 2.
[0134] In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit a congenital heart disease at the time of treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit a history of
refractory atrial fibrillation that has been pharmacologically or electrically cardioverted. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, or a non- cardiovascular cause at the time of treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit syncope at the time of treating.
[0135] In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit any serious or life threatening medical condition other than cardiac arrhythmia at the time of treating. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit an acute pathogenic infection at the time of treating. [0136] In some embodiments, a subject treated with a pharmaceutical composition of the disclosure has not exhibited a drug or alcohol dependence within 12 months prior to administration of the pharmaceutical composition. In some embodiments, a subject treated with a pharmaceutical composition of the disclosure does not exhibit a body mass index greater than 40 Kg/m2 at the time of treating.
[0137] The therapy provided herein can comprise or be suitable for inhalation, e.g., oral or nasal inhalation. In some cases, during administration via oral inhalation, the pharmaceutical agent is inhaled by the patient through the mouth and absorbed by the lungs. In some cases, during administration via nasal inhalation, the pharmaceutical agent is inhaled by the patient through the nose and absorbed by the nasal mucous and/or the lungs.
[0138] The inhalation route can avoid first-pass hepatic metabolism, hence dosing variability can be eliminated. Unlike the case for oral tablets or pills, the patient’s metabolic rates can not matter as the administration is independent of the metabolic paths experienced when a drug is administered via oral route through gastrointestinal tract, e.g., as tablets, pills, solution, or suspension. A fast onset of action, a potential improvement in efficacy, and/or a reduction in dose can be achieved with the fast absorption of drugs from the nasal mucosa and/or lungs.
[0139] The fast absorption rate of drugs through the lungs can be achieved because of the large surface area available in the lungs for aerosols small enough to penetrate central and peripheral lung regions. Consequently, the rate and extent of absorption of drugs delivered via inhalation can yield plasma concentrations vs. time profiles that are comparable with the IV route of administration.
[0140] In some cases, the therapy provided herein is provided to a subject for more than once on an as-needed basis. For instance, the present disclosure can involve a follow-up inhalation if no cardioversion occurs after an initial inhalation. In some instances, if no cardioversion occurs within 30 minutes of the initial inhalation, the follow-up dosage is higher or the same as the initial dosage.
[0141] The time for onset of action can be short. For instance, the patient can have normal sinus rhythm within 20 minutes of initiating the administering, such as within 15 minutes, within 10 minutes, or within 5 minutes of initiating the administering. In some cases, the rapid onset of action is advantageous because the longer a patient remains in arrhythmia (i.e. atrial fibrillation), the more difficult it will be to restore normal sinus rhythm.
[0142] In some embodiments, the method of the present disclosure allows the patient to avoid other therapies, such as ablation and/or electrical cardioversion. In other embodiments, the method of the present disclosure is used in combination with other therapies, such as before or after electrical cardioversion and/or ablation therapy.
DOSAGE
[0143] The pharmaceutical composition can be administered to the patient on an as-needed basis. [0144] In some embodiments, the unit dosage is about 50 mg to about 350 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 50 mg to about 350 mg of the anti arrhythmic pharmaceutical agent wherein the anti arrhythmic pharmaceutical agent is flecainide or a pharmaceutically acceptable salt thereof. In some embodiments, the unit dosage is about 100 mg to about 350 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 150 mg to about 350 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 200 mg to about 350 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 250 mg to about 350 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 300 mg to about 350 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 50 mg to about 300 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 50 mg to about 250 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 50 mg to about 200 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 50 mg to about 150 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 50 mg to about 100 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 100 mg to about 300 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 150 mg to about 250 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 100 mg to about 150 mg of the anti arrhythmic pharmaceutical agent. In some embodiments, the unit dosage is about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about
220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, or about 350 mg of the antiarrhythmic pharmaceutical agent.
[0145] The dosage necessary and the frequency of dosing of the antiarrhythmic pharmaceutical agent depend on the composition and weight ratio of the antiarrhythmic pharmaceutical agent to cyclodextin within the composition. In some cases, the dose is less than about 10%, 20 %, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% of its normal intravenous dose. In some cases, the dose is about 5% to about 10%, is about 10% to about 20%, is about 20% to about 30%, is about 30% to about 40%, is about 50% to about 60%, is about 60% to about 70%, is about 70% to about 80%, is about 80% to about 90%, or is about 90% to about 95% of the intravenous dose.
[0146] The pharmaceutical composition of one or more embodiments of the present disclosure can have improved emitted dose efficiency. The emitted dose (ED) of the particles of the present disclosure can be greater than about 30%, such as greater than about 40%, greater than about 50%, greater than about 60%, or greater than about 70%. The dose of the antiarrhythmic agent, e.g., flecainide salt, e.g., flecainide acetate, can be administered during a single inhalation or can be administered during several inhalation sessions. The fluctuations of antiarrhythmic pharmaceutical agent concentration can be reduced by administering the pharmaceutical composition more often or can be increased by administering the pharmaceutical composition less often. Therefore, the pharmaceutical composition provided herein can be administered from about four times daily to about once a month, such as about once daily to about once every two weeks, about once every two days to about once a week, and about once per week.
[0147] In one embodiment, the pharmaceutical compostion of the disclosure is administered via oral inhalation. In some embodiments, “inhalation session” refers to a period starting from when the patient begins inhalation of the pharmaceutical composition and ending when the patient ceases inhalation of the pharmaceutical composition. In some cases, the antiarrhythmic pharmaceutical agent is delivered over two or more inhalation sessions. In some cases, time between the two or more inhalation sessions is from about 0.1 to 10 minutes. The antiarrhythmic pharmaceutical agent is administered in the described dose in less than 60 minutes, less than 50 minutes, less than 40 minutes, less than 30 minutes, less than 20 minutes, less than 15 minutes, less than 10 minutes, less than 7 minutes, less than 5 minutes, in less than 3 minutes, in less than 2 minutes, or in less than 1 minute. In some cases, delivery of the required dose of antiarrhythmic pharmaceutical agent is completed with 1, 2, 3, 4, 5, or 6 inhalation sessions. In some cases, each inhalation session is performed for about 0.5, 1, 1.2, 1.5, 1.8, 2, 2.2, 2.5, 2.8, 3, 3.2, 3.5, 3.8, 4, 4.2, 4.5, 4.8, or 5 minutes. In some cases, each inhalation session is performed for longer than 5 minutes. In some cases, each inhalation session is performed for up to 4.5 minutes. In some cases, each inhalation
session comprises at least 60 inhalation breaths, 50 inhalation breaths, 40 inhalation breaths, 30 inhalation breaths, 20 inhalation breaths, 10 inhalation breaths, 8 inhalation breaths, 6 inhalation breaths, 4 inhalation breaths, 3 inhalation breaths, 2 inhalation breaths or 1 inhalation breath. In some cases, each inhalation session comprises no more than 100 inhalation breaths, 90 inhalation breaths, 80 inhalation breaths, 70 inhalation breaths, 60 inhalation breaths, 50 inhalation breaths, 40 inhalation breaths, 30 inhalation breaths, or 20 inhalation breaths. In some cases, inhalation session of the anti arrhythmic pharmaceutical agent is performed with deep lung breath that lasts for longer than 1 second, 2 seconds, 3 seconds, or 4 seconds. In some cases, inhalation session of the anti arrhythmic pharmaceutical agent is performed with deep lung breath that lasts for about 1 second, 2 seconds, 3 seconds, or 4 seconds.
[0148] In some embodiments, the subject inhales an aerosolized pharmaceutical composition of the disclosure via tidal breathing. As used herein, “tidal breathing” can refer to inhalation and exhalation during restful breathing. For example, tidal breathing can include inhaling the arosolized pharmaceutical composition while breathing at a rate of 10 to 14 breaths a minute.
[0149] In some embodiments, during inhalational delivery of the anti arrhythmic pharmaceutical agent, the subject takes, or is instructed to take, a break between two inhalation sessions. In such embodiments, the break between two inhalation session lasts for about 0.1 to 10 minutes, such as, 0.2 to 5, 1 to 5, 1.5 to 5, 2 to 5, 3 to 5, 4 to 5, 1 to 1.5, 1 to 2, 1 to 2.5, 1 to 3, 1 to 3.5 , 1 to 4, 1.5 to 2, 1.5 to 2.5, or 1.5 to 3 minutes. In some cases, the subject takes, or is instructed to take, a break for about 1 minute between two inhalation sessions. In some cases, the inhalation pattern for delivery of a single dose goes as follows: a first inhalation session for about 4 to 4.5 minutes, a break for about 1 minute, and a second inhalation session for about 4 to 4.5 minutes; a first inhalation session for about 4 to 4.5 minutes, a break for about 30 seconds, and a second inhalation session for about 4 to 4.5 minutes; a first inhalation session for about 4 to 4.5 minutes, a first break for about 1 minute, and a second inhalation session for about 4 to 4.5 minutes; a second break for about 1 minutes, and a third inhalation session for about 4 to 4.5 minutes; or a first inhalation session for about 4 to 4.5 minutes, a first break for about 30 seconds, and a second inhalation session for about 4 to 4.5 minutes; a second break for about 30 seconds, and a third inhalation session for about 4 to 4.5 minutes.
[0150] In one version, the antiarrhythmic can be administered daily. In this case, the daily dosage of the flecainide acetate ranges from about 0.1 mg to about 600 mg, such as about 0.5 mg to about 500 mg, about 1 mg to about 400 mg, about 2 mg to about 300 mg, and about 3 mg to about 200 mg.
[0151] In some cases, the therapy provided herein is provided to a subject for more than once on an as-needed basis. For instance, the present disclosure can involve a follow-up inhalation if no
cardioversion occurs after an initial inhalation. In some instances, if no cardioversion occurs within 30 minutes of the initial inhalation, the follow-up dosage is higher or the same as the initial dosage. [0152] The dosing can be guided by how the patient feels. Additionally or alternatively, dosing can be guided by using a portable/mobile ECG device. For instance, the dosing can be guided by using a Holter monitor.
[0153] In another version, the pharmaceutical composition is administered prophylactically to a subject who is likely to develop an arrhythmia. For example, a patient who has a history of arrhythmias can be prophylactically treated with a pharmaceutical composition comprising anti arrhythmic pharmaceutical agent to reduce the likelihood of developing an arrhythmia.
[0154] The pharmaceutical composition can be administered to a patient in any regimen which is effective to prevent an arrhythmia. Illustrative prophylactic regimes include administering an anti arrhythmic pharmaceutical agent as described herein 1 to 21 times per week.
[0155] In some cases, patient receiving administration of pharmaceutical composition according to the method described herein needs to meet one or more of the following ECG criteria: P waves not seen on the ECG; fibrillatory waves are coarse; there are varying RR intervals; there are irregular-irregular QRS complexes; or there is an elevated ventricular rate. In some cases, method of treatment disclosed herein comprises confirming a patient in atrial fibrillation episode via ECG. In some cases, the method comprises confirming a patient having the following ECG features before administering the pharmaceutical composition as described herein: P waves not seen on the ECG; fibrillatory waves are coarse; there are varying RR intervals; there are irregular-irregular QRS complexes; and there is an elevated ventricular rate. In some cases, a patient receiving administration of pharmaceutical composition according to the method described herein has a medical history that is current within predetermined time period and qualifies the patient to receive flecainide safely. In some cases, the patient’s current AF episode has had a duration of less than 48 hours. In some cases, total flecainide exposure the patient receives within past 24 hour period does not exceed 320 mg.
[0156] The amount of the flecainide salt that is delivered to the subject (e.g., approximately the amount of the flecainide salt exiting a mouthpiece when being inhaled by the subject) for the treatment of arrhythmia, e.g., atrial arrhythmia, e.g., atrial fibrillation, can be from about 50 mg to about 300 mg, such as 50 mg to 60 mg, 50 mg to 70 mg, 50 mg to 80 mg, 50 mg to 90 mg, 50 mg to 100 mg, 50 mg to 110 mg, 50 mg to 120 mg, 50 mg to 130 mg, 50 mg to 140 mg, 50 mg to 150 mg, 50 mg to 160 mg, 50 mg to 170 mg, 50 mg to 180 mg, 50 mg to 190 mg, 50 mg to 200 mg, 50 mg to 210 mg, 50 mg to 220 mg, 50 mg to 230 mg, 50 mg to 240 mg, 50 mg to 250 mg, 50 mg to 260 mg, 50 mg to 270 mg, 50 mg to 280 mg, 50 mg to 290 mg, 70 mg to 80 mg, 70 mg to 90 mg, 70 mg to 100 mg, 70 mg to 110 mg, 70 mg to 120 mg, 70 mg to 130 mg, 70 mg to 140 mg,
70 mg to 170 mg, 70 mg to 160 mg, 70 mg to 170 mg, 70 mg to 180 mg, 70 mg to 190 mg, 70 mg to 200 mg, 70 mg to 210 mg, 70 mg to 220 mg, 70 mg to 230 mg, 70 mg to 240 mg, 70 mg to 270 mg, 70 mg to 260 mg, 70 mg to 270 mg, 70 mg to 280 mg, 70 mg to 290 mg, 70 mg to 300 mg, 80 mg to 90 mg, 80 mg to 100 mg, 80 mg to 110 mg, 80 mg to 120 mg, 80 mg to 130 mg, 80 mg to 140 mg, 80 mg to 150 mg, 80 mg to 160 mg, 80 mg to 170 mg, 80 mg to 180 mg, 80 mg to 190 mg, 80 mg to 200 mg, 80 mg to 210 mg, 80 mg to 220 mg, 80 mg to 230 mg, 80 mg to 240 mg, 80 mg to 250 mg, 80 mg to 260 mg, 80 mg to 270 mg, 80 mg to 280 mg, 80 mg to 290 mg, 80 mg to 300 mg, 100 mg to 110 mg, 100 mg to 120 mg, 100 mg to 130 mg, 100 mg to 140 mg, 100 mg to 150 mg, 100 mg to 160 mg, 100 mg to 170 mg, 100 mg to 180 mg, 100 mg to 190 mg, 100 mg to 200 mg, 100 mg to 210 mg, 100 mg to 220 mg, 100 mg to 230 mg, 100 mg to 240 mg, 100 mg to 250 mg, 100 mg to 260 mg, 100 mg to 270 mg, 100 mg to 280 mg, 100 mg to 290 mg, 100 mg to 300 mg, 120 mg to 140 mg, 120 mg to 150 mg, 120 mg to 160 mg, 120 mg to 170 mg, 120 mg to 180 mg, 120 mg to 190 mg, 120 mg to 200 mg, 120 mg to 210 mg, 120 mg to 220 mg, 120 mg to 230 mg, 120 mg to 240 mg, 120 mg to 250 mg, 120 mg to 260 mg, 120 mg to 270 mg, 120 mg to 280 mg, 120 mg to 290 mg, 120 mg to 300 mg, 150 mg to 160 mg, 150 mg to 170 mg, 150 mg to 180 mg, 150 mg to 190 mg, 150 mg to 200 mg, 150 mg to 210 mg, 150 mg to 220 mg, 150 mg to 230 mg, 150 mg to 240 mg, 150 mg to 250 mg, 150 mg to 260 mg, 150 mg to 270 mg, 150 mg to 280 mg, 150 mg to 290 mg, 150 mg to 300 mg, 180 mg to 200 mg, 180 mg to 210 mg, 180 mg to 220 mg, 180 mg to 230 mg, 180 mg to 240 mg, 180 mg to 250 mg, 180 mg to 260 mg, 180 mg to 270 mg, 180 mg to 280 mg, 180 mg to 290 mg, 180 mg to 300 mg, 200 mg to 220 mg, 200 mg to 230 mg, 200 mg to 240 mg, 200 mg to 250 mg, 200 mg to 260 mg, 200 mg to 270 mg, 200 mg to 280 mg, 200 mg to 290 mg, 200 mg to 300 mg, 220 mg to 240 mg, 220 mg to 250 mg, 220 mg to 260 mg, 220 mg to 270 mg, 220 mg to 280 mg, 220 mg to 290 mg, 220 mg to 300 mg, 250 mg to 260 mg, 250 mg to 270 mg, 250 mg to 280 mg, 250 mg to 290 mg, 250 mg to 300 mg, 280 mg to 260 mg, 280 mg to 270 mg, 280 mg to 280 mg, 280 mg to 290 mg, or 280 mg to 300 mg.
[0157] In one version, the amount of the flecainide salt that is delivered to the subject (e.g., approximately the amount of the flecainide salt exiting the aerosolization device when being inhaled by the subject) for the treatment of arrhythmia, e.g., atrial arrhythmia, e.g., atrial fibrillation, is at least about 50 mg, at least about 60 mg, at least about 70 mg, at least about 80 mg, at least about 90 mg, at least about 100 mg, at least about 110 mg, at least about 120 mg, at least about 130 mg, at least about 140 mg, at least about 150 mg, at least about 160 mg, at least about 170 mg, at least about 180 mg, at least about 190 mg, at least about 200 mg, at least about 210 mg, at least about 220 mg, at least about 230 mg, at least about 240 mg, at least about 250 mg, at least about 260 mg, at least about 270 mg, at least about 280 mg, or at least about 290 mg.
[0158] In one version, the amount of the flecainide salt that is delivered to the subject (e.g., approximately the amount of the flecainide salt exiting a mouthpiece when being inhaled by the subject) for the treatment of arrhythmia, e.g., atrial arrhythmia, e.g., atrial fibrillation, is at most about 100 mg, at most about 110 mg, at most about 120 mg, at most about 130 mg, at most about 140 mg, at most about 150 mg, at most about 160 mg, at most about 170 mg, at most about 180 mg, at most about 190 mg, at most about 200 mg, at most about 210 mg, at most about 220 mg, at most about 230 mg, at most about 240 mg, at most about 250 mg, at most about 260 mg, at most about 270 mg, at most about 280 mg, or at most about 290 mg.
[0159] In some cases, the amount of the flecainide salt that is delivered to the subject (e.g., approximately the amount of the flecainide salt exiting a mouthpiece when being inhaled by the subject) for the treatment of arrhythmia, e.g., atrial arrhythmia, e.g., atrial fibrillation, is about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, or about 290 mg.
[0160] This method of treatment results in a pulsatile pharmacokinetic profile and transient pharmacodynamic effect mimicking the effect of an IV. This method delivers high drug concentrations that are safe and effective to the heart, while the distribution to the rest of the body results in the drug being diluted to sub-therapeutic levels. This method is the shortest route of delivery to the heart next to intracardial injection. This provides the convenience of selfadministration like the “pill-in-the-pockef ’ approach, but the effectiveness and fast onset of action of an IV. Although the delivery of medications through the lung for systemic effect is not new, it was thought it wouldn’t be effective to the heart, because of the fast passage of drug through it.
[0161] In one or more embodiments, the anti arrhythmic pharmaceutical agent is a class I, class II, class III, or class IV anti arrhythmic. In some embodiments, the anti arrhythmic pharmaceutical agent is a class Ic, anti arrhythmic. In other embodiments, the anti arrhythmic pharmaceutical agent is flecainide or a pharmaceutically acceptable salt thereof.
[0162] In some cases, the compositions and methods provided herein confer a reduced negative inotropic burden to the subject receiving inhalational delivery of the anti arrhythmic pharmaceutical agent, e.g., flecainide, as compared to receiving delivery of a corresponding dose of the same agent via a different route (e.g., oral or intravenous delivery). Certain antiarrhythmic drugs can have negative inotropic effect, which can limit their use for acute cardioversion of new- onset paroxysmal atrial fibrillation (AF). For instance, intravenous delivery of flecainide can exert negative inotropic burden to the subject’s heart, which can be measured by left ventricular (LV) contractility. In some embodiments, the negative inotropic burden of inhalational delivery of a
therapeutically effective dose of anti arrhythmic pharmaceutical agent according to the methods described herein is lower than that of a corresponding therapeutically effective dose of the same agent delivered via a different route (e.g., oral or intravenous delivery).
KITSAND SYSTEMS
[0163] In one aspect, also provided herein are kits for treatment of heart conditions via inhalation. The kits can include one or more pharmaceutical agents, for instance, a salt of flecainide, or some additional active agent(s) as described herein. In some cases, the kits include container for the pharmaceutical agents or compositions. In some cases, unit doses of the pharmaceutical agents as discussed above are provided in the kits. In some cases, the kits also include containers/receptacles for containing the pharmaceutical agents.
[0164] The pharmaceutical composition according to one or more embodiments of the disclosure may, if desired, contain a combination of anti arrhythmic pharmaceutical agent (e.g., flecainide salt) and one or more additional active agents.
[0165] In some cases, all the starting materials are sterilized by established technologies that meet the standards for medical use. Typically, manufacturing equipment is sterilized before use. In some embodiments, the inhalable dry powder pharmaceutical composition described herein can be added into a suitable container, z.e., capsule, blister pack, blister strip, reservoir, and cartridge. Some or all of other additional pharmaceutically acceptable carrier or excipient, solubilizer, or other additional ingredients of the pharmaceutical composition (e.g., cyclodextrin, e.g., HPpCD; e.g., acids, e.g., acetic acid, hydrochloric acid, nitric acid, or citric acid; e.g., saccharin, e.g., saccharin sodium) can added into a suitable container.
[0166] In some cases, the kits include separate containers/receptacles for containing the pharmaceutical composition as described herein. In some other cases, the kits include a single container for containing the pharmaceutical composition. The kits can further include instructions for methods of using the kit. The instructions can be presented in the form of a data sheet, a manual, on a piece of paper, printed on one or more containers or devices of the kit. Alternatively, the instructions can be provided in electronic form, for instance, available in a disc or online with a weblink available from the kit. The instructions for use of the kit can comprise instructions for use of the pharmaceutical composition and the aerosolization device (e.g., a dry powder inhaler) to treat any applicable indication, e.g., a heart condition, e.g., cardiac arrhythmia, e.g., atrial arrhythmia. The instructions for use of the kit can comprise instructions for use of the pharmaceutical composition and the aerosolization device (e.g., a dry powder inhaler ) to treat atrial fibrillation. In some cases, the kits include a nose clip. A nose clip can be used to hinder
passage of air through a nose of a subject during inhalation and increase the proportion of a total inhaled volume that is the aerosol issued by the a dry powder inhaler .
[0167] Unit doses of the pharmaceutical compositions can be placed in a container. Examples of containers include, but are not limited to, capsule, blister pack, blister strip, reservoir, cartridge, or container closure systems made of metal, polymer (e.g., plastic, elastomer), glass, or the like.
[0168] The container can be inserted into an aerosolization device. The container can be of a suitable shape, size, and material to contain the pharmaceutical composition and to provide the pharmaceutical composition in a usable condition. For example, the capsule or blister can comprise a wall which comprises a material that does not adversely react with the pharmaceutical composition. In addition, the wall can comprise a material that allows the capsule to be opened to allow the pharmaceutical composition to be aerosolized. In one version, the wall comprises one or more of gelatin, hydroxypropyl methylcellulose (HPMC), polyethyleneglycol-compounded HPMC, hydroxyproplycellulose, agar, aluminum foil, or the like.
[0169] In some cases, the DPI are pre-filled with doses of the pharmaceutical composition. In some embodiments, the DPI are pre-filled with a single dose. In some embodiments, the DPI are pre-filled with multiple doses. In some cases, the DPI is disposable after usage. In some cases, the DPI or aerolization device does not contain a capsule for the pharmaceutical compsotion, while the device itself has a compartment or compartments for filling and/or refilling of the pharmaceutical composition. In some cases, the DPI uses a capsule comprising the pharmaceutical composition. In some cases, the DPI or aerolization device requires inhalation of the patient to aerolize the pharmaceutical composition.
TERMINOLOGY
[0170] As used herein, “heart condition” can refer to a condition where heart has an abnormal function and/or structure, for example, heart is beating in an irregular rhythm, experiencing arrhythmia, atrial fibrillation, and/or tachycardia, there is myocardial infarction, and/or coronary heart disease. As used herein, “atrial arrhythmia” can refer to an arrhythmia that affects at least one atrium and does not include bradycardia. For instance, atrial arrhythmia can originate in and affect at least one atrium. As used herein, “tachycardia” can refer to an arrhythmia in which the heart beat is too fast. For instance, tachycardia can involve a resting heart rate of over 100 beats per minute, such as greater than 110, greater than 120, or greater than 130 beats minute. In some cases, tachycardia can comprise sinus tachycardia, atrial fibrillation, atrial flutter, AV nodal reentrant tachycardia, accessory pathway mediated tachycardia, atrial tachycardia, multifocal atrial tachycardia, junctional tachycardia, ventricular tachycardia, supraventricular tachycardia, or any combination thereof. As used herein, the phrase “heart rhythm arrhythmia” can refer to an arrhythmia in which the heart beat is irregular. As used herein, the term “atrial fibrillation” can
refer to an abnormal heart rhythm characterized by rapid and irregular beating of the atria. As used herein, the term “cardioversion” can refer to a process by which an abnormally fast heart rate (tachycardia) or other cardiac arrhythmia is converted to a normal sinus rhythm. Cardioversion can be induced by electricity, drugs, or both.
[0171] As used herein, the singular forms “a,” “an,” and “the” can include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an anti arrhythmic agent” can include not only a single active agent but also a combination or mixture of two or more different active agents.
[0172] Reference herein to “one embodiment,” “one version,” or “one aspect” can include one or more such embodiments, versions or aspects, unless otherwise clear from the context.
[0173] As used herein, the term “pharmaceutically acceptable solvate” can refer to a solvate that retains one or more of the biological activities and/or properties of the anti arrhythmic pharmaceutical agent and that is not biologically or otherwise undesirable. Examples of pharmaceutically acceptable solvates include, but are not limited to, anti arrhythmic pharmaceutical agents in combination with water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, ethanolamine, or combinations thereof.
[0174] As used herein, the term “salt” is equivalent to the term “pharmaceutically acceptable salt,” and can refer to those salts that retain one or more of the biological activities and properties of the free acids and bases and that are not biologically or otherwise undesirable. Illustrative examples of pharmaceutically acceptable salts include, but are not limited to, sulfates, pyrosulfates, bi sulfates, sulfites, bi sulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, mal onates, succinates, suberates, sebacates, fumarates, maleates, butyne- 1,4-dioates, hexyne- 1,6- dioates, benzoates, chlorobenzoates, methylbenzoates, di nitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenyipropionates, phenylbutyrates, citrates, lactates, y-hydroxybutyrates, glycolates, tartrates, methanesulfonates, propanesulfonates, naphthal ene-1 -sulfonates, naphthalene-2-sulfonates, and mandelates.
[0175] The term “about” in relation to a reference numerical value can include a range of values plus or minus 10% from that value. For example, the amount “about 10” includes amounts from 9 to 11, including the reference numbers of 9, 10, and 11. The term “about” in relation to a reference numerical value can also include a range of values plus or minus 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% from that value.
[0176] As used herein, “atrial arrhythmia” can refer to an arrhythmia that affects at least one atrium and does not include bradycardia. For instance, atrial arrhythmia can originate in and affect at least one atrium.
[0177] As used herein, “tachycardia” can mean an arrhythmia in which the heart beat is too fast, e.g., faster than normal. For instance, tachycardia can involve a resting heart rate of over 100 beats per minute, such as greater than 110, greater than 120, or greater than 130 beats minute.
[0178] As used herein, the phrase “heart rhythm arrhythmia” can refer to an arrhythmia in which the heart beat is irregular.
[0179] As used herein, the amount of an agent as described herein in the coronary circulation of the heart can be measured by extracting a sample from any vascular region of the coronary circulation of the heart (e.g., arteries, veins, including coronary sinus) by using a cannula. The amount of the agent in the sample can then be determined by known means, such as bioanalytical techniques that employ analytical equipment such as LC-MS/MS. Thus, the amount of the agent in the blood in the heart can be measured for any particular time.
[0180] As used herein, the terms “treating” and “treatment” can refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, reduction in likelihood of the occurrence of symptoms and/or underlying cause, and/or remediation of damage. Thus, “treating” a patient with an active agent as provided herein can include prevention of a particular condition, disease, or disorder in a susceptible individual as well as treatment of a clinically symptomatic individual.
[0181] As used herein, “nominal amount” can refer to the amount contained within the unit dose receptacle(s) that are administered.
[0182] As used herein, “effective amount” can refer to an amount covering both therapeutically effective amounts and prophylactically effective amounts.
[0183] As used herein, a “therapeutically effective amount” of an active agent can refer to an amount that is effective to achieve a desired therapeutic result. A therapeutically effective amount of a given active agent can vary with respect to factors such as the type and severity of the disorder or disease being treated and the age, gender, and weight of the patient. In some cases, “inhalation” (e.g., “oral inhalation” or “nasal inhalation”) refers to inhalation delivery of a therapeutically effective amount of a pharmaceutical agent contained in one unit dose receptacle, which, in some instance, can require one or more breaths, like 1, 2, 3, 4, 5, 6, 7, 8, 9, or more breaths. For example, if the effective amount is 90 mg, and each unit dose receptacle contains 30 mg, the delivery of the effective amount can require 3 inhalation sessions.
[0184] Unless otherwise specified, the term “therapeutically effective amount” can include a “prophylactically effective amount,” e.g., an amount of active agent that is effective to prevent the onset or recurrence of a particular condition, disease, or disorder in a susceptible individual.
[0185] As used herein, the phrase “minimum effective amount” can mean the minimum amount of a pharmaceutical agent necessary to achieve an effective amount.
[0186] As used herein, “mass median diameter” or “MMD” can refer to the median diameter of a plurality of particles, typically in a polydisperse particle population, e.g., consisting of a range of particle sizes.
[0187] As used herein, “geometric diameter” can refer to the diameter of a single particle, as determined by microscopy, unless the context indicates otherwise.
[0188] As used herein, “mass median aerodynamic diameter” or “MMAD” can refer to the median aerodynamic size of a plurality of particles or particles, typically in a polydisperse population. The “aerodynamic diameter” can be the diameter of a unit density sphere having the same settling velocity, generally in air, as a powder and is therefore a useful way to characterize an aerosolized powder or other dispersed particle or particle formulation in terms of its settling behavior. The aerodynamic diameter encompasses particle or particle shape, density, and physical size of the particle or particle. As used herein, MMAD refers to the median of the aerodynamic particle or particle size distribution of aerosolized particles determined by cascade impaction, unless the context indicates otherwise.
[0189] By a “pharmaceutically acceptable” component is meant a component that is not biologically or otherwise undesirable, e.g., the component can be incorporated into a pharmaceutical formulation of the disclosure and administered to a patient as described herein without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the formulation in which it is contained. When the term “pharmaceutically acceptable” is used to refer to an excipient, it can imply that the component has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug Administration.
[0190] As used herein, “P wave” can represent the wave generated by the electrical depolarization of the atria (right and left) and is usually 0.08 to 0.1 seconds (80-100 ms) in duration.
[0191] As used herein, “active dry powder inhaler” refers to an inhalation device that does not rely solely on a patient’s inspiratory effort to disperse and aerosolize a pharmaceutical composition contained within the device in a reservoir or in a unit dose form and does include inhaler devices that comprise a means for providing energy to disperse and aerosolize the drug composition, Such as pressurized gas and vibrating or rotating elements.
[0192] As used herein, “room temperature” can refer to a temperature that is from 18 °C to 25 °C.
EXAMPLES
[0193] The following examples are provided to further illustrate some embodiments of the present disclosure, but are not intended to limit the scope of the disclosure; it will be understood by their exemplary nature that other procedures, methodologies, or techniques known to those skilled in the art can alternatively be used.
Example 1: Vacuum dried de-constituted Flecainide acetate pH study
[0194] This example illustrates the change in pH of flecainide acetate when dried for certain vacuum dried formulations. In order to determine any loss of acid of vacuum dried flecainide acetate, a 10 mL solution with 20 mg/mL of flecainide acetate with varying amounts of acids were prepared as shown in Table 1. A 1 mL aliquot from each sample was dried for 12 hours in vacuum. The dried flecainide acetate test samples were then reconstituted in 1 mL water to the original concentration. The pH was measured to verify any acid loss.
Example 2: Formulations of spray drying Flecainide powder study
[0195] This example demonstrates preparation of certain spray dried flecainide powders. Different pre-formulated powders were made via spray drying in order to determine the effects of several variables on the final product characteristics as shown in Table 2.
[0196] Feedstock was prepared with the composition quantities and pH targets shown in Table 3 prior to spray drying.
[0197] A specified quantity for each component was added to a fixed volume of deionized water (DI water) to achieve the desired formulation composition and solids percentage in solution. All components were readily soluble in water. The pH of the feedstock solution was adjusted by either adding acetic acid or citric acid for the feedstock.
Example 3: Characteristics of Flecainide acetate powder formulations
[0198] This example characterizes certain test formulations of Flecainide acetate powder prepared in Example 2. In order to determine any acid loss during spray drying, the bulk powder was reconstituted in DI water at the same concentration as the original feedstock. The pH of the reconstituted solution was measured and compared to that of the original feedstock. The solubility of the dry powder during reconstitution was also observed. The pH was measured using an Orion Star Al l i from Thermo Scientific.
Flecainide acetate powder density study.
[0199] Dry powder density was determined by bulk density and puck density. Bulk density was determined by adding a known mass of dry powder into a tared Eppendorf tube and filled up to 0.5 cubic centimeter. The weight of the powder was measured on Mettler Toledo, AT261 balance. Bulk powder density was calculated as the powder weight over the volume. Puck density was determined by using a capsule filler tool with a cavity volume of 832 p in3 (0.0136 cm3) with a vacuum pressure of 80 ±1 kPa and 1.5 to 1.7 L/min flow. The puck was extracted from the cavity and weighed on a Mettler Toledo AT261 balance. Puck density was calculated as the puck weight over the volume of the cavity.
Flecainide acetate powder particle size distribution study.
[0200] Dry powder particle size distribution was performed on a LS 13 320 Beckman Coulter laser diffraction. The suspension media was Paraffin. The concentration of the mixture was 5 mg of dry powder in 3 mL of Paraffin. The mixture was sonicated in water bath between 5 to 8 minutes and at a sonication power of 42 kHz (180 Watt) prior to analyzing the suspension.
Flecainide acetate powder thermal analysis study.
[0201] Thermal analysis using Differential Scanning Calorimetry (DSC) was performed on the powder samples to determine phase transition profiles of the samples. Thermal analysis was performed on a DSC TA QI 000 at a temperature change rate of 10 °C per minute and a range of - 60 °C to 200 °C.
Flecainide acetate powder crystallinity study.
[0202] Powder crystallinity using X-ray diffraction (XRPD) was performed on selected samples to determine the crystallinity of the pre-formulated Flecainide acetate powder. The analysis was performed on a X'pert Pro (PANalytical).
Table 5. Investigation of reconstituted Flecainide acetate pH
precipitates upon reconstitution in DI water. For these test compositions, there was evidence of acid loss after vacuum drying over 12 hours as evident from the small amount of pH increase upon reconstitution.
Pre-formulation spray dried powder study.
[0204] Table 6 shows the observations as well as powder reconstitution results for all the preformulation spray drying campaigns. Table 6 displays some test compositions or batches that were were spray dried using identical spray drying process conditions.
[0205] A test composition of neat flecainide acetate powder without excipients (Batch A) was coarse and appeared crystalline. Another test composition, Batch C, with similar formulation to Batch A but using only citric acid to adjust feedstock pH, did not yield any dry powder during spray drying. Two different test compositions, Batches B and D, containing >50%w/w flecainide acetate with trileucine did not yield any dry powder regardless of the amount of trileucine in the formulation or the type of acid used to adjust the feedstock pH. Powder from another two test compositions, Batches E and F, appeared visually fine. Batches E and F were prepared from a feedstock with a pH under 5, andcontained less than 50%w/w flecainide acetate with leucine.
[0206] For the powder reconstitution in DI water, powder formulations with drug loading higher than 20%w/w were not readily soluble in water, unlike the native flecainide acetate drug. All samples reconstituted back into water had pH ranging from 7.2 to 8.1, which was much higher than the respective feedstock pH for each batch shown in Table 3, indicating that regardless of the amount and type of acid added to the feedstock, there was acid lost during spray drying. This was especially apparent for Batch I, where the reconstituted solution had a pH of 7.7 despite a feedstock
pH of 3.3, with 60%w/w of acetic acid. Powder batches with drug loading higher than 20%w/w were not reconstituted back into water.
[0207] Batches with flecainide acetate loading ranging from 20%w/w to 48%w/w with leucine produced the most uniform and smallest particle size distribution. Batch formulations with neat flecainide powder, 70%w/w flecainide acetate with leucine, and batches spray dried with feedstock pH of 3.5 or 6.8 yielded large particle size distribution.
[0208] Based on the bulk density results, the powder formulation with 48%w/w drug flecainide acetate (Batch F) had denser packing compared to the preparation containing 20%w/w flecainide acetate (Batch E). At 48%w/w drug loading, the puck density was about twice that of 20%w/w flecainide acetate. Based on this information, the following projected dose per capsule for 20%w/w and 48%w/w flecainide acetate drug loading values for a size 2 and 3 Capsugel HPMC capsules were calculated:
• Size 2 Capsule (0.37ml fill volume based on Capsugel) 48%w/w drug loading = 42.6 mg flecainide acetate/Capsule 20%w/w drug loading = 9.6 mg flecainide acetate/capsule
• Size 3 Capsule (0.30 ml fill volume based on Capsugel) 48%w/w drug loading = 34.6 mg flecainide acetate/Capsule 20%w/w drug loading = 7.8 mg flecainide acetate/capsule
[0209] Bulk and puck densities of powders with leucine plus 20%w/w flecainide acetate , as well as those with leucine plus 48%w/flecainide acetate were measured. The results show that the batch with 48%w/w flecainide loading with leucine had slightly higher bulk density and about twice the puck density as the batch with 20%w/w drug loading with leucine. Therefore, more mass per volume can be filled into a single capsule using the 48%w/w drug loading powder formulation compared to the 20%w/w drug loading powder formulation.
[0210] The particle size distributions shown in FIG. 1 were determined using a Beckman Coulter laser diffraction system.
[0211] Neat flecainide powder (Batch A) without excipients had an X50 of 40.8 pm. Batches E and F, containing leucine and less than 50%w/w flecainide acetate, and prepared from a feedstock with a pH of 5, resulted in the most uniform and smallest particle size distribution compared to other batches.
[0212] Batches containing less than 50% w/w flecainide acetate that were prepared from a feedstock with pH of 3.5 or 6.8 (H and I) yielded large particle size distribution. A preparation containing leucine and 70%w/w flecainide acetate exhibited a bimodal distribution in particle size, which indicates that the resulting bulk powder was a mixture of larger neat flecainide crystals and smaller particles. The particle size distributions observed for each of the preformulated bulk powders are shown in FIG. 1. Neat flecainide acetate powder without any excipients exhibited a powder morphology resembling large crystalline needles.
[0213] Batches containing leucine plus 20%w/w to 48%w/w flecainide acetate (batches E and F) contained small, uniform round particles. However, as flecainide loading increased to 70%/w/w (batch G), a mixture of small particles with larger, needle-shaped crystalline flecainide acetate was present in the powder sample, which is in line with the bimodal particle size distribution observed for this batch. Furthermore, there was observable presence of agglomerated particles observed in 70%w/w flecainide acetate powder.
Powder crystallinity study.
[0214] Selected test flecainide acetate powder samples were analyzed using XRPD as a tool to determine any changes to the native pure flecainide acetate drug after it was processed through spray drying. FIG. 2 compares the pure drug and the neat flecainide acetate (Batch A). The formulated flecainide acetate powder at various drug loading values with leucine as excipient (Batches E, F, and G) exhibited amorphous XRPD profiles. Batches C and D, which did not produce dry powder, exhibited amorphous XRPD profiles (FIG. 4) unlike the pure flecainide acetate. Powder thermal analysis for batches containing leucine in combination with 20%w/w, 48%w/w, or 70%w/w flecainide loading exhibited glass transition temperatures (Tg) ranging from 27-33 °C. Neat flecainide acetate powder exhibited a lower glass transition and melting temperature compared to that of pure flecainide acetate.
Example 4: Method of manufacturing and characterization of selected flecainide acetate / HP-P-CD compositions
[0215] Spray drying feasibility was conducted on a custom laboratory scale dryer with 35 kg/hr drying gas capacity for five example compositions, Batches J-N.
[0216] Two different solution preparation methods were evaluated as part of the initial feasibility screen. In the first method (Method #1) the nebulized formulation is prepared at a higher concentration, and then diluted to the target spray solution concentration. The second method (Method #2) followed a simplified procedure where the solution was prepared at the spray solution concentration without any intermediate dilution steps. A comparison of the two methods are presented in Table 9.
Spray drying study.
[0217] Table 10 summarizes the manufacturing conditions for the Batches J - Batch N. Batch J - Batch L varied solution flow rate in order to evaluate the impact of relative humidity on yield. Atomization gas-to-liquid (G/L) ratio for the three batches was matched in order to target similar particle sizes. No significant difference in yield was observed between the lowest and highest humidity conditions. The lower yield on Batch J compared to Batch K and Batch L is likely due to start-up losses. Changing solution preparation method in Batch M did not negatively impact process yield. Increased active loading in Batch N resulted in a low yield (~30 %), and likely decreased the over glass transition temperature (Tg) of the formulation below the outlet temperature of the dryer, resulting in sticking and particle fusion.
Table 10. Manufacturing summary
in water, water content by Karl Fisher, particle size distribution by laser diffraction, particle morphology by scanning electron microscopy, thermal transitions by differential scanning calorimetry and physical state by X-ray powder diffraction. Results are summarized in Table 11.
1 Water (MilliQ grade) had a pH value of 8.70 so “A from reference” is the difference between water only and solution containing formulation. Negative value indicates that it is acidic; positive indicates basic. 2DNT: Did Not Test as this formulation became gel like when reconstituted so it could not be measured.
3 Values reported are the onset glass transition temperatures, the mid-point temperature is reported in Table 16
Purity and potency study.
[0219] The purity and potency of the five formulations was determined using HPLC. The same lot of flecainide acetate used in manufacturing Batches J - Batch N were used for the reference material.
[0220] Purity of the samples was determined as 100 % as no additional peaks were observed on any of the five formulations. The amount of material tested was measured in terms of the formulation rather than scaled to the theoretical active amount, as the loadings are approximately 22 % and any potential impurities can be at a concentration below detection. Two replicate samples were prepared per formulation and the potency results are presented in Table 12. Batch M and Batch N were more difficult to handle relative to Batches J - Batch L. Batch M and Batch N were impacted by electrostatic cling, which can be related to the moisture content. This can also contribute to the variability in the potency results for those two samples. Overall, the potency of the formulations were close to target.
[0221] As the formulation is spray dried, acetic acid can be removed during the manufacturing process through vaporization, resulting in formation of the free base in the dry formulation. Accordingly, the pH of the reconstituted formulation in water was measured to determine the amount of acetate remaining in the formulation. Approximately 120 mg of each formulation was dissolved in 3 mL of high purity (MilliQ) water to target the same solids content of the spray solutions (4 wt %). Formulation Batch N (50 % API loading) formed a gel so it was further diluted with an additional 3 mL. The additional water still afforded a gel, and pH was not measured. The pH values of the reconstituted formulations are presented in Table 13.
[0222] The pH of the high purity water was significantly high (8.70) so ~4 wt% and 1 wt% reference solutions were made using the in-going flecainide lot and tested for comparison. Both solutions exhibited a lower pH (more acidic) than the water.
[0223] Formulations manufactured according to the Method #1 (Table 9) exhibited pH values that differed from water by 0.5. Formulation Batch N, prepared according toMethod #2, exhibited a larger pH difference of 1.0.
Geometric particle size distribution study.
[0224] Geometric particle size distributions were measured by laser diffraction using a Malvern Mastersizer 3000 equipped with an Aero S dispersion unit at a dispersive air pressure of 3 bar. The Mie scattering theory was applied to the diffraction pattern to obtain the particle size distribution (refractive index of the particle was set at 1.55 with the absorption set as 0.1). The particle size distribution summary is presented in Table 14 and graphically depicted in FIG. 5.
[0225] Similar particle size distributions were observed for Batch J, Batch L, and Batch M. Broader distribution and an apparent shoulder in the distribution observed in Batch N suggest particle fusion and is consistent with manufacturing observations. A larger particle size but lack of shoulder in Batch K suggests that the increase in particle size is likely due to atomization conditions at the lower end (where atomization pressure was lowered to 20 psi to maintain G/L ratio due to the solution flow rate) and not due to particle fusion.
Water content study.
[0226] Water content was evaluated by Coulometric Karl Fischer analysis and the comparison of the results against inlet temperature and calculated relative humidity is shown in Table 15.
[0227] For formulations containing 23 % flecainide acetate, the calculated relative humidity correlate well with the water content, while higher flecainide acetate loading (Batch N) appears to have a lower water content with the same theoretical relative humidity. It should be noted that for formulation Batch N, a higher inlet temperature was required (170 °C vs -150 °C) to achieve the same outlet temperature (60 °C).
Particle morphology study.
[0228] The morphology for Batch J, Batch K, and Batch L show typical corrugated (collapsed sphere) particles with no signs of fusion or crystallinity. Batch M shows a similar morphology as Batch J, Batch K, and Batch L, but there are few elongated particles present. Batch N shows significantly more elongated particles which can fuse the other particles together.
Thermal transitions study.
[0229] Thermal transitions were determined using a TA Instruments Q2000 Differential Scanning Calorimeter. Samples were sealed in a Tzero hermetic pan and scans were performed in triplicate. For each analysis, the samples were heated from -30 °C to 140 °C at a scan rate of 2.5 °C per minute and a temperature modulation of ± 1.5 °C per minute. Three glass transitions were observed for four of five samples and all values are presented in Table 16. The 50/50 formulation Batch N exhibited a different heat flow versus temperature profile as compared to the other formulations (FIG. 6) and only exhibited one glass transition (FIG. 7). The thermograms for each formulation are presented in FIGS. 22-26.
[0230] Use of a spray drying outlet temperature of 60 °C could explain the reason for poor collection yield for 50/50 formulation Batch N, where a single significant glass transition was observed. This could be because there is less cyclodextrin available to increase the overall glass transition temperature.
X-ray Powder Diffraction (XRPD) study.
[0231] Physical state was measured by a Rigaku MiniFlex 600. The results are shown in FIG. 8. Batches J - N were amorphous, while Batch N exhibited additional peaks indicating that there can
be some order (or partial crystallinity) present in the powder. These can result in elongated particles.
Dynamic vapor sorption (DVS) study.
[0232] Three of the five compositions were evaluated for moisture uptake as a function of environmental humidity conditions. The three samples selected each containined 23/77 Flecainide Acetate/HP-P-CD, but were prepared under different process conditions (formulations Batch J, Batch K, and Batch L). The dynamic vapor sorption (DVS) technique was employed at 25 °C to evaluate the sorption and desorption of water. Each analysis initiated at ambient conditions (40 % RH) to avoid changes to the material during the initial desorption and sorption.
[0233] Each sample exhibited a similar isotherm profile relative to others (Batch J, 7 g/min, diluted nebulization solution preparation, FIG. 9; Batch K, 4 g/min, diluted nebulization solution preparation, FIG. 10; Batch M, 7 g/min, direct solution preparation, FIG. 11) irrespective of preparation method. These results suggest that the composition contributes more significantly than differences in manufacturing process.
[0234] The isotherms can be compared directly in the overlay of FIG. 12. The difference between formulation Batch M with respect to formulations Batch J and Batch K is likely due to the sample size and experimental variation. At 90 % RH, the change in mass was 24.9 %, 25.2 %, and 26.7 % for formulations Batch J, Batch K, and Batch M, respectively, however, the 1.8 % delta for a sample size of 3.6 mg in formulation Batch M is equivalent to 0.0648 mg.
[0235] With respect to mass change as a function of time, any loss in mass at a given relative humidity can be an indication of amorphous content recrystallizing. No negative change in mass during the sorption cycle was observed for the standard spray drying condition and solution preparation (Batch J, FIG. 13), while a change was observed with a slower feed rate (4 g/min, Batch K, FIG. 14) or solution preparation (direct to concentration, Batch M, FIG. 15).
Example 5: Stability studies of exemplar compositions
[0236] Selected samples (Batch J, Batch K, and Batch M) were placed on accelerated stability (1- month) to evaluate any changes to the physicochemical properties. Environmental conditionsof 40 °C/75 % RH open and 40 °C/75 % RH closed were evaluated, where open denotes storage in a vial covered with foil punctured with pin holes, and closed denotes storage in a vial stored with desiccant in a heat sealed mylar bag.
[0237] Batch properties over time are compared to initial values in Table 17 (Batch J), Table 18 (Batch K), and Table 19 (Batch M).
Purity and potency study.
[0238] The purity and potency of the Batches J - Batch M were determined using the HPLC. The same lot of flecainide acetate used in manufacturing Batches J - Batch N was used for the reference material. Purity of the samples was determined to be 100 %, as no additional peaks were observed in any of the samples above LOQ. The amount of material tested was adjusted for the 23 % loading to achieve a nominal concentration of 1.5 mgA/mL. The results are summarized in Table 20.
Water content and residual solvent
[0239] Water content was evaluated by coulometric Karl Fischer analysis after 1-month of storage. There was insignificant change in water content of the closed condition the compositions tested, but those stored under open conditions appeared to have taken up a large amount of water (Table 21). This may be attributable to a physical form change (recrystallization of the formulation) or it can be an effect from exposure at 75 % RH (~12 % water content, FIG. 12) and the absence of an opportunity to re-equilibrate back to room condition when the sample was hermetically sealed in the sample vial for analysis.
[0240] Residual solvent was not measured in the initial sample because the spray solution was just water. However, residual solvent was evaluated on the 1-month stability samples to determine if any volatile material was present. A small amount of an unknown solvent was detected that was not part of the standard suite solvents assayed by gas chromatography (MeOH, EtOH, acetone, IP A, ACN, DCM, EtOAc, THF, and heptane).
*One value reported; other value below LOQ
[0241] Overall, the values were consistent and did not significantly vary with process condition or stability storage condition (between 0.04 and 0.07 wt%). Any variance could potentially be due to loss of acetate or a residual solvent used as part of the synthesis. pH of Reconstituted Formulations.
[0242] Reconstitution of spray dried formulations stored in the closed condition for one month at 40 °C/ 75 % RH was undertaken at a concentration of approximately 40 mg/mL (not normalized to active loading), and the solutions were then measured for pH (Table 23). The pH of the high purity water was measured as reference.
Table 23. pH values of reconstituted formulations - initial vs. 1-month samples
did not impact the overall pH values of the reconstituted samples.
Geometric Particle Size Distribution Study
[0244] Geometric particle size distributions were measured by laser diffraction using a Malvern Mastersizer 3000 equipped with an Aero S dispersion unit at a dispersive air pressure of 3 bar, utilizing the same process parameters as time initial (Mie scattering theory, refractive index of the particle was set at 1.55 with the absorption set as 0.1). The particle size distribution summary is presented in Table 24 and the distribution is depicted in FIG. 16. Batch K D(v 0.9) was smaller (5.3 pm) than that observed in the initial data set (5.4 pm, see Table 14). This difference is within experimental error.
Table 24. Particle size distributions of Flecainide acetate spray dried powders after 1-month accelerated stability, closed condition
Particle Morphology.
[0245] Filaments were observed in each of the one month closed condition Batch samples. Thermal Transitions.
[0246] Thermal transitions were evaluated by modulated differential scanning calorimetry using hermetically sealed sample pans. Three broad glass transition temperatures were observed at varying temperatures (Table 25). The first glass transition temperature was lower in the open samples, likely due to the uptake of water on stability (>10 wt %). Thermograms are shown for closed, reversing (FIG. 17); closed, non-reversing (FIG. 18); open, reversing (FIG. 19); open, non-reversing (FIG. 20).
X-Ray Powder Diffraction (XRPD) study
[0247] The physical state of the the batch samples at 1 month were evaluated by Rigaku Miniflex 600. The diffractogram overlay is shown in FIG. 21. Batch J, Batch K, and Batch M in the closed condition did not show any signs of crystallization by XPRD. However, peaks are present in samples stored under open conditions, indicating a signification amount of crystallization. Several peaks do not comport with flecainide acetate, and may be attributable to flecainide free base.
Example 6: Aerosolization studies of exemplary compositions
[0248] This example summarizes aerosol performance of three exmemplary flecainide dry powder compositions. Specifically, the three engineered powders of spray dried flecainide acetate were characterized for aerosol performance by measuring the aerosol powder release kinetics from inhaler/capsule by laser photometry and aerodynamic particle size by Next Generation Impactor (NGI). Three spray dried flecainide acetate lots and two bulk powder storage stability conditions were evaluated; T=0M (starting time point; ambient conditions) and T=1M (1 month; 40°C/75% RH). Powders were puck filled in hypromellose size 3 capsules at a target powder mass of 50 mg and tested in the Plastiape RS01 family of Dry Powder Inhalers, medium (0.10R) and high (0.16R) flow resistance models.
[0249] Through these experiments, it was found that: (a) Aerosol performance for T=0M bulk powders was comparable when tested in RS01 medium and high flow resistance devices at a 4 kPa pressure drop; (b) T=0M and T=1M bulk powders gave similar aerosol performance when evaluated with a RS01 medium flow resistance device at a 4 kPa pressure drop; and (c) Faster aerosol (T=0M) powder emptying from inhaler/capsule for RS01 medium than high flow resistance devices with emptying volumes of <1.2 L and <2.1 L, respectively. Aerosol powder emptying characteristics were consistent for all three powder lots.
[0250] Table 26 and Table 27 show the test outline of the aerosol testing performed for T=0M and T=1M spray dried flecainide acetate powders, respectively, in this study.
Table 26. In vitro aerosol performance for T=0M powders and two flow resistance inhaler devices (0.10R and 0.16R). Three replicate runs performed for each laser photometry (2 kPa and 4 kPa) and NGI (only at 4 kPa) testing.
Table 27. In vitro aerosol performance for T=1M powders and RS01 medium flow resistance device (0.10R). Three replicate runs performed for NGI testing at 4 kPa.
[0251] Capsule Filling And Polishing
[0252] Table 28 summarizes capsule filling parameters used for manufacturing the capsules in this study. Empty hypromellose size 3 capsules were preconditioned overnight at 10 to 15%RH before filling. Mean fill mass for each powder batch is summarized below. Filled capsules were pouched and stored inside a vacuum box maintained at <30% RH (ambient temperature). Capsules were used within 14 days after manufacturing.
1 Lot A, n = 16; Lot B, n = 25; Lot D, n = 25
[0253] Capsule Emptying Study by Laser Photometry
[0254] Table 29 and Table 30 summarize the capsule emptying study results for RS01 medium and high flow resistance devices, respectively, and a 50 mg powder mass per capsule. Two pressure drops where evaluated for each inhaler and powder lot. For the medium resistance device, aerosol powder clearance volume was <1.2 liters for 2 and 4 kPa inspiratory efforts, suggesting an adult with tidal volume >1.5L can empty the 50 mg capsule in a single inhalation breath. However, longer emptying volumes were observed for the high flow resistance inhaler, suggesting a second inhalation may be required.
Table 29. Laser photometry summary results for 0.10R devices. Mean of three replicates with standard deviation in parenthesis.
Table 30. Laser photometry summary results for 0.16R devices. Mean of three replicates with standard deviation in parenthesis.
[0255] Potency Determination of Bulk Powder by RP-HPLC
[0256] Potency determination by RP-HPLC for each spray dried flecainide acetate bulk powder determined drug content (flecainide acetate) to be approximately 21% (Table 31).
[0257] APSD Analysis for T=0M Powders (Lot A, Lot B, and Lot D) with Medium Flow Resistance RS01 DPI (0.1 OR)
[0258] Table 32 and FIG. 27 present the aerosolized particle agglomerates tested with RS01 medium flow resistance device at 4 kPa (corresponding to 64 L/min) for T=0M powders. Aerosol performance data show powders Lot A and Lot D were comparable, and resulted in a finer aerosol quality than powder Lot B. Of note, this corresponds with the fact that powders Lot A and Lot D were manufactured under similar spray dried parameters and conditions, differing only by solution feedstock preparation. While the solution feedstock preparation procedure was similar between Lot B and Lot A, the spray drying parameters and conditions differed. Lot A corresponds to Batch
J in Example 4, Lot B corresponds to Batch K, and Lot C to Batch M. These results also correspond with primary particle size measured by the client by laser diffraction which saw smaller particle sizes for Lot A (1.9 pm) and Lot D (1.7 pm) compared to Lot B (2.4 pm).
Table 32. Aerodynamic particle size by NGI for T=0M powders tested in the RS01 medium flow resistance (0.10R) device with a 50 mg capsule powder mass. Mean of three replicates with standard deviation in parenthesis.
1NGI total recovery normalized to actual capsule powder fill mass.
[0259] APSD Analysis for T=0M Powders (Lot B and Lot D) with High Flow Resistance RS01 DPI (0.16R)
[0260] Table 33 and FIG. 28 summarize the aPSD results and particle size distribution plot, respectively, for the RS01 high flow resistance device tested at 4 kPa (corresponding to 40 L/min) with the Lot B and Lot D T=0M powders. Mean MMAD was 3.9 pm and 3.2 pm for Lot B and Lot D powders, respectively, which is comparable in performance to the corresponding result for each powder with the RS01 medium flow resistance device (Table 32).
Table 33. Aerodynamic particle size by NGI for T=0M powders tested in the RS01 high flow resistance (0.16R) device with a 50 mg capsule powder mass. Mean of three replicates with standard deviation in parenthesis.
1NGI total recovery normalized to actual capsule powder fill mass.
[0261] APSD Analysis for T=1 Month At 40°C/75% Relative Humidity Powders (Lot A, Lot B, and Lot D) with Medium Flow Resistance RS01 DPI
[0262] For the T=1M storage timepoint, powders were stored at the Client’s powder manufacturing facility at 40°C/75% RH in glass vials and protected from moisture using over-
pouching. After the 1 -month stability pull, powders were shipped for aerosol analysis. Each powder lot was filled into size 3 capsules using similar capsule filling conditions and parameters, and capsule polishing to the T=0M powders. The same RS01 medium flow resistance device at 4 kPa pressure was used to evaluate the aerosol performance for the T=1M powders. Summary aerosol data and particle size distribution plot comparing the aerosol performance for all 3 powder lots are presented in Table 34 and FIG. 29, respectively. Aerosol performance results for the T=1M powders were comparable to T=0M powders for all three lots, indicating no physical impact to powder properties after 1 -month storage at 40°C/75% RH.
Table 34. Aerodynamic particle size by NGI for T=1M powders tested in RS01 medium flow resistance (0.10R) and 50 mg capsule powder fill mass. Mean of three replicates with standard deviation in parenthesis.
1NGI total recovery normalized to actual capsule fill mass.
[0263] Performance of RS01 Medium Versus High Flow Resistance Devices
[0264] Aerosol powder release kinetics from the inhaler/capsule by laser photometry show faster capsule emptying for RS01 medium than high flow resistance device for all 3 powder lots and at both 2 and 4 kPa tested pressure drops. Therefore, patients that are able to generate inhaled volume of >1.5 L can receive the dose from a 50 mg capsule powder mass in a single inhalation maneuver
(FIGS. 30-33)
[0265] APSD Performance Comparing Two Flow Resistance Inhaler Devices (0.10R and 0.16R) with two different lots of T=0M powders
[0266] Aerosol performance for RS01 medium and high flow resistance devices tested at 4 kPa pressure drop were comparable (Table 35 and FIG. 34).
Table 35. NGI summary for T=0M powders tested in RS01 medium and high flow resistance devices (0.10R and 0.16R) at 4 kPa and 50 mg capsule powder fill mass. Mean of three replicates with standard deviation in parenthesis.
[0267] APSD Performance Comparing Two Stability Time Points, T=0M and T=1M (40°C/75%RH), with RS01 Medium Flow Resistance Inhaler Device
[0268] Aerosol quality for T=0M and T=1M (40°C/75% RH) powders tested with the RS01 medium flow resistance device was comparable, see Table 36 and FIGS. 35-38).
Table 36. NGI summary for T=0M and T=1M powders tested in RS01 medium flow resistance (0.10R) at 4 kPa and 50 mg capsule powder fill mass. Mean of three replicates with standard deviation in parenthesis.
[0269] While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the disclosure. It should be understood that various alternatives to the embodiments of the present disclosure may be employed in practicing the present disclosure. It is intended that the following claims define the scope of the present disclosure and that methods and structures within the scope of these claims and their equivalents be covered thereby.
Claims
1. A pharmaceutical composition, comprising: a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof, and cyclodextrin, wherein said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 5:95 to about 95:5, and wherein said pharmaceutical composition is in a form of an inhalable dry powder.
2. The pharmaceutical composition of claim 1, wherein said cyclodextrin is selected from the group consisting of: a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, hydroxypropyl-P- cyclodextrin, hydroxyethyl-P-cyclodextrin, hydroxypropyl-y-cyclodextrin, hydroxyethyl-y- cyclodextrin, dihydroxypropyl-P-cyclodextrin, glucosyl-a-cyclodextrin, glucosyl-P- cyclodextrin, diglucosyl-P-cyclodextrin, maltosyl-a-cyclodextrin, maltosyl-P-cyclodextrin, maltosyl-y-cyclodextrin, maltotriosyl-P-cyclodextrin, maltotriosyl-y-cyclodextrin dimaltosyl- P-cyclodextrin, succinyl-P-cyclodextrin, 6A-amino-6A-deoxy-N-(3-hydroxypropyl)-P- cyclodextrin, sulfobutylether-P-cyclodextrin, sulfobutylether-y-cyclodextrin, sulfoalkylether- P-cyclodextrin, and sulfoalkylether-y-cyclodextrin.
3. The pharmaceutical composition of claim 1, wherein said cyclodextrin comprises hydroxy propyl -P -cy cl odextrin .
4. A pharmaceutical composition, comprising: a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof; and hydroxy propyl -P -cy cl odextrin; wherein said pharmaceutical composition is in a form of an inhalable dry powder.
5. The pharmaceutical composition of claim 4, wherein said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 5:95 to about 95:5.
6. The pharmaceutical composition of claim 4, wherein said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 10:90 to about 90: 10, from about 15:85 to about 85: 15, from about 20:80 to about 80:20, from about 25:75 to about 75:25, from about 30:70 to about 70:30, from about 35:65 to about 65:35, from about 40:60 to about 60:40, or from about 45:55 to about 55:45.
The pharmaceutical composition of any one of claims 1-6, wherein said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio of about 50:50. The pharmaceutical composition of any one of claims 1-6, wherein said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio of about 23:77. The pharmaceutical composition of any one of claims 1-8, wherein said pharmaceutical composition further comprises a pharmaceutically acceptable excipient or carrier. The pharmaceutical composition of claim 9, wherein said pharmaceutically acceptable excipient or carrier comprises lactose, mannitol, sorbitol, erythritol, raffinose, sucrose, xylitol, trehalose, dextrose, a cyclodextrin, maltitol, maltose, glucose, hydroxyapatite, or any combination thereof. The pharmaceutical composition of claim 9, wherein said pharmaceutically acceptable excipient or carrier comprises porous particles, a crystallization inhibitor, a biodegradable polymer, ammonium bicarbonate, an amino acid, or any combination thereof. The pharmaceutical composition of claim 11, wherein said crystallization inhibitor comprises polymers, polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), polysaccharide, hydroxypropyl methylcellulose (HPMC or Hypromellose), hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), polyethylene oxide, hydroxypropyl-P-cyclodextrin (HP-P- CD), sulfobutylether-P-cyclodextrin, hydroxypropyl methylcellulose acetate succinate (HPMC-AS-HF), polyethylene glycol (PEG), or any combination thereof. The pharmaceutical composition of claim 11, wherein said pharmaceutically acceptable excipient or carrier comprises L-leucine or L-isoleucine. The pharmaceutical composition of any one of claims 1-13, wherein reconstitution of said pharmaceutical composition at a concentration of 9 mg/mL in water to 10 mg/mL affords a solution with a pH of about 5.0 to about 8.0. The pharmaceutical composition of any one of claims 1-13, wherein reconstitution of said pharmaceutical composition at a concentration of 9 mg/mL in water to 10 mg/mL affords a solution with a pH of about 5.5 to about 7.0. The pharmaceutical composition of any one of claims 1-13, wherein reconstitution of said pharmaceutical composition at a concentration of 9 mg/mL in water to 10 mg/mL affords a solution with a pH of about 6.7. The pharmaceutical composition of any one of claims 1-16, wherein said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof comprises flecainide acetate.
The pharmaceutical composition of any one of claims 1-17, wherein said pharmaceutical composition further comprises an acid. The pharmaceutical composition of claim 18, wherein said acid comprises acetic acid, aconitic acid, adipic acid, alginic acid, benzoic acid, caprylic acid, citric acid, cholic acid, formic acid, lactic acid, linoleic acid, malic acid, maleic acid, propionic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, tartaric acid, glutamic acid, hydrochloric acid, phosphoric acid, ascorbic acid, erythorbic acid, sorbic acid, thiodipropionic acid, or any combination thereof. The pharmaceutical composition of claim 18, wherein said acid comprises acetic acid. The pharmaceutical composition of any one of claims 1-20, wherein said dry inhalable powder is formulated for administration via oral inhalation. The pharmaceutical composition of any one of claims 1-21, wherein said dry powder has a mass median aerodynamic diameter of about 0.3 pm to about 20 pm. The pharmaceutical composition of any one of claims 1-22, wherein said dry powder has a mass median aerodynamic diameter of about 4.0 pm. The pharmaceutical composition of any one of claims 1-22, wherein said dry powder has a mass median aerodynamic diameter of about 5.0 pm. The pharmaceutical composition of any one of claims 1-22, wherein said dry powder has a mass median aerodynamic diameter of about 6.0 pm. The pharmaceutical composition of any one of claims 1-25, wherein said pharmaceutical composition has a glass transition temperature of about 15 °C to about 70 °C. The pharmaceutical composition of any one of claims 1-26, wherein said pharmaceutical composition has a glass transition temperature of about 45.0 °C. The pharmaceutical composition of any one of claims 1-26, wherein said pharmaceutical composition has a glass transition temperature of about 65.0 °C. The pharmaceutical composition of any one of claims 26-28, wherein said glass transition temperature is measured by Differential Scanning Calorimetry (DSC). A unit dose of said pharmaceutical composition of any prior claim, comprising about 50 mg to about 350 mg of said flecainide or said pharmaceutically acceptable salt thereof. The unit dose of claim 30, comprising from about 100 mg to about 150 mg of said flecainide or said pharmaceutically acceptable salt thereof. A kit, comprising: said pharmaceutical composition or said unit dose of any prior claim and instructions for use of said pharmaceutical composition for treatment of a heart condition. The kit of claim 32, further comprising a container that contains said pharmaceutical composition.
The kit of claim 31, wherein said container is selected from the group consisting of a capsule, blister pack, blister strip, reservoir, and cartridge. A kit, comprising: a) a pharmaceutical composition that comprises i) a therapeutically effective amount of flecainide or pharmaceutically acceptable salt thereof; and ii) a cyclodextrin; b) a receptacle containing said pharmaceutical composition; c) instructions for use of a dry powder inhaler for inhalation of a dose of said pharmaceutical composition in aerosol to a subject, wherein said pharmaceutical composition is in the form of an inhalable dry powder; and wherein said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 5:95 to about 95:5. The kit of claim 35, wherein said kit comprises a unit dose of said pharmaceutical composition, and wherein said unit dose comprises from about 50 mg to about 350 mg of said flecainide or said pharmaceutical acceptable salt thereof. A system, comprising: said pharmaceutical composition of any prior claim and a dry powder inhaler. The system of claim 37, further comprising instructions for use of said dry powder inhaler and said pharmaceutical composition for treatment of a heart condition. The system of claim 38, wherein said heart condition comprises atrial arrhythmia. The system of any one of claims 37-39, wherein said instructions contain instructions for use of said dry powder inhaler to deliver said pharmaceutical composition in a unit dose that comprises from about 50 mg to about 350 mg of flecainide or said pharmaceutically acceptable salt thereof. A system, comprising: a) a pharmaceutical composition that comprises: i) a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof; and ii) a cyclodextrin; b) a dry powder inhaler configured to deliver said pharmaceutical composition as an inhalable dry powder;
c) instructions for use of said dry powder inhaler to deliver said pharmaceutical composition in a unit dose that comprises about 50 mg to about 350 mg amount of flecainide or said pharmaceutically acceptable salt thereof; wherein said pharmaceutical composition is in the form of an inhalable dry powder that has said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 5:95 to about 95:5. A method of treating a subject suffering from a heart condition, comprising: administering to said subject via inhalation a pharmaceutical composition in the form of an inhalable dry powder, wherein said pharmaceutical composition comprises: i) a therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof; and ii) a cyclodextrin; wherein said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof and said cyclodextrin have a weight ratio from about 5:95 to about 95:5. The method of claim 42, wherein said cyclodextrin is selected from the group consisting of: a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, hydroxypropyl-P-cyclodextrin, hydroxyethyl- P-cyclodextrin, hydroxypropyl-y-cyclodextrin, hydroxyethyl-y-cyclodextrin, dihydroxypropyl-P-cyclodextrin, glucosyl-a-cyclodextrin, glucosyl-P-cyclodextrin, diglucosyl-P-cyclodextrin, maltosyl-a-cyclodextrin, maltosyl-P-cyclodextrin, maltosyl-y- cyclodextrin, maltotriosyl-P-cyclodextrin, maltotriosyl-y-cyclodextrin dimaltosyl-P- cyclodextrin, succinyl-P-cyclodextrin, 6A-amino-6A-deoxy-N-(3-hydroxypropyl)-P- cyclodextrin, sulfobutylether-P-cyclodextrin, sulfobutylether-y-cyclodextrin, sulfoalkylether- P-cyclodextrin, and sulfoalkylether-y-cyclodextrin. The method of claim 42, wherein said cyclodextrin comprises hydroxypropyl-P-cyclodextrin. The method of any one of claims 42-44, wherein said therapeutically effective amount of flecainide or a pharmaceutically acceptable salt thereof comprises from about 50 mg to about 350 mg of flecainide or said pharmaceutically acceptable salt thereof. The method of any one of claims 42-45, wherein said administration of said pharmaceutical composition is performed in up to six inhalation sessions. The method of any one of claims 42-46, wherein said administration of said pharmaceutical composition is performed in one or two inhalation sessions. The method of any one of claims 42-47, wherein said administration is performed via a dry powder inhaler.
The method of any one of claims 42-48, wherein said heart condition comprises atrial arrhythmia. The method of claim 49, wherein said atrial arrhythmia comprises tachycardia. The method of claim 50, comprising acute treatment after detection of said atrial arrhythmia. The method of any one of claims 42-48, wherein said heart condition comprises atrial fibrillation. The method of claim 52, wherein said atrial fibrillation is recurrent atrial fibrillation. The method of claim 52, wherein said atrial fibrillation is paroxysmal atrial fibrillation. A method, comprising converting a solution containing flecainide to an inhalable dry powder, thereby producing said pharmaceutical composition of any one of claims 1-31. The method of claim 55, wherein said converting said solution containing flecainide to said inhalable dry powder comprises using spray drying, freeze drying, spray-freeze drying, emulsion spray drying, or an aerosol flow reactor method. The method of claim 56, wherein said spray drying comprises spray drying at a solution flow rate of about 1.0 g/min to about 15.0 g/min; an atomization pressure of about 10 psi to about 100 psi; an inlet temperature of about 100 °C to about 200 °C; or an outlet temperature of about 40 °C to about 70 °C. The method of claim 56, wherein said spray drying comprises spray drying a solution flow rate of about 1.0 g/min to about 15.0 g/min; an atomization pressure of about 10 psi to about 100 psi; an inlet temperature of about 100 °C to about 200 °C; and an outlet temperature of about 40 °C to about 70 °C. The method of claim 56, wherein said solution containing flecainide further comprises a cyclodextrin. The method of claim 59, wherein said cyclodextrin comprises hydroxypropyl-P-cyclodextrin. The method of any one of claims 56, 59, or 60, wherein said solution containing flecainide further comprises an acid. The method of claim 61, wherein said acid comprises acetic acid, aconitic acid, adipic acid, alginic acid, benzoic acid, caprylic acid, citric acid, cholic acid, formic acid, lactic acid (e.g., D-(-)-lactic acid or L-(+)-lactic acid), linoleic acid, malic acid, maleic acid, propionic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, tartaric acid, glutamic acid, hydrochloric acid, phosphoric acid, ascorbic acid, erythorbic acid, sorbic acid, thiodipropionic acid, or any combination thereof. The method of claim 61, wherein said acid comprises acetic acid.
The method of any one of claims 55-63, wherein said solution containing flecainide is prepared by dissolving flecainide or a pharmaceutically acceptable salt thereof, cyclodextrin, and pH buffer agents in water, thereby providing said solution containing flecainide. The method of claim 64, wherein said cyclodextrin is selected from the group consisting of: a-cyclodextrin, P-cyclodextrin, y-cyclodextrin, hydroxypropyl-P-cyclodextrin, hydroxyethyl- P-cyclodextrin, hydroxypropyl-y-cyclodextrin, hydroxyethyl-y-cyclodextrin, dihydroxypropyl-P-cyclodextrin, glucosyl-a-cyclodextrin, glucosyl-P-cyclodextrin, diglucosyl-P-cyclodextrin, maltosyl-a-cyclodextrin, maltosyl-P-cyclodextrin, maltosyl-y- cyclodextrin, maltotriosyl-P-cyclodextrin, maltotriosyl-y-cyclodextrin dimaltosyl-P- cyclodextrin, succinyl-P-cyclodextrin, 6A-amino-6A-deoxy-N-(3-hydroxypropyl)-P- cyclodextrin, sulfobutylether-P-cyclodextrin, sulfobutylether-y-cyclodextrin, sulfoalkylether- P-cyclodextrin, and sulfoalkylether-y-cyclodextrin. The method of claim 64, wherein said cyclodextrin comprises hydroxypropyl-P-cyclodextrin. The method of any one of claims 56-66, wherein said converting said solution containing flecainide further comprises heating said solution containing flecainide. The method of claim 67, comprising heating said solution containing flecainide to about 40 °C. The method of any one of claims 64-68, wherein said solution containing flecainide is cooled to 25 °C prior to spray drying. The method of any one of claims 64-69, wherein said flecainide solution is diluted with water prior to spray drying. The method of any one of claims 55-70, wherein pH of said solution containing flecainide is adjusted to about 6.0 using said a pH buffer agent prior to spay drying. The method of claim 71, wherein said pH buffer agent comprises sodium hydroxide. The method of any one of claims 55-70, wherein reconstitution of said inhalable dry powder pharmaceutical composition at a concentration of 9 mg/mL to 10 mg/mL in water affords a solution with a pH of about 5.0 to about 8.0. The method of any one of claims 55-70, wherein reconstitution of said inhalable dry powder pharmaceutical composition at a concentration of 9 mg/mL to 10 mg/mL in water affords a solution with a pH of about 5.5 to about 7.0. The method of any one of claims 55-70, wherein reconstitution of said inhalable dry powder pharmaceutical composition at a concentration of 9 mg/mL to 10 mg/mL in water affords a solution with a pH of about 6.7. The method of any one of claims 55-73, wherein the inhalable dry powder pharmaceutical composition has a mass median aerodynamic diameter of about 0.3 pm to about 20 pm.
The method of any one of claims 55-74, wherein said pharmaceutical composition has a glass transition temperature of about 15 °C to about 70 °C. The method of any one of claims 55-75, wherein said flecainide or said pharmaceutically acceptable salt thereof comprises flecainide acetate. The method of any one of claims 55-75, further comprising packaging said pharmaceutical composition in unit dose form. The method of claim 78, wherein said unit dose form further comprises a container selected from the group consisting of: a capsule, blister pack, blister strip, reservoir, and cartridge.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163146155P | 2021-02-05 | 2021-02-05 | |
US63/146,155 | 2021-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022170081A1 true WO2022170081A1 (en) | 2022-08-11 |
Family
ID=82741898
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/015293 WO2022170081A1 (en) | 2021-02-05 | 2022-02-04 | Antiarrhythmic formulation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022170081A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116178592A (en) * | 2023-03-17 | 2023-05-30 | 山东滨州智源生物科技有限公司 | Preparation method of 6-O-sulfobutyl-beta-cyclodextrin |
WO2024132080A1 (en) * | 2022-12-22 | 2024-06-27 | Colonis Pharma Ltd | Liquid pharmaceutical composition containing flecainide and process for the preparaton thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050059825A1 (en) * | 2003-09-17 | 2005-03-17 | Zhi-Xian Wang | Novel process for the preparation of flecainide, its pharmaceutically acceptable salts and important intermediates thereof |
US20180028519A1 (en) * | 2013-07-24 | 2018-02-01 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Use of Flecainide as an Anti-Connexin Agent and Method for Potentiating the Effects of a Psychotropic Drug |
US20210030732A1 (en) * | 2019-08-01 | 2021-02-04 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
-
2022
- 2022-02-04 WO PCT/US2022/015293 patent/WO2022170081A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050059825A1 (en) * | 2003-09-17 | 2005-03-17 | Zhi-Xian Wang | Novel process for the preparation of flecainide, its pharmaceutically acceptable salts and important intermediates thereof |
US20180028519A1 (en) * | 2013-07-24 | 2018-02-01 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Use of Flecainide as an Anti-Connexin Agent and Method for Potentiating the Effects of a Psychotropic Drug |
US20210030732A1 (en) * | 2019-08-01 | 2021-02-04 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
US20210030670A1 (en) * | 2019-08-01 | 2021-02-04 | Incarda Therapeutics, Inc. | Novel antiarrhythmic formulation |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024132080A1 (en) * | 2022-12-22 | 2024-06-27 | Colonis Pharma Ltd | Liquid pharmaceutical composition containing flecainide and process for the preparaton thereof |
CN116178592A (en) * | 2023-03-17 | 2023-05-30 | 山东滨州智源生物科技有限公司 | Preparation method of 6-O-sulfobutyl-beta-cyclodextrin |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190060230A1 (en) | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration | |
EP1589947B1 (en) | Pharmaceutical formulation with an insoluble active agent for pulmonary administration | |
WO2022170081A1 (en) | Antiarrhythmic formulation | |
AU2013248242B2 (en) | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration | |
US20070031342A1 (en) | Sustained release microparticles for pulmonary delivery | |
US20230226032A1 (en) | Kits and methods for induction of cardioversion in subjects with atrial arrhythmias | |
US20220241278A1 (en) | Inhalable imatinib formulation | |
US10744087B2 (en) | Method to slow ventricular rate | |
AU2016256776B2 (en) | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration | |
WO2006124446A2 (en) | Sustained release microparticles for pulmonary delivery | |
WO2023107640A1 (en) | Inhaled therapy for cardiac arrhythmia | |
WO2024015518A1 (en) | Inhalable imatinib formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22750457 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22750457 Country of ref document: EP Kind code of ref document: A1 |